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Resumen 
Los ganglios basales son una serie de núcleos subcorticales interconectados que incluyen el estriado (caudado y 
putamen en primates), el globo pálido (segmentos internos y externos), el núcleo subtalámico y la sustancia nigra 
(pars reticulata y pars compacta). Se trata de un nodo fundamental para muchos procesos conductuales y 
neurobiológicos como el control afectivo, la actividad motora y las funciones cognitivas. La mayoría (~ 95%) de las 
neuronas del estriado son neuronas GABAérgicas espinosas medianas (del inglés medium spiny neurons, MSNs), que 
reciben aferencias glutamatérgicas principalmente de la corteza y el tálamo. Está bien establecido que existen dos 
poblaciones principales de MSNs: las MSNs de la vía directa, que proyectan principalmente a la sustancia nigra pars 
reticulata y el globo pálido interno, y expresan receptores de dopamina de tipo 1 (D1R-MSNs), y las MSNs de la vía 
indirecta, que proyectan principalmente al globo pálido externo y expresan receptores de dopamina de tipo 2 (D2R-
MSNs). Dada su heterogeneidad neuroquímica y funcional, no es de extrañar que el desequilibrio entre la MSNs de la 
vía directa e indirecta subyazca a la patogenia de diversos trastornos de los ganglios basales como la enfermedad de 
Huntington (EH) y la enfermedad de Parkinson (EP). Se han descrito cambios notables en la actividad 
electrofisiológica de las D1R-MSNs, más que de las D2R-MSNs, en modelos de EH durante diferentes etapas de la 
enfermedad, lo que sugiere un papel importante de esta población neuronal en el desarrollo y progresión de la 
patología. Por otra parte, en pacientes y modelos animales de EH se ha observado una pérdida selectiva de D2R-
MSNs. 
Muchos modelos conceptuales apoyan la hipótesis de que estas dos poblaciones de MSNs son mecánica y 
funcionalmente opuestas. Sin embargo, la obtención de evidencias empíricas que demuestren sus funciones ha sido 
difícil, debido a que ambas poblaciones celulares se encuentran físicamente entremezcladas y son morfológicamente 
indistinguibles. La aplicación de la optogenética, para controlar la actividad neuronal con exquisita resolución 
temporal a través de la ingeniería de opsinas, ha proporcionado una plataforma de expansión para descifrar las 
funciones de estriado. Más recientemente, los receptores de diseño activados exclusivamente por drogas de diseño 
(DREADDs) han sido desarrollados para controlar remotamente la actividad neuronal. Esta poderosa herramienta se 
basa en la modificación molecular de los receptores metabotrópicos humanos, principalmente muscarínicos, lo que 
conduce a una ínfima potencia y eficacia en su interacción con el ligando natural (acetilcolina) y a una elevadísima 
potencia y eficacia de moléculas como la clozapina-N-óxido (CNO), de alta biodisponibilidad por vía oral y 
farmacológicamente inertes. Es asimismo destacable que los DREADDs carecen de actividad constitutiva y de 
procesos de desensibilización detectables in vitro e in vivo, ofreciendo por tanto un complejo receptor-efector 
atractivo para modificar la actividad celular remotamente mediante la manipulación de las vía de señalización 
dependientes de proteínas Gi, Gq y Gs. El uso de animales transgénicos, o su expresión mediante virus recombinantes 
adeno-asociados (rAAV), permite expresar un DREADD en una población celular particular de una región 
determinada del cerebro. La administración de CNO a estos animales mutantes ha demostrado la capacidad de 
cambiar patrones conductuales y electrofisiológicos de forma dependiente de la población celular y la vía molecular 
involucrada. Curiosamente, al expresar DREADD-Gq en neuronas principales, altas dosis de CNO son incluso capaces 
de inducir eventos excitotóxicos. Así, este sistema permite un control remoto, específico y reversible de la actividad 
neuronal en poblaciones celulares específicas, siendo adecuado para estudios tanto a corto como a largo plazo. 
La señalización dependiente de receptores metabotrópicos es absolutamente necesaria para el correcto 
funcionamiento del estriado. Así, numerosos neurotransmisores/neuromoduladores como dopamina, glutamato, 
adenosina, acetilcolina y endocannabinoides controlan la actividad y la plasticidad de las MSNs a través de diversas 
familias de receptores acoplados a proteínas G (GPCRs). En concreto, los principales receptores de dopamina 
presentes en las MSNs, D1R y D2R, están acoplados a proteínas Gs/olf y Gi, respectivamente, y se han descrito 
detalladamente sus mecanismos de señalización en el estriado. Los receptores acoplados a Gq, como los receptores 
metabotrópicos de glutamato mGlu1/5 y los receptores muscarínicos de acetilcolina M1/3/5, son también muy 
importantes en el control de la excitabilidad de las MSNs, habiéndose descrito una sobre-activación de la señalización 
dependiente de ellos en algunos modelos de enfermedades relacionadas con los ganglios basales, como la EH y la 
adicción a drogas. Sin embargo, hasta ahora no se ha dilucidado el impacto preciso y el modo de acción de esta 
señalización a través de proteínas Gq en las MSNs. 
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Una pregunta sin respuesta en la mayoría de las enfermedades neurodegenerativas es qué factores precisos dictan el 
daño selectivo de una población neuronal determinada. Específicamente en la EH, una enfermedad 
neurodegenerativa devastadora donde las estructuras principalmente afectadas son el estriado y la corteza, no se 
conocen enteramente los mecanismos que hacen que las neuronas más abundantes en el estriado (las MSNs) sean 
tan vulnerables. Durante muchos años, se han acumulado evidencias que apoyan la implicación en la progresión de 
la EH de una desregulación progresiva de las redes neuronales que enlazan la corteza y el estriado. En particular, la 
hipótesis de la excitotoxicidad de la EH sostiene que la neurodegeneración estriatal está mayoritariamente causada 
por un exceso de impulsos excitadores corticales deletéreos, debido a factores como la liberación masiva de 
glutamato en los terminales corticoestriatales y al consiguiente aumento en la entrada de Ca2+ a través de los 
receptores ionotrópicos de glutamato en las MSNs. En la actualidad, no existe ningún tratamiento neuroprotector o 
curativo para la EH, y ésta representa además el modelo más estudiado y representativo de las enfermedades 
neurodegenerativas producidas por expansiones de un triplete, como es el caso, por ejemplo, de algunas ataxias. Por 
lo tanto, descubrir el mecanismo patogénico subyacente a la EH y encontrar un tratamiento eficaz desde el punto de 
vista de la neuroprotección o erradicación podría tener implicaciones inmediatas para cualquier otra enfermedad 
neurodegenerativa causada por expansiones de un triplete. Un número importante de estudios ha analizado la 
expresión y el papel del sistema endocannabinoide en la EH. De hecho, como se expone más adelante, la EH 
constituye uno de los mejores modelos de enfermedad actualmente disponibles para evaluar la relevancia 
fisiopatológica y terapéutica del sistema endocannabinoide en las enfermedades neurodegenerativas.  
La planta del cáñamo (Cannabis sativa L.) y sus derivados se han utilizado en medicina desde hace al menos cincuenta 
siglos. Sin embargo, la estructura química de sus componentes activos (los cannabinoides) no fue aclarada hasta la 
década de 1960. Tres décadas más fueron necesarias para la identificación en el organismo de receptores específicos 
de cannabinoides. Hasta ahora, dos receptores de cannabinoides han sido bien caracterizados: el de tipo 1 (CB1R), 
que es especialmente abundante en las áreas del sistema nervioso central implicadas en el control de la actividad 
motora (ganglios basales, cerebelo), aprendizaje y memoria (corteza, hipocampo), emociones (amigdala), 
percepción sensorial (tálamo) y varias funciones autónomas y endocrinas (hipotálamo, médula), y el de tipo 2 (CB2R), 
que se expresa preferentemente en las células (linfocitos B y T macrófagos) y tejidos (bazo, ganglios linfáticos) del 
sistema inmune, aunque también está presente en algunas células del sistema nervioso, mayoritariamente en 
microglía. Las moléculas endógenas que interaccionan con los receptores cannabinoides, los endocannabinoides 
(anandamida y 2-araquidonilglicerol), también han sido aislados. La generación de endocannabinoides se produce 
"bajo demanda" a partir de precursores de lípidos de la membrana plasmática y está estrechamente controlada por 
la actividad neuronal. La señalización endocannabinoide proporciona un importante mecanismo de 
retroalimentación para atenuar la excesiva actividad presináptica y, así, sintoniza la funcionalidad y la plasticidad de 
muchas sinapsis, especialmente glutamatérgicas y GABAérgicas. Junto con esta función neuromoduladora, estudios 
en diversos modelos animales apoyan que CB1R desempeña un papel importante en la supervivencia neuronal en 
entornos fisiopatológicas como la lesión cerebral aguda y situaciones de neuroinflamación. Sin embargo, la 
evaluación de la relevancia fisiológica y el potencial terapéutico del CB1R en las enfermedades neurológicas se ve 
impedida, al menos en parte, por la falta de conocimiento de la especificidad celular de acción de CB1R. Entre todas 
las enfermedades neurodegenerativas, la EH constituye uno de los mejores modelos disponibles actualmente para el 
estudio del potencial neuroprotector de CB1R debido a varias razones:  
(I) CB1R es uno de los GPCRs más abundantes en el cerebro; en concreto, se expresa en gran cantidad en los ganglios 
basales, en las sinapsis establecidas por neuronas que contienen GABA (especialmente MSNs, las células que 
degeneran principalmente en la EH) o glutamato (especialmente neuronas de proyección corticoestriatales, que 
controlan críticamente la función de las MSNs) como transmisores, y desempeña un papel clave en el control del 
comportamiento motor (uno de los procesos más característicamente alterados en la EH). 
(II) En pacientes con EH y en modelos animales de la enfermedad existe una disminución selectiva, notable y con un 
gradiente dorsolateral de CB1R en los ganglios basales. Además, esta pérdida de CB1R parece reflejar, al menos en 
parte, el patrón de daño de neuronas GABAérgicas característico de la enfermedad. 
(III) La antedicha pérdida de CB1R ocurre en etapas tempranas de HD y antes de la aparición de síntomas clínicos 
manifiestos, neurodegeneración y cambios bruscos en otros parámetros neuroquímicos. 
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(IV) En el contexto del bien establecido papel neuroprotector de los cannabinoides, nuestro grupo y otros han 
demostrado previamente un papel neuroprotector de CB1R en modelos transgénicos de ratón de la EH. 
En este contexto, el OBJETIVO GLOBAL de esta Tesis Doctoral comprende el estudio de los mecanismos de la vía 
directa e indirecta implicados en la disfunción corticoestriatal y la neurodegeneración, así como el emplazamiento 
neurobiológico selectivo de la acción neuroprotectora del CB1R en dicho contexto. 
Este objetivo global se puede dividir en 2 OBJETIVOS ESPECÍFICOS:  
Objetivo 1. Examinar los mecanismos moleculares y la relevancia fisiopatológica de la señalización dependiente de 
proteínas Gq en las MSNs de la vía directa e indirecta del estriado dorsal.  
Objetivo 2. Estudiar el papel de las diferentes poblaciones de CB1R, es decir, los situados en las neuronas 
GABAérgicas (MSNs), glutamatérgicas (neuronas de proyección corticoestriatal) o astrocitos, en la vulnerabilidad 
diferencial de las MSNs de la vía directa e indirecta del estriado dorsal.  
Los RESULTADOS obtenidos se han dividido en dos bloques: 
En el primer bloque de Resultados, utilizando diferentes aproximaciones experimentales, especialmente la 
tecnología DREADD, demostramos que la activación sostenida de la señalización a través de proteínas Gq deteriora 
la funcionalidad de las MSNs y desvelamos el mecanismo molecular exacto que subyace a este proceso, que consiste 
en el eje de señalización PLC/Ca2+/PYK2/JNK. Además, esta ruta de señalización intracelular se encuentra implicada 
en el control del funcionamiento del estriado dorsal de ratón in vivo, como se demuestra a través de la alteración de 
la integridad neuronal y el comportamiento. Así, la activación aguda de la señalización por Gq en las MSNs de la vía 
directa o vía indirecta produce un aumento o una disminución, respectivamente, de parámetros dependiente de 
actividad. Por el contrario, la activación continua de la señalización por Gq deteriora la funcionalidad de las MSNs de 
la vía directa y vía indirecta y altera el comportamiento, y el patrón electroencefalográfico relacionado con la 
actividad, controlados por ambos circuitos neuroanatómicos. 
En el segundo bloque de Resultados,  mediante el empleo de un conjunto de estrategias genéticas, quimiogenéticas 
y farmacológicas destinadas a manipular la función del CB1R de forma espaciotemporalmente restringida in vivo, 
mostramos que la población de CB1R situada en las proyecciones corticoestriatales, mediante la disminución de la 
liberación de glutamato, protege selectivamente las MSNs de la vía directa del estriado dorsal del ratón frente al daño 
inducido por la expresión de huntingtina mutante (mtHtt) en la corteza. En concreto, la expresión de mtHtt en la 
corteza motora daña las D1R-MSNs pero no las D2R-MSNs (i) cuando CB1R se bloquea farmacológicamente con 
rimonabant o (ii) cuando CB1R se inactiva genéticamente  de forma condicional en neuronas corticales principales. 
Este proceso neurotóxico se rescata mediante la administración de MK-801, un antagonista del receptor NMDA. 
Asimismo, se observa una mayor vulnerabilidad selectiva de las D1R-MSNs frente a las  D2R-MSNs cuando se 
sobreactivan las proyecciones glutamatérgicas corticoestriatales mediante el uso de DREADD y CB1R se encuentra 
farmacológicamente bloqueado. El pool de CB1R situado en las proyecciones corticoestriatales, mediante la 
inhibición de la transmisión glutamatérgica, también es capaz de proteger las MSNs del daño derivado de la expresión 
de mtHtt en astrocitos estriatales. Por último, la MGL (enzima responsable de la degradación del 2-
araquidonilglicerol) controla desde los astrocitos la disponibilidad del 2-araquidonilglicerol involucrado en la 
protección de las MSNs. 
Los resultados obtenidos en esta tesis nos permiten obtener las siguientes CONCLUSIONES:  
I. Los circuitos del estriado dorsal pueden ser "activados" por la señalización aguda de proteínas Gq o 
"apagados" por la señalización sostenida de proteínas Gq. Específicamente, la activación sostenida de la 
señalización por Gq inactiva las MSNs del estriado dorsal a través de una vía intracelular que converge en JNK. 
 
II. La población de  CB1R situada en las proyecciones corticoestriatales, al menos en gran parte mediante la 
inhibición de la liberación de glutamato, protege selectivamente las D1R-MSNs del estriado dorsal frente al 
daño cortical producido por excitotoxicidad o mtHtt. 
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Colectivamente, estos resultados definen el mecanismo molecular y señalan la relevancia funcional de la señalización 
dependiente de proteínas Gq en los circuitos estriatales, en estados normales y de sobreactivación, y definen al pool 
de CB1R cortical como uno de los elementos neuroquímicos implicados en la diferente vulnerabilidad que presentan 
las D1R-MSNs frente a las D2R-MSNs en la EH. Todo ello puede contribuir a entender el papel de una señalización 
cannabinérgica-glutamatérgica coordinada en el control de las vías directa e indirecta corticoestriatales y su 
desregulación en enfermedades que afectan a los ganglios basales. 
  
7 
 
8 
 
SUMMARY 
The basal ganglia are a series of interconnected subcortical nuclei including the striatum (caudate and putamen in 
primates), the globus pallidus (internal and external segments), the subthalamic nucleus, and the substantia nigra 
(pars reticulata and pars compacta). They are a key node for many behavioural and neurobiological processes such as 
motor activity, cognitive functions, and affective control. The vast majority (~95%) of neurons within the striatum are 
GABAergic medium spiny neurons (MSNs), which receive glutamatergic inputs primarily from the cortex and from 
specific thalamic nuclei. It is well established that there are two major populations of MSNs: direct pathway MSNs, 
that project mainly to the substantia nigra pars reticulata and express dopamine type 1 receptors (D1R-MSNs), and 
indirect pathway MSNs, that project mainly to the external globus pallidus and express dopamine type 2 receptors 
(D2R-MSNs). Given their neurochemical and functional heterogeneity, it is not surprising that the imbalance between 
direct and indirect pathway’s MSNs may underlie the pathogenesis of several basal ganglia disorders as Huntington’s 
disease (HD) and Parkinson´s disease (PD). Remarkable changes in the electrophysiological activity of D1R-MSNs, 
rather than of D2R-MSNs, have been shown in mouse models of HD at different disease stages, pointing out to an 
important role of the former neuronal population. On the other hand, a somewhat selective loss of indirect pathway’s 
MSNs has been observed in HD patients and animal models.  
Many conceptual models hypothesize that those two MSN populations oppose one another both mechanistically and 
functionally. However, obtaining empirical evidence to support their roles has proven difficult because these cell 
populations are physically intermingled and morphologically indistinguishable. The implementation of optogenetics 
to control neuronal activity with exquisite temporal resolution using engineered opsins has provided an expanding 
platform for decoding striatal functions. More recently, the designer receptor exclusively activated by designer drug 
(DREADD) technology has been developed for controlling neuronal activity remotely. This powerful tool is very 
frequently based on the molecular evolution of human muscarinic receptors, leading to reduced potency and efficacy 
of the native ligand (acetylcholine) and high potency and efficacy of the orally bioavailable, pharmacologically inert 
ligand clozapine-N-oxide (CNO). Importantly, DREADDs lack detectable constitutive activity and desensitization 
processes in vitro and in vivo, thus providing an attractive receptor-effector complex to modify cellular activity 
remotely by manipulating Gi-, Gq- and Gs-coupled pathways. The use of transgenic animals and/or recombinant 
adeno-associated virus (rAAV)-mediated gene delivery allows to express the DREADD in a particular cell population 
of a given brain region. Administration of CNO to these mutant animals has been shown to strongly change 
behavioural and electrophysiological patterns according to the cell population and molecular pathway involved. 
Interestingly, by engaging DREADD-Gq expressed in principal neurons, high doses of CNO are even able to induce 
excitotoxic seizures. Thus, this system allows a specific and reversible remote control of neuronal activity in specific 
cell populations and is suitable for long-term studies. 
Metabotropic signalling is absolutely necessary for the proper functioning of the striatum. 
Neurotransmitters/neuromodulators such as dopamine, glutamate, adenosine, acetylcholine, and endocannabinoids 
control the activity and plasticity of MSNs by engaging various G protein-coupled receptor (GPCR) families. 
Specifically, the main dopamine receptors present in MSNs, namely D1R and D2R, are coupled to Golf and Gi proteins, 
respectively, and the detailed roles of these signalling axes on striatal functions have been reported. Gq-coupled 
receptors such as metabotropic glutamate mGlu1/5 receptors and muscarinic acetylcholine M1/3/5 receptors are also 
very important in the control of MSN excitability, and an overactive Gq-protein-driven signalling has been shown to 
occur in various models of basal ganglia-related diseases such as HD and drug addiction. However, the precise impact 
and mode of action of Gq-protein signalling on MSNs have not been clarified so far. 
A key unanswered question in most neurodegenerative diseases is what precise factors dictate the selective damage 
of a particular neuronal population. Specifically in HD, a devastating neurodegenerative disease where the primarily 
affected structures are the cortex and striatum, the mechanisms by which striatal principal neurons (MSNs) are so 
highly vulnerable are incompletely understood. For many years, evidence has accumulated supporting that a 
progressive dysregulation of the neuronal networks linking deep-cortical and striatal pathways is involved in HD 
pathology. Particularly, the excitotoxicity hypothesis of HD supports that striatal neurodegeneration is majorly 
caused by an excess of deleterious cortical excitatory inputs due to factors such as massive glutamate release from 
corticostriatal terminals and overactivation of ionotropic glutamate receptors ad Ca2+ influx in MSNs. At present, no 
neuroprotective or curative treatment exists for HD, and it represents the most studied model and the most prevalent 
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of the neurodegenerative diseases produced by triplet expansions, to which some ataxias also belong. Therefore, 
discovering the pathogenic mechanism underlying HD, and finding an effective treatment from the point of view of 
neuroprotection or eradication, could thus have immediate implications for any other neurodegenerative disease 
caused by triplet expansions. A significant number of studies have dealt with the expression and role of the 
endocannabinoid system in HD. As a matter of fact, as discussed below, HD constitutes one of the best currently 
available model disease to assess the pathophysiological relevance and therapeutic potential of the endocannabinoid 
system in neurodegenerative diseases.  
The hemp plant (Cannabis sativa L.) and its derivatives have been used in medicine for at least fifty centuries. 
However, the chemical structure of their active components (the cannabinoids) was not elucidated until the early 
1960s. Three decades more were necessary for the identification in our body of specific cannabinoid receptors to be 
achieved. So far, two cannabinoid receptor types have been well characterized: CB1R, which is especially abundant 
in areas of the central nervous system involved in the control of motor activity (basal ganglia, cerebellum), learning 
and memory (cortex, hippocampus), emotions (amygdala), sensory perception (thalamus) and various autonomic 
and endocrine functions (hypothalamus, medulla), and CB2R, which is preferentially expressed in cells (B and T 
lymphocytes, macrophages) and tissues (spleen, lymph nodes) of the immune system, although it is also present in 
the nervous system, mainly in microglia. Endogenous molecules that engage cannabinoid receptors, the so-called 
endocannabinoids (anandamide and 2-arachidonoylglycerol), have also been isolated. Endocannabinoid generation 
occurs by “on-demand” synthesis and cleavage of plasma membrane lipid precursors, and is tightly controlled by 
neuronal activity. Endocannabinoid signalling serves as a major feedback mechanism to prevent excessive 
presynaptic activity and thus tunes the functionality and plasticity of many synapses, especially glutamatergic and 
GABAergic. In concert with this neuromodulatory function, studies in various animal models support that the CB1R 
plays an important role in the promotion of neuron survival in pathophysiological settings such as acute brain injury 
and neuroinflammatory conditions. However, the assessment of the physiological relevance and therapeutic 
potential of CB1R in neurological diseases is hampered, at least in part, by the lack of knowledge of the cell-population 
specificity of CB1R action. Among all the neurodegenerative diseases, HD constitutes one of the best currently 
available models to study the neuroprotective potential of CB1R due to several reasons: 
(I) CB1R is one of the most abundant GPCRs in the brain; specifically, it is highly expressed in the basal ganglia at 
synapses established by neurons containing GABA [especially MSNs, the cells that primarily degenerate in HD] or 
glutamate (especially corticostriatal projecting neurons, which critically control MSNs function) as transmitters, and 
play a key role in the control of motor behaviour (one of the processes that is most characteristically affected in HD).  
(II) A remarkable and dorsolaterally-selective down-regulation of CB1R has been documented in the basal ganglia of 
HD patients and animal models, and, of interest, this loss of CB1R seems to reflect, at least in part, the GABAergic-
neuron damage pattern characteristic of the disease.  
(III) The aforementioned loss of CB1R occurs at early stages of HD and prior to the appearance of overt clinical 
symptoms, neurodegeneration and bulk changes in other neurochemical parameters.  
(IV) In the context of the well-established neuroprotective role of cannabinoids, our group and others have 
demonstrated a neuroprotective role of CB1R in transgenic mouse models of HD. 
In this context, the GLOBAL AIM of this Doctoral Thesis embraces the study of direct-pathway versus indirect-
pathway mechanisms involved in corticostriatal dysfunction and neurodegeneration, as well as the selective 
neurobiological site(s) of CB1R neuroprotective action within the corticostriatal circutry. 
This main objective can be divided into 2 SPECIFIC AIMS: 
Objective 1. To examine the molecular mechanisms and physiopathological relevance of Gq-protein signalling in 
D1R-MSNs and D2R-MSNs within the dorsal striatum. 
Objective 2. Study the role of different CB1R pools, namely those situated on GABAergic neurons (MSNs), 
glutamatergic neurons (corticostriatal projection neurons) or astrocytes, in the differential vulnerability of D1R-MSNs 
and D2R-MSNs within the dorsal striatum. 
The RESULTS obtained have been divided into two blocks: 
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In the first block of Results, by using different experimental approaches, especially the DREADD technology, we 
show that sustained activation of Gq-protein signaling impairs the functionality of striatal neurons and unveil the 
precise molecular mechanism underlying this process, which involves a PLC/Ca2+/PYK2/JNK pathway. Moreover, 
engagement of this intracellular signaling route is functionally active in the mouse dorsal striatum in vivo, as proven 
by the disruption of neuronal integrity and behavioral tasks. Acute Gq-protein activation in direct-pathway or 
indirect-pathway neurons produces an enhancement or a decrease, respectively, of activity-dependent parameters. 
In contrast, sustained Gq-protein activation impairs the functionality of direct-pathway and indirect-pathway 
neurons and disrupts the behavioral performance and electroencephalography-related activity tasks controlled by 
either anatomical framework.  
In the second block of Results, by using an array of genetic, chemogenetic and pharmacological strategies to 
manipulate cannabinoid CB1R function in a spatiotemporally-restricted manner in vivo, we show that CB1R located 
on corticostriatal projections, by blunting glutamatergic output, selectively safeguards D1R-MSNs of the mouse 
dorsal striatum from cortical mutant huntingtin (mtHtt)-induced damage. Specifically, expression of mtHtt in the 
motor cortex damages D1R-MSNs but not D2R-MSNs upon (i) pharmacological blockade of CB1R with rimonabant 
or (ii) conditional genetic deletion of CB1R in cortical principal neurons. This neurotoxic process is rescued by 
administration of the NMDA receptor antagonist MK-801. Likewise, a selective vulnerability of D1R-MSNs vs. D2R-
MSNs is observed when corticostriatal glutamatergic projections are overactivated remotely by means of a DREADD 
pharmacogenetics approach and CB1R is pharmacologically blocked. CB1R located on corticostriatal projections, by 
inhibiting glutamatergic transmission, also protects MSNs from mtHtt-expressing striatal astroglia. Finally, astroglial 
MGL controls the availability of the 2-AG to ensure protection of MSNs.  
The results obtained in this Thesis allow us to obtain the following CONCLUSIONS: 
I. Striatal circuits can be “turned on” by acute Gq-protein signalling or “turned off” by sustained Gq-protein 
signalling. Specifically, sustained Gq-protein signalling inactivates MSNs of the dorsal striatum by an 
intracellular pathway that relies on JNK.  
 
II. CB1R located on corticostriatal projections, mainly by blunting glutamatergic output, selectively safeguards 
D1R-MSNs of the dorsal striatum. 
 
Collectively, these findings define the molecular mechanism and functional relevance of Gq-protein-driven signals in 
striatal circuits under normal and overactivated states, and define cortical CB1R as a key neurochemical player in 
dictating a dissimilar vulnerability of D2R-MSNs vs. D1R-MSNs. Altogether, they may contribute to understand the 
role of coordinated cannabinergic-glutamatergic signaling in the control of the direct and indirect corticostriatal 
pathways, and their dysregulation in basal ganglia disorders. 
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ABBREVIATIONS 
2-AG: 2-Arachidonoylglycerol 
ABHD: α/β-Hydrolase 
AC: Adenylyl cyclase 
AEA: N-arachidonoylethanolamine (anandamide) 
AMPK: AMP-activated protein kinase 
ATF-2: Activating transcription factor 2 
BAC: Bacterial artificial chromosome 
BDNF: Brain-derived neurotrophic factor 
BG: Basal ganglia 
CaM: Calmodulin 
CaMK: Calmodulin-dependent kinase 
cAMP: 3’,5’-Cyclic adenosine monophosphate 
CaN: Calcineurin (Ca2+-sensitive protein phosphatase 2B) 
CB1R: Cannabinoid receptor, type 1 
CB2R: Cannabinoid receptor, type 2 
CNS: Central nervous system 
COX: Cyclooxygenase 
CREB: cAMP response element-binding protein 
CRIP1a: Cannabinoid receptor-interacting protein 1a 
Cx: Cortex 
D1R: Dopamine receptor, type 1 
D2R: Dopamine receptor, type 2 
DARPP-32: Dopamine- and cAMP-regulated phosphoprotein of 32 kDa 
DAG: Diacylgycerol 
DAGL: Diacylgycerol lipase 
DGK: Diacylglycerol kinase 
DPE: Depolarization-induced potentiation of excitation 
DREADD: Designer receptor exclusively activated by designer drug 
DSE: Depolarization-induced suppression of excitation 
DSI: Depolarization-induced suppression of inhibition 
DYN: Dynorphin 
eCB: Endocannabinoid 
ENK: Enkephalin 
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Epac: Exchange protein directly activated by cAMP 
ERK: Extracellular signal-regulated kinase 
FAAH: Fatty acid amide hydrolase 
FAN: Factor associated with neutral sphingomyelinase activation 
GABA: γ-Aminobutyric acid 
GIRK: G-protein-activated inwardly rectifying K+ channel 
GLT-1: Glutamate transporter 1 
GPCR: G protein-coupled receptor 
GPe: Globus pallidus, external segment 
GPi: Globus pallidus, internal segment 
GRK: GPCR kinase 2 
GSK-3β: Glycogen synthase 3β 
HCN: Hyperpolarization-activated cyclic nucleotide-gated channel 
HD: Huntington’s disease 
Htt: Huntingtin 
IL-2: Interleukin-2  
IP3: Inositol 1,4,5-trisphosphate 
IP3R: Inositol 1,4,5-trisphosphate receptor 
IT: Intratelencephalic neuron 
JNK: c-Jun N-terminal kinase 
KO: Knock-out 
LTD: Long-term depression 
LTP: Long-term potentiation 
mAChR: Muscarinic acetylcholine receptor 
MAPK: Mitogen-activated protein kinase 
MGL: Monoacylglycerol lipase 
mGluR: Metabotropic glutamate receptor 
MSN: Medium-sized spiny neurons 
mtHtt: Mutant huntingtin 
mTOR: Mammalian target of rapamycin  
mTORC1: Mammalian target of rapamycin complex 1  
NAE: N-acylethanolamine 
NAPE: N-acylphosphatidylethanolamine 
NFAT: Nuclear factor of activated T-cells 
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NMDA: N-methyl-D-aspartate 
NMDAR: N-methyl-D-aspartate receptor 
NO: Nitric oxide 
PA: Phosphatidic acid 
PD: Parkinson´s disease 
PDE: Phosphodiesterase  
PI3K: Phosphatidylinositol 3-kinase 
PIP2: Phosphatidylinositol 4,5-bisphosphate 
PKA: Protein kinase A 
PKC: Protein kinase C 
PKD: Protein kinase D 
PLA2: Phospholipase A2 
PLC: Phospholipase C 
PLD: Phospholipase D 
polyQ: Polyglutamine 
PP1: Protein phosphatase 1 
PP2A: Protein phosphatase 2A 
PPAR: Peroxisome proliferator-activated receptors 
PSD-95: Postsynaptic density protein of 95 kDa 
PT: Pyramidal tract 
RasGRP: Ras guanyl nucleotide-releasing protein  
ROCK: Rho-associated protein kinase 
SNc: Substantia nigra pars compacta 
SNr: Substantia nigra pars reticulata 
STN: Subthalamic nucleus  
SP: Substance P 
Str: Striatum 
THC: Δ9-Tetrahydrocannabinol 
TNFα: Tumor necrosis factor-α 
TRPV1: Transient receptor potential cation channel subfamily V member I 
VGCC: Voltage-gated Ca2+ channel 
WT: Wild-type 
wtHtt: Wild-type huntingtin 
YAC: Yeast artificial chromosome 
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CORTICOSTRIATAL CIRCUITRY 
 
The corticostriatal circuitry includes the functional 
loop between the cortex (Cx), basal ganglia (BG) and 
thalamus, and is an integrative centre for numerous 
cognitive processes and motor functions, such as 
action selection, motor coordination, sequential 
learning and habituation (Shepherd 2013). 
 
The striatum is the main entry to the BG circuitry, and 
receives excitatory input from the cortex and the 
thalamus, as well as dense innervation from 
mesencefalic dopaminergic neurons, mainly from the 
substantia nigra pars compacta (SNc). The vast 
majority (~95%) of neurons within the striatum are 
GABAergic medium spiny neurons (MSNs), which are 
topographically connected to the cortical surface and 
project directly (“direct pathway”) or indirectly 
(“indirect pathway”), through the external segment 
of the globus pallidus (GPe) and through the 
subthalamic nucleus (STN), to the basal ganglia output 
nuclei, including the internal segment of the globus 
pallidus (GPi) and the substantia nigra pars reticulata 
(SNr) (Grillner et al. 2005) (Figure 1). 
 
MSNs received their name owing to its morphology, 
characterized by a soma of approximately 12-20 μm in 
diameter, from which around 7-10 dendrites 
moderately branched and densely covered with thorns 
radiate. They also have a collateral axon that projects 
within the striatum, in addition to their projecting axon 
(DiFiglia et al. 1976). These neurons are divided into 
two populations, represented in approximately the 
same proportion, according to their direct or indirect 
connection with the projection nuclei of the BG, and 
although physically intermingled and morphologically 
indistinguishable, they can be differentiated by some 
specific markers. Thus, the direct pathway is formed 
by MSNs expressing dopamine D1 receptor (D1R-
MSNs), substance P (SP), and dynorphin, while the 
indirect pathway is composed of MSNs expressing 
dopamine D2 receptor (D2R-MSNs), adenosine A2A 
receptor (A2AR), and encephalin (ENK) (Gerfen & 
Young 1988; Bäckman et al. 2003) (Figure 1). 
 
D2R-MSNs are more excitable than D1R-MSNs as, at 
similar current intensities they fire more action 
potentials (Kreitzer & Malenka 2007), and have smaller 
dendritic surface area and bigger axospinous 
asymmetric corticostriatal terminals (Lei et al. 2004). 
In addition, D2R-MSNs display a higher frequency of 
spontaneous excitatory postsynaptic currents and a 
unique pattern of large-amplitude excitatory events, 
all of which supports the idea that D2R-MSNs may be 
intrinsically more susceptible to damaging excitatory 
inputs (Kreitzer & Malenka 2008). 
 
A 
 
B 
Figure 1. The striatal medium spiny projection neuron. A. 
Striatum. A´. High magnification of a medium spiny neuron. B. 
Diagram of the direct and indirect pathway neurons. Both neurons 
are GABAergic and receive glutamatergic corticostriatal inputs. 
Direct pathway neurons express the D1 receptor, the stimulatory 
Gs/olf G-proteins, as well as the neuropeptides substance P (SP) 
and dynorphin (DYN). These neurons project to the GPe, GPi and 
SNr. Indirect pathway neurons express the D2 receptor, the A2A 
adenosine receptor, and the neuropeptide ENK. The D2 receptor is 
coupled to the inhibitory Gi-protein, while the A2A receptor is 
coupled to the stimulatory Gs/olf G-protein. Adapted from Gerfen 
& Bolam 2010. 
 
Much fewer in number, but not necessarily in 
functional relevance, are the interneurons, which 
account for the remaining 5% of striatal neurons. The 
striatum is essentially composed of one type of large 
cholinergic interneurons, and three types of 
neurochemically and electrophysiologically distinct 
GABAergic interneurons: medium-sized 
GABA/parvalbumin interneurons (also known as fast-
spiking interneurons), GABA/calretinin interneurons, 
and somatostatin/neuropeptide Y/nitric oxide 
synthase/ GABA interneurons. GABAergic 
interneurons play a predominant role in regulating 
spike timing in the spiny output neurons through 
feedforward inhibition, while cholinergic interneurons 
discharge tonically. All striatal interneurons are aspiny 
in comparison to the striatal spiny projection neurons 
(Goldberg & Wilson 2010; Tepper 2010). 
 
The three major types of glial cells present in the 
central nervous system (CNS), namely astrocytes, 
oligodendrocytes, and microglia, also reside within 
the striatum. All these types are key players for the 
functional fine tuning within the circuitry. Particularly, 
astrocytes have been shown to couple their activity to 
a specific subset of neurons belonging to the direct or 
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indirect pathway, and they subsequently respond 
attempting for balance between both networks 
(Martín et al. 2015). 
 
Alterations at any level of the corticostriatal and BG 
circuitry can give rise to pathophysiological changes 
that are characteristic of many neurological diseases, 
including Huntington´s disease (HD), Parkinson’s 
disease (PD), schizophrenia, obsessive-compulsive 
disorder, autistic spectrum disorder and other 
pathologies. 
 
THE DIRECT AND INDIRECT PATHWAYS 
 
The striatum act as an integrative node where MSN’s 
information depends on cortical and thalamic inputs. 
Cortical neurons providing striatal inputs are located in 
several cortical areas including sensory, motor, and 
association regions. The connection is bilateral, with 
an ipsilateral predominance, and it is thought to 
provide the striatum with the sensory and motor 
planning information it needs to execute its role in 
motor control. The topographic organization of 
corticostriatal projections was embodied in the 
concept of functional regions within the striatum 
being dependent on the cortical origin of inputs to 
these regions (Alexander et al. 1986). Thus, dorsal 
regions of the striatum receiving inputs from premotor 
and motor cortical areas are characterized as “motor” 
regions of the striatum, whereas more ventral regions 
receiving inputs from limbic cortical areas are 
characterized as “limbic”. Corticostriatal neurons are 
divided in two types of cortical excitatory neurons: 
intratelencephalic (IT) neurons, which project 
ipsilaterally or bilaterally (via the external capsule and 
corpus callosum) within the telencephalon (cortex and 
striatum) and can be found in layers II–VI of the cortex, 
and pyramidal tract (PT) neurons, which are 
restricted to deep layer V, projecting to the brainstem 
and in some cases also to the spinal cord (via the 
internal capsule, cerebral peduncle and pyramidal 
tract), and extend branches to the ipsilateral cortex 
and numerous subcortical regions including the 
striatum.(Shepherd 2013). 
 
The cortical excitatory input to the striatum functions 
as a dysinhibitory mechanism. Thus, activation of 
D1R-MSNs by excitatory input from the cortex results 
in inhibition of the tonic inhibitory output of the basal 
ganglia, resulting in locomotor activation/movements. 
On the contrary, the main target of D2R-MSNs are 
GABAergic neurons in the GPe, which project to the 
output neurons of the basal ganglia and to the STN. 
Thus, cortical excitation of the indirect pathway 
inhibits the GPe, resulting in dysinhibition of the 
output neurons of the basal ganglia and the STN, thus 
decreasing movement (Gerfen & Bolam 2010) (Figure 
2). This classical model, however, entails a 
simplification of one of the most hyper-connected 
areas within the CNS, and the specific functional 
outputs from interactions between each of its 
components are still unknown. Nonetheless, it is well 
accepted that, in general terms, the activity of the 
direct and indirect striatal pathways provides 
counterbalanced or antagonistic regulation of BG 
output, and this activity switch plays a central role in 
motor control and action initiation (Donahue & 
Kreitzer 2015). 
 
 
 
Figure 2 Direct and indirect pathways. A.The direct and indirect 
striatal projection pathways arise from D1R-MSNs and D2R-MSNs, 
respectively. D1R-MSNs, providing an axon with collaterals to the 
GPe, project to the GPi and SNr output nuclei. D2R-MSNs are 
indirectly connected to the GPi and SNr through connections that 
involve the GPe and the STN. B. Sagittal slices from a BAC 
transgenic mouse expressing GFP under the control of genomic 
regulatory elements for the dopamine D2 receptor (D2-GFP), or 
the muscarinic M4 receptor (M4-GFP), which labels indirect- and 
direct pathway MSNs, respectively. Adapted from Kreitzer & 
Malenka 2008; Gerfen &Bolam 2010. 
  
To complicate things further, dopaminergic neurons 
projecting from SNc modulate the activity of both 
pathways by means of D1R-MSNs and D2R-MSNs. 
A 
B 
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Dopamine signalling trough D1R and D2Rhas opposite 
cellular consequences, since it engages stimulatory 
Gαs/olf or inhibitory Gαi/o proteins, respectively 
(Bronson & Konradi 2010; Surmeier et al. 2007), but in 
both cases it ultimately enhances movement (Albin et 
al. 1989). By modulating these two MSN populations, 
dopamine is believed to regulate not only ongoing 
choices about what to do and what not to do, but also 
to lay down a memory of the consequences of those 
choices that helps guide future behaviour (Freeze et al. 
2013). 
 
Most previous data on the two MSNs populations are 
based on the use of dopamine receptor knockout 
mice, pharmacology treatments and selective 
expression of toxins that generate cell-type-specific 
lesions or inactivation (Kreitzer & Berke 2011). The 
difficulty to distinguish between the two MSN 
populations has been largely overcome in the past 
years by the development of BAC transgenic mice, 
using either D1R or M4 lines to identify direct-pathway 
MSNs, and D2R or A2AR lines to identify indirect-
pathway MSNs (Gong et al. 2007). Experiments based 
on these lines have revealed that D1R-MSNs and D2R-
MSNs actually exhibit significant differences in 
dendritic morphology (Gertler et al. 2008), excitability 
(Kreitzer & Malenka 2007), gene expression (Gerfen & 
Young 1988), response to local GABAergic input, and 
mechanisms of plasticity (Kreitzer & Malenka 2007).  
 
One example of such studies is the neuronal 
expression of long-term depression (LTD) and long-
term potentiation (LTP) processes. MSNs show 
characteristic shifts of membrane potential between 
two preferred levels, one that is more polarized, so-
called the down-state (varying from -94 to -61 mV), 
and another one that is more depolarized, so-called 
the up-state (varying from -71 to -40 mV), triggered by 
increased activity of many convergent corticostriatal 
neurons (Wilson & Kawaguchi 1996). Manipulation of 
excitability of MSNs, considering these two levels, can 
trigger striatal LTP or LTD. LTD has been shown to be 
D2R-dependent (Kreitzer & Malenka 2007) but, 
although still a matter of debate, instead of being a 
D2R-MSN-specific process, it seems to be present at 
both types of MSNs depending on the stimulation 
protocol used, and maybe involving a cholinergic 
interneuron-mediated mechanism in the case of D1R-
MSNs (Wang et al. 2006; Bagetta et al. 2011). On the 
other hand, D1R has been implicated in striatal LTP (Di 
Filippo & Calabresi 2010). However, it has also been 
described that LTP could be elicited at both D1R-
MSNs and D2R-MSNs, being dopamine-independent 
in D2R-MSNs, which required A2A receptors instead 
(Shen et al. 2008). Together, these distinct properties 
are believed to endow each MSN population with 
unique functions within the BG network. 
In addition, optogenetics has provided a valuable tool 
for dissecting direct and indirect corticostriatal 
pathway functional output (Kreitzer & Berke 2011). 
This has unveiled that, according to the BG classical 
model, excitation of D1R and D2R-MSNs acts in a 
bidirectional way on locomotion. For example, it has 
been shown how bilateral excitation of indirect 
pathway MSNs elicited a parkinsonian-like state, 
characterized by freezing, bradykinesia and decreased 
locomotor initiation, while activation of direct 
pathway MSNs reduced freezing and increased 
locomotion (Kravitz et al. 2010) In addition, by 
manipulating direct and indirect striatal pathways, it 
was reported that both, goal-directed learning, which 
depends on reward outcome, and habit formation, 
are totally dependent on striatal function. In this 
context, activation of direct-pathway circuits has been 
proposed to facilitate or select appropriate 
movements, whereas activation of the indirect 
pathway may inhibit unwanted or inappropriate 
movements (Kreitzer & Malenka 2008). Interestly, 
recent data support that activation of both direct and 
indirect pathways occurs during action initiation (Cui 
et al. 2013). Actually, the two MSN populations are 
involved in a different way during sensorimotor 
processing and goal-directed behaviour (Sippy et al. 
2015; Lee et al. 2016). 
Figure. 3. Designer Receptors Exclusively Activated by Designer 
Drug (DREADDs) with their pharmacologically inert ligand 
clozapine-N-oxide (CNO) and G protein-coupling properties. 
hM3Dq and hM4Di are point-mutated human M3 and M4 
muscarinic DREADDs, coupled to Gq and Gi signalling, 
respectively. rM3Ds consists of a chimeric point-mutated rat M3 
muscarinic DREADD with intracellular loops from the turkey β1-
adenoceptor, coupled to Gs signalling. CNO stimulation of hM3Dq 
and hM3Ds activates neurons. CNO stimulation of hM4Di inhibits 
neurons. Adapted from Sizemore et al. 2016. 
 
Another recently developed tool, the designer 
receptors exclusively activated by designer drugs 
(DREADDs) (Figure 3), has been applied for assessing 
the remote control of neuronal activity (Rogan & Roth 
2011). This chemogenetic method is based on the 
expression of engineered G protein-coupled 
receptors (GPCRs) that are selectively and potently 
activated by systemically bioavailable, brain-
penetrant and otherwise pharmacologically inert 
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ligands such as clozapine-N-oxide (CNO) (Armbruster 
et al. 2007). DREADDs have no detectable constitutive 
activity and, by using conserved and canonical GPCR-
dependent signalling pathways, allow a 
spatiotemporally-selective and physiological 
manipulation of them. Moreover, since G protein-
coupled receptor pathways are involved in a multitude 
of CNS disorders, their manipulation both illuminates 
disease processes and identifies potential avenues of 
treatment.  
 
The DREADD technology is broadly used in 
neurosciences (Wess et al. 2013). Specifically in the 
striatum, expression of hM4Di (Gi-coupled DREADD), 
the most commonly used inhibitory DREADD, drives 
synaptic plasticity (Kozorovitskiy et al. 2012), and 
modulated amphetamine sensitization in a MSN-type 
specific way (Ferguson et al. 2011). On the other hand, 
activation of MSNs through hM3Ds (Gs-coupled 
DREADD) has been also performed in the context of 
decision-making (Ferguson et al. 2013) and locomotor 
behaviour (Farrell et al. 2013). The first report that 
CNO-induced activation of hM3Dq depolarized and 
excited genetically defined neurons appeared in 2009 
(Alexander et al. 2010). Since then, hM3Dq has been 
widely used to enhance neuronal firing, modulating 
processes as locomotion and striatal synaptogenesis 
(Kozorovitskiy et al. 2012). Because hM3Dq activation 
induces intracellular Ca2+ release, it has also been used 
to ‘‘activate’’ astrocytes (Bang et al. 2016), and iPS-
derived neuroblasts (Dell’Anno et al. 2014) (Figure 3). 
 
GPCRs AND STRIATAL CELL FUNCTION 
 
Metabotropic signalling is absolutely necessary for the 
proper functioning of the striatum, and many 
neurotransmitters/neuromodulators such as 
dopamine, glutamate, adenosine, acetylcholine and 
endocannabinoids control the activity and plasticity of 
MSNs by engaging various members of the GPCR 
superfamily. GPCRs are integral membrane proteins 
that mediate signals from, for example, 
neurotransmitters, hormones, neuropeptides and 
cytokines. They can be divided into three families. 
Family 1 is the largest and contains the majority of 
GPCRs, including opioid, muscarinic, adenosine, 
cannabinoid, dopamine, somatostatin and tachykinin 
receptors, amongst others. Family 2 includes a 
number of peptide hormones and is not significantly 
represented in the BG. Family 3 is a small family but 
includes the metabotropic glutamate and GABA 
receptors, which are of considerable importance in the 
BG (Emson et al. 2010). All GPCRs contain seven 
transmembrane domains and derive their name from 
the interaction with intracellular heterotrimeric G 
proteins, Gαβγ. Upon activation by GPCRs, G proteins 
exchange GDP for GTP, causing dissociation of the Gα 
subunit from the Gβγ subunit, and subsequent 
initiation of a plethora of internal signalling pathways 
(Bronson & Konradi 2010) (Figure 4).There are four 
families of Gα subunits, three of them, Gi/o, Gs/olf and 
Gq/11, are majorly involved in BG receptor signalling. 
The Gi/o family is usually termed inhibitory as these G 
proteins inhibit adenylyl cyclases (ACs) (Figure 4) and 
are sensitive to pertussis toxin ribosylation, which 
prevents them from being aactivated by GPCRs. Apart 
from ACs, Gi also inhibits Ca2+ channels, activates 
mitogen-activated protein kinases (MAPKs) and can 
interact with other signalling pathways. Members of 
the Gs family, which includes Golf very abundantly in 
MSNs, all stimulate ACs (Figure 4), but can also 
activate tyrosine kinases (Gs) or phosphoinositide 
turnover (Golf). Members of the Gq/11 family 
stimulate, among several effectors, the various 
phospholipase Cβ (PLCβ) isoforms (Figure 4) 
(Bronson & Konradi 2010). 
 
Among the different GPCR effectors, AC and its 
product, cyclic AMP (cAMP), are highly relevant in 
MSN function. D1R as well as A2AR upregulate cAMP 
production through Gαs/olf proteins. Such elevation 
on cAMP can triggers multiple signalling pathways, 
such as protein kinase A (PKA), extracellular signal-
regulated kinase (ERK) and cAMP response element-
binding protein (CREB) (Girault, 2012; Cahill et al., 
2014). Other striatal receptors, such a D2R, groups 2 
and 3 of metabotropic glutamate receptors (mGluRs), 
opioid receptors, cannabinoid receptors (CBRs), and 
muscarinic acetylcholine M2/4 receptors (mAChRs), 
inhibit AC activity trough Gαi, opposing Gαs/olf action 
and promoting hyperpolarization of the plasma 
membrane by inhibiting Na+ and Ca2+ channels, while 
opening K+ channels (Surmeier et al. 2007). 
 
Gq-coupled receptors, such as metabotropic 
glutamate mGlu1/5 receptors (mGluR1/5) and 
muscarinic acetylcholine M1/3/5 receptors, are also 
very important in the control of MSN excitability, and 
an overactive Gq protein-driven signalling has been 
shown to occur in various models of BG-related 
diseases such as Huntington’s disease and drug 
addiction (Conn et al. 2005; Kreitzer 2009; Cahill et al. 
2014).. Gαq/11 activates PLCβ, which converts 
phosphatidylinositol-4,5-bisphosphate into 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate 
(IP3). The most prominent target of DAG is the protein 
kinase C (PKC) family of Ser/Thr kinases (Figure 4). 
However, a number of alternative targets with PKC 
homology domains exist as well. These include protein 
kinase D (PKD), diacylglycerol kinase (DGK), Ras 
guanyl nucleotide-releasing protein (RasGRP), 
chimaerins, and mammalian uncoordinated13 
(Munc13).
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Figure 4. GPCR signalling pathways in the striatum. Scheme of the principal downstream effectors of GPCR activation in the striatum. After 
binding of the ligand to the GPCR, the Gβγ subunits dissociate from the Gα. Depending on the Gα subtype, different downstream pathways 
are activated. Gβγ subunits also trigger several cascade activation. Accumulation of cAMP can further stimulate HCNs and cation influx from 
extracellular space. PDE; phosphodiesterase, PP1/PP2A; protein phosphatase 1/ protein phosphatase 2, AC5; adenilato cyclase 5, HCN; 
hyperpolarization-activated cyclic nucleotide–gated channels. Adapted from Bronson & Konradi 2010. 
 
 
IP3, the second metabolite of phosphatidylinositol-
4,5-bisphosphate hydrolysis, enhances Ca2+ release 
from the endoplasmic reticulum through its 
interaction with IP3 receptors (IP3R) (Bronson & 
Konradi 2010). 
 
The cytosolic rise in free Ca2+, due to the influx from 
internal storages or from external sources upon 
activation of voltage-gated Ca2+ channels (VGCCs) or 
ligand-gated ion channels (such as NMDA and AMPA 
receptors), can activate a number of signal 
transduction pathways, including the cAMP/PKA 
pathway, the Ca2+/calmodulin (CaM) / CaM kinase 
(CaMK) pathways, and the MAPK pathways. Known 
MAPK pathways include ERK1 and 2, c-Jun N-terminal 
kinase (JNK) 1, 2 and 3, p38 MAP kinases α, β, γ and 
δ, and ERK5. MAPKs such as ERK1/2 can translocate 
to the nucleus, where they phosphorylate/activate 
downstream kinases and transcription factors such as 
CREB, c-Jun, c-Fos and others (Bronson & Konradi 
2010).  
 
The Gβγ dimeric subunit also participates in signal 
transduction pathways. First, it is required for Gα-
mediated nucleotide exchange and for the inactivation 
of Gα subunits, but, in addition, it triggers various 
downstream cascades. Some examples, that have an 
important physiological role, include the inwardly-
rectifying K+ channels, GPCR kinase 2 (GRK2), N-type 
and P/Q type Ca2+ channels, phosphatidylinositol 3-
kinase (PI3K), phospholipase A2 (PLA2), PLCβ, and 
ACs (Figure 4). On the presynaptic side, the Gβγ 
subunit can affect Ca2+ channel-mediated 
neurotransmitter release. It can directly bind to 
presynaptic Ca2+ channels and reduce the sensitivity to 
membrane depolarization Moreover, it has a direct 
inhibitory effect on the transmitter release machinery 
by binding to proteins of the SNARE complex. Finally, 
there is some indication that Gβγ might translocate to 
the cell nucleus, where it interacts with transcription 
factors and histone-modifying enzymes (Bronson & 
Konradi 2010). 
 
Then, several molecules share common upstream 
activators, and the regulation of their activity can be 
triggered by different GPCR-related signalling 
pathways. For example, although activation of the 
ERK pathway in the striatum can be readily achieved 
by D1R and ionotropic (NMDAR) glutamate receptors, 
being a Gαs/olf-coupled protein and a Ca2+ permeable 
ion channel, respectively, mGluR1/5, which interact 
with Gq/11 proteins, also activates this pathway in 
synergy with D1R, thereby engaging, for example, 
drug-induced behavioural plasticity (Girault 2012).  
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In addition to interacting trough downstream 
signalling molecules, GPCRs in the striatum can also 
interact between each other, thus forming 
heteromers. One example is the A2AR-D2R complex, 
which couples to Gαq/11, thus opposing the activity of 
D2R alone. In that respect, it has been proposed that a 
GTPase-activating protein called regulator of G-
protein signalling 4 (RGS4), links D2R and A2AR 
signalling to group I mGluR signalling, thus modulating 
endocannabinoid  production by D2R-MSNs (Lerner & 
Kreitzer 2012). Furthermore, although it is well 
established that D1R and D2R are segregated in the 
adult striatum (Bäckman et al. 2003), in areas where 
they are co-expressed they can form hetero-oligomers 
that couple to Gαq/11 (Rashid et al. 2007). Very 
recently, heteromeric complexes of A2AR-CB1R have 
been fully characterized in the dorsal striatum. 
Coupling of these receptor heteromers to Gq proteins 
is found in D2R-MSNs, which leads to a decrease in the 
downstream signalling of both components, a process 
that becomes dysfunctional in HD (Moreno et al. 2017).  
 
Hence, since there are multiple signalling possibilities 
inside one single striatal cell, integration of signalling 
properties from different G proteins plays a pivotal 
role in determining how the cell responds to multiple 
neurotransmitters that are active in BG. Imbalance in 
this fine modulatory network sets at the basis of 
several motor dysfunctions, and determines 
progression of BG neurodegenerative diseases. 
 
STRIATAL CELL DISFUNCTION AND MOTOR 
DISORDERS 
 
A large number of molecular and cellular mechanisms 
that lead to the degeneration of MSNs has been 
defined in preclinical models of striatal damage 
(Mitchell & Griffiths 2003; Han et al. 2010; Rikani et al. 
2014). However, a still unsolved and intriguing aspect 
of neuronal death, not only in the corticostriatal 
circuitry but also in other brain areas affected by 
neurodegenerative diseases, is the identification of 
the precise molecular factors that determine the 
differential susceptibility of neuronal types.  
 
Movement disorders, in general, result from or are 
coupled to an imbalanced activity of the direct and 
indirect striatal pathways. For example, in PD, which is 
marked by akinesia, the loss of dopaminergic input to 
the striatum, as a consequence of degeneration of the 
nigrostriatal dopamine system, has opposite effects 
on the direct and indirect pathways, with increased 
function of the indirect pathway and decreased 
function of the direct pathway (Gerfen 2010). As 
mentioned above, MSNs have some differences in 
morphology, molecular composition and 
electrophysiological properties and, therefore, it is 
conceivable that they have unequal responses against 
neurotoxic insults. For example, different signalling 
mechanisms in D1R-MSNs and D2R-MSNs occur in L-
DOPA-induced dyskinesia, a major complication of 
the treatment of Parkinson’s disease. which depends 
on both increased D1R–ERK signalling pathway in 
D1R-MSNs neurons and altered Ca2+ signalling in D2R-
MSNs neurons (Valjent et al. 2009). 
 
Particularly, in HD, in which the neurodegenerative 
process originates primarily from the cortex and 
striatum (Vonsattel & DiFiglia 1998), there is abundant 
evidence supporting that dissimilar alterations in the 
two MSN populations occur at different stages of 
disease progression. Over the years, a great number of 
HD models has been developed (Box 1). This, together 
with the emergence of highly efficient viral vectors for 
mutant huntingtin (mtHtt; the main protein linked to 
HD) delivery in the CNS, has thrown light on several 
aspects of corticostriatal dysfunction and clinical 
targets. Specifically, the viral vector approach offers 
some advantages over genetic mice models, as a local 
and massive overexpression of the disease gene, a 
rapid and highly flexible in vivo paradigm to study 
impact of mtHtt expression, and the possibility to 
avoid the emergence of compensatory mechanism by 
viral infection in adult animals. Notably, the 
implementation of viral vectors with cell-specific 
promoters is particularly suited for dissecting the 
contribution of each component, within the circuitry, 
to the pathogenic process (Ruiz & Déglon 2012). 
Although huntingtin (Htt) is ubiquitously expressed, 
its mutant form (mtHtt) causes differential cell toxicity 
throughout the brain. Htt is a large protein of 348kDa 
that is subject to multiple transcriptional and post-
transcriptional modifications, and it is involved in 
many cellular functions, from regulation of 
transcriptional activity to mitochondrial dynamics, 
vesicular trafficking or autophagy, to mention just a 
few. The pathogenic mechanisms of mtHtt have been 
largely described in the literature, and entail both loss 
and gain of protein function (Saudou & Humbert 
2016). In addition to cell-autonomous effects, 
neurodegenerative progression in HD is also 
dependent on non-cell-autonomous processes. 
Among neuronal subtypes, the MSN receives the most 
massive combination of glutamatergic and 
dopaminergic input, which favours their increased 
vulnerability to damage. In fact, there are differential 
and complex imbalances in glutamate and dopamine 
modulation on D1R-MSNs and D2R-MSNs during HD 
progression (André et al. 2011). 
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BOX1. MODELLING HD 
HD represents a prototypal model of a monogenic, fully penetrant neurodegenerative disorder characterized by an 
accumulation of misfolded proteins. Since the cloning of the HTT gene and identification of the mutation as a CAG 
expansion in the region that encodes the N-terminal part of the protein, a plethora of HD models have been developed.  
CELLULAR MODELS 
Cell lines offer a valuable tool for biochemical studies and are particularly suitable for transient, stable or inducible 
expression strategies. On the other hand, primary neurons or mixed cultures reproduce some cell–cell interactions, 
though not all the complexities of neuronal circuits, and these cultures have been extensively used to study disease 
pathogenesis and therapeutic screening. It can be mentioned a number of in vitro models:  
1) Neuron-like cell lines expressing mtHtt with various length polyQ expansions (Lunkes & Mandel 1998).  
2) Primary neurons derived from transgenic HD mouse models (Petersén A et al. 2001)  
3) Striatal cells isolated from HTT knock-in mice (Trettel et al. 2000) 
4) Induced pluripotent stem cells derived from HD patients (Park et al. 2008) 
ANIMAL MODELS 
In vivo models, although presenting differences among each other and none of them recapitulating completely human 
HD, have been the most powerful approach to characterize some of the key pathological features of the disease. Some 
examples are the following: 
# Fragment transgenic models 
R6/2 mice (exon 1 around 150 CAG repeats)  
Very aggressive, rapidly progressing phenotype, similar to the juvenile form of HD. 
Overt behavioural symptoms as early as 4-5 weeks of age, die at about 15 weeks.  
Alterations include nuclear inclusions (Davies et al. 1997), changes in neurotransmitter receptor expression (Cha et al. 
1998; Ariano et al. 2002) and altered signalling mechanisms (Bibb et al. 2000; Luthi-Carter et al. 2000)  
Motor (Carter et al. 1999) and learning deficits (Lione et al. 1999), as well as deficits in synaptic plasticity in the striatum 
of symptomatic animals (Raymond et al. 2011).  
R6/1 mice (exon 1 around 110 CAG repeats) 
Decreased mtHtt expression compared to R6/2 mice. 
Similar phenotypic alterations as R6/2 but in a longer-term manner (Mangiarini et al. 1996).  
Aberrant synaptic plasticity (Milnerwood et al. 2006). 
ROSA-HD Cre/LoxP conditional mice (exon 1 with 103 CAG repeats)(Gu et al. 2005) 
Cre dependent mtHtt expression in cortical pyramidal neurons and glia or all neural cells. 
Cell-autonomous mHtt aggregation. 
Progressive motor deficits and cortical neuropathology only observed when mtHtt expression is in multiple neuronal 
types. 
GFAP-HD (208 aa of N-term with 106 polyQ) (Bradford et al. 2009) 
Body weight loss, motor function deficits, and die earlier than wild-type mice. 
mtHtt aggregation and gliosis, but not neuronal death. 
Decreased expression of the glutamate transporter GLT-1. 
# Full-length transgenic models 
Yeast artificial chromosome (YAC) expressing normal (YAC18) and mutant (YAC46, YAC72, and YAC128) full-length 
human Htt (Van Raamsdonk et al. 2007; Slow et al. 2003). They are named after the size of the polyQ repeat. 
Bacterial artificial chromosome (BACHD) expressing full-length human mHtt with 97 polyQ (Gray et al. 2008). It is a 
conditional model, with loxP sites flanking mtHTT exon 1 with the polyQ repeat, and hence its expression can be 
genetically reduced in Cre-expressing cell lineages. Using this advantage it has been described, for example: 
Reduction of cortical mtHtt expression improves striatal activity and behavioural deficits but does not improve 
neurodegeneration (Wang, Gray, X.-H. Lu, et al. 2014; Estrada-Sanchez et al. 2015). 
Reduction of mtHtt expression in cortical and MSNs populations consistently ameliorates all behavioural deficits and 
selective brain atrophy (Wang, Gray, X.-H. Lu, et al. 2014). 
Although with some differences, full-length models demonstrate slowly progressive but relatively robust motor 
dysfunction, psychiatric-related behaviours and cognitive deficits, and selective atrophy in the striatum and cortex (Lee 
et al. 2013). 
# Knock-in models 
They express full-length mtHTT in its native genomic context. Several models differing mainly in the number of CAG 
repeats (from 48 to 200) have been generated (Levine et al. 1999; Trettel et al. 2000).They show behavioural 
abnormalities after one year of age, but present micro-aggregates very early in the course of the disease. Nuclear 
inclusions are observed only in older mice (10–18 months), and loss of MSNs occurs at about 2 years (Cepeda et al. 2010).
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Classically, D2R-MSNs have been considered more 
vulnerable and the first to become dysfunctional in 
HD. Several lines of evidence from both HD genetic 
mouse models and postmortem brain samples from 
HD patients show a preferential loss of D2R-MSNs 
markers (Reiner et al. 1988; Ariano et al. 2002; Walker 
2007). Disruption of D2R signalling, for example, is 
associated with alterations in the GSK3β pathway, 
triggering, for example, an impairment of the 
elimination of mtHtt aggregates through the 
ubiquitin-proteasome system (Rangel-Barajas & 
Rebec 2016b). In terms of motor symptoms, their 
preferential loss is believed to reduce the amount of 
inhibitory control over unwanted movements, leading 
to the chorea and hyperkinesia typically associated 
with HD (Walker, 2007).  
 
Figure 5. Representation of glutamate, GABA, and dopamine 
projections onto D1R-MSNs and D2R-MSNs in HD. In WT mice 
(left), DA released by nigrostriatal inputs activates glutamate and 
GABA release onto D1R-MSNs while it decreases glutamate and 
GABA release onto D2R-MSNs. In early HD (middle), increased DA 
transmission leads to increased release of glutamate and GABA 
onto D1R-MSNs. There is no change onto D2R-MSNs, suggesting 
that it might occur at different time points or involve other 
mechanisms. In late HD (right), D1R-MSNs display decreases in 
glutamate transmission, presumably due to loss of corticostriatal 
inputs and/ or decreased DA transmission. In contrast, D2R-MSNs 
display only a small decrease in glutamate synaptic inputs while 
GABA synaptic transmission is increased, probably through altered 
D2R function. Adapted from André, Cepeda, et al. 2011.  
 
On the other hand, there is also data indicating that an 
early dysfunction of D1R-MSNs also occurs in HD 
patients (Hedreen & Folstein 1995), and genetic 
mouse models (André et al. 2011; Raymond et al. 
2012). Thus, D1R signalling has been shown to be 
increased in pre-symptomatic HD mouse models, 
while its expression is decreased at symptomatic 
stages. The ERK signalling pathway, which is directly 
modulated by D1R, is altered in HD, and favours 
transcriptional dysregulation trough CREB, which, in 
turn, can accelerate the formation of mtHtt nuclear 
aggregates (Rangel-Barajas & Rebec 2016). These 
findings are also in line with a number of studies 
showing that D1R activation enhances NMDAR-
evoked excitotoxic signalling on MSNs, while D2R 
activation usually reduces NMDA receptor-dependent 
responses (Cepeda & Levine 1998). In fact, D1R 
engagement has been shown to potentiate 
glutamate-evoked excitotoxic signalling to provoke 
the death of MSNs (Figure 5) (Cepeda & Levine 1998; 
Tang et al. 2007; Paoletti et al. 2008). 
 
Additional evidence suggests that altered cellular and 
synaptic properties may result in aberrant 
overexcitation and eventual glutamate excitotoxicity 
(Levine et al. 1999). A particular point of view is that, 
although the loss of MSNs has an obvious role in the 
symptoms of HD, the onset and progression of the 
behavioural phenotype is rather caused by 
dysfunctional corticostriatal activity, which precedes 
cell death (Cepeda et al. 2007; Rangel-Barajas &. 
Rebec 2016). In fact, both cortical pyramidal neurons 
and MSNs show impaired electrophysiological 
properties along with HD-related motor deficits (Miller 
et al. 2008) Mice that model HD, for example, show 
behavioural symptoms long before significant cell loss. 
Moreover, these performance changes are 
accompanied by shifts in the intrinsic properties of 
MSNs. When studied in vitro, MSNs show exaggerated 
glutamate-dependent responses, more depolarized 
resting membrane potentials, reductions in both 
inwardly and outwardly rectifying K+ currents, 
increased input resistance, and increased intracellular 
Ca2+ levels (Miller et al. 2008). 
 
Changes in the glutamatergic system overlap with the 
functional alterations observed in astrocytes from HD 
patients and mouse models (Shin et al. 2005; Faideau 
et al. 2010; Jiang et al. 2016). Astrocytes are the main 
responsible cells for glutamate clearance from the 
synaptic cleft. In HD, their specific glutamate 
transporter GLT-1 is downregulated at  very early 
stages of the neurodegenerative process (Liévens et 
al. 2001; Jiang et al. 2016). In addition, recent work in 
an HD mouse model has shown that astrocytes 
downregulate the expression of a key K+ channel 
(Kir4.1), resulting in an elevation in extracellular K+ 
concentration. This rise in extracellular K+ would 
depolarize MSNs and make them more vulnerable to 
NMDAR-evoked excitotoxicity (Tong et al. 2014).This 
strong exposure to glutamate excitotoxicity may be 
counteracted by some presynaptic receptors, located 
on corticostriatal terminals, such as group II 
metabotropic glutamate (mGluR2 and mGluR3), 
GABAB (GABABR), cannabinoid (CB1R), and 
adenosine (A1R) receptors (Cepeda et al. 2010). Any 
functional alteration in cortical pyramidal neurons, or 
in the receptors on its corticostriatal terminals, can be 
critical for the impairment and neurodegeneration of 
the whole corticostriatal circuitry. 
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THE (ENDO)CANNABINOID SYSTEM 
 
CANNABINOID RECEPTORS 
 
The hemp plant (Cannabis sativa L.) and its 
derivatives have been used in medicine for at least 50 
centuries. However, the chemical structure of their 
active components (the cannabinoids) was not 
elucidated until the early 1960s (Gaoni & Mechoulam 
1964), when the principal component of marihuana in 
terms of abundance and potency, Δ9-
tetrahydrocannabinol (THC), was isolated from the 
plant. Around 30 years later, the first receptor of these 
molecules was cloned from rat cerebral cortex 
(Matsuda et al. 1990), human brain and testis (Gérard 
et al. 1991), and mouse brain (Chakrabarti et al. 1995), 
and termed as cannabinoid receptor 1 (CB1R). 
Shortly after, a second cannabinoid receptor was 
identified in rat (Munro et al. 1993), and mouse (Shire 
et al. 1996), and named cannabinoid receptor 2 
(CB2R). Finally, the crystal structure of CB1R  has been 
obtained very recently (Hua et al. 2016; Shao et al. 
2016) (Figure 6), which opens a new and promising  
opportunity for understanding the biochemistry of 
these molecules. 
 
Figure 6. Crystal structure of the CB1R-AM6538 complex. A side 
view of the CB1R-AM6538 complex. The receptor is shown in grey 
cartoon representation. The ligand AM6538, shown with green 
sticks, demarcates the binding pocket, which is partially occluded 
by the N-terminal loop (red). The nitrate group is not modelled in 
the experimental crystal structure, as the electron density was not 
observed. The extracellular loops (ECLs) are shown in brown and 
the intracellular loops (ICLs) are shown in purple. B Top view of the 
extracellular side. The disulphide bond in ECL2 is shown as yellow 
sticks. Adapted from Hua et al. 2016. 
 
There is a 44% homology between CB1R and CB2R, 
and they are encoded by different genes, giving rise to 
several isoforms of each receptor. They belong to the 
GPCR superfamily, and therefore are essentially 
composed of 7 transmembrane domains plus an N-
terminal and a C-terminal domain. In addition, a third 
GPCR, named GPR55, with 14% of sequence similarity 
with CB1R and CB2R (Ross 2009), interacts specifically 
with some cannabinoid compounds and it has been 
shown to mediate part of their effects, at least in vitro, 
in a number of pharmacological studies (Ryberg et al. 
2007; Kapur et al. 2009). Other protein sometimes 
considered a cannabinoid receptor, owing to its ability 
to bind some fatty acylethanolamides and N-
arachidonoyldopamines, is the transient receptor 
potential cation channel subfamily V member I 
(TRPV1), a ligand-dependent ion channel responsible 
for the response to capsaicin (Bisogno et al. 2001; 
Pertwee et al. 2010). Lastly, some nuclear receptors of 
the peroxisome proliferator-activated receptor 
(PPAR) family could also respond to cannabinoids, at 
least in some contexts, although in a more subtle way 
and less sensitive manner than CB1R and CB2R 
(O’Sullivan 2007; Pertwee et al. 2010). 
 
CB1R is the one of the most abundant GPCRs in the 
mammalian brain (Herkenham et al., 1990; Kano et al., 
2009). It is preferentially expressed in areas of the CNS 
involved in the control of motor activity (basal 
ganglia, cerebellum), learning and memory (cortex, 
hippocampus), emotions (amigdala), sensory 
perception (thalamus), and various autonomic and 
endocrine functions as feeding behaviour, body 
temperature maintenance and pain perception 
(hypothalamus, medulla) (Figure 7). Indeed, CB1R is 
involved in critical life processes such as nervous 
system development and inflammation (Katona & 
Freund 2012; Lutz et al. 2015). CB1R is mainly present 
in mature neurons, and its expression is higher in 
GABAergic than glutamatergic populations 
(Marsicano & Lutz 1999). However, this expression 
pattern does not account for its activity potential, 
which reflects most likely the efficacy of receptor 
coupling to intracellular transductors (Steindel et al. 
2013). In addition, it is expressed in other neural cells 
such as astrocytes (Sánchez et al. 1998; Stella 2004), 
where it modulates neuron-astrocyte communication 
(Venance et al. 1995; Navarrete & Araque 2008), 
microglia (Stella 2004; Stella 2010), and 
oligodendrocytes (Molina-Holgado et al. 2002). 
 
Figure 7. Expression pattern of CB1R mRNA in adult mice. CB1R 
mRNA in situ hybridization is shown at the indicated stage. 
Adapted from Diaz Alonso et al. 2012. 
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Figure 8. CB1R expression in rodent brain is primarily 
presynaptic. B. Electron-dense reaction product is present in both 
inhibitory (bi) and excitatory (be) boutons. Note that the excitatory 
boutons synapse onto spines (s) while the inhibitory boutons form 
synapses on a dendritic shaft. Dendritic structures are 
pseudocolored blue for ease of identification. C. Higher 
magnification image showing a CB1R-positive inhibitory terminal 
synapsing onto the shaft of a dendrite. D. Higher magnification 
image showing a CB1R-positive excitatory bouton forming an 
asymmetric synapse onto a dendritic spine. Scale bar ¼ 200 nm in 
B. Adapted from Hu & Mackie 2015. 
 
At the cellular level, CB1R is mostly located at the 
plasma membrane of synaptic buttons, where it is 
well known that it inhibits neurotransmitter release 
(Figure 8) (Katona et al. 1999; Katona et al. 2006). 
However, it can also be found in the postsynaptic 
zone, participating in cell-autonomous regulation 
processes (Bacci et al. 2004; Marinelli et al. 2008; 
Maroso et al. 2016). Additionally, part of the receptor 
is present on intracellular structures, mostly 
endosomes, due to its constitutive recycling (Leterrier 
et al. 2004). A new location for CB1R, described in the 
last years, is the outer membrane of the 
mitochondria. There, cannabinoid compounds are 
able to modulate respiration, and therefore neuronal 
activity, thereby interfering with memory processes 
(Bénard et al. 2012; Hebert-Chatelain et al. 2016). 
 
CB2R is preferentially expressed in the periphery, 
mainly in cells (B and T lymphocytes, macrophages) 
and tissues (spleen, lymph nodes) of the immune 
system (Herkenham et al. 1990; Glass et al. 1997; Tsou 
et al. 1998), hematopoietic system (Cabral & Staab 
2005), endocrine pancreas (Juan-Picó et al. 2006), 
bone (Idris et al. 2005) and adipose tissue (Pagano et 
al. 2008). It is also present in the brain, mainly in 
microglial cells and, perhaps in some contexts, 
astrocytes (Stella 2004; Maresz et al. 2005). It has 
been also described that CB2 expression may occur in 
some restricted populations of neurons, although at 
low levels (Van Sickle et al. 2005; Lanciego et al. 2011; 
García et al. 2015), as well as in neural progenitors 
(Palazuelos et al. 2006). 
 
THE ENDOCANNABINOID SYSTEM 
 
Cannabinoid receptors interact with endogenous 
molecules known as endocannabinoids (eCBs). They 
present molecular similarities with the active 
ingredients of C. Sativa, the phytocannabinoids, thus 
enabling a functional mimesis between them (Pertwee 
et al., 2010). N-arachidonoyletanolamine or 
anandamide (AEA) was the first eCB identified 
(Devane et al. 1992), followed by 2-
arachidonylglycerol (2-AG) (Mechoulam et al. 1995; 
Sugiura et al. 1995). 
 
Although there may be other endogenous molecules 
capable of interacting with cannabinoid receptors, 
AEA and 2-AG are to date the best established eCBs 
and the most relevant in terms of biological functions. 
2-AG has lower affinity for cannabinoid receptors than 
AEA, but is a fully effective agonist at both CB1R and 
CB2R, and it is increasingly more accepted that it 
represents the main ligand of presynaptic CB1R in the 
control of synaptic activity and plasticity (Katona & 
Freund 2008). AEA is a high-affinity, low-efficacy CB1R 
agonist, with even lower efficacy at CB2R, and 
although it is also a presynaptic CB1R ligand, is likely 
more involved in complementary forms of eCB-
mediated plasticity, for example though TRPV1 
(Grueter et al. 2010; Puente et al. 2011). 
 
Unlike most other neurotransmitters and 
neuromodulators, eCB generation occurs by “on-
demand” synthesis and cleavage of plasma membrane 
lipid precursors, which are hydrophobic molecules 
with polyunsaturated fatty acyl chains, in a tightly 
controlled process related to neuronal activity 
(Mechoulam et al. 1998; Piomelli 2003). The principal 
pathway for AEA synthesis is from N-
acylphosphatidylethanolamine (NAPE), which is in 
turn generated by N-acylation of 
phosphatidylethanolamine trough a Ca2+-dependent 
N-acyltransferase. Subsequently, N-acylethanolamine 
(NAE) is released from NAPE by a phosphodiesterase 
of the phospholipase D type (NAPE-PLD), to finally 
generate phosphatidic acid (PA) and AEA (Di Marzo et 
al. 1994) (Figure 8). AEA synthesis is usually dependent 
on cytosolic Ca2+ elevation, but can also be Ca2+-
independent (Di Marzo et al. 1994; Leung et al. 2006). 
Furthermore, the activation of some GPCRs, like D2R, 
mGluR1/5R and M3R, can trigger AEA production 
(Piomelli 2003). 2-AG is generated mainly from the 
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hydrolysis of phosphatidylinositol, first by PLC, and 
then by diacylglycerol lipase (DAGL). DAGL has two 
known isozymes, DAGLα and DAGLβ (Bisogno et al. 
2003), being the α isoform the more abundant and 
apparently relevant within the adult brain (Gao et al. 
2010; Tanimura et al. 2010). Neuronal 2-AG production 
can be initiated by an increase in cytosolic Ca2+ 
(Piomelli et al. 1997) triggered by the activation of 
metabotropic (Jung et al. 2007) or ionotropic (Stella & 
Piomelli 2001) receptors (Figure 9). 
 
Degradation of eCBs, and therefore termination of 
their activity, is a fine-tune process, triggered by 
specific serine hydrolases. Fatty acid amide 
hydrolase (FAAH) is the main enzyme responsible for 
the degradation of AEA (Cravatt et al. 1996). and 
within the mammalian brain it is particularly highly 
expressed in the cerebellum, hippocampus and cortex 
(Leishman et al. 2016). Monoacylglycerol lipase 
(MGL) preferentially catabolizes 2-AG into arachidonic 
acid and glycerol and is widely expressed in the brain 
throughout the rat cortex, hippocampus, cerebellum, 
thalamus, striatum, amygdala and pontine nuclei 
(Dinh et al. 2002). These two hydrolases are 
differentially distributed across the synaptic cleft, 
being FAAH in the postsynaptic dendrites and soma 
while MGL resides in the presynaptic axon membrane, 
where it co-localizes with CB1R (Gulyas et al. 2004) 
(Figure 9). 
 
Aside from these two major degradative pathways, 
both AEA and 2-AG can be metabolized by alternative 
ways. For example, the serine hydrolases ABHD6 and 
ABHD12 (Blankman et al. 2007; Marrs et al. 2010), and 
oxidative enzymes as ciclooxygenases and 
lipoxygenases, use these same eicosanoid substrates 
to generate different active metabolites (Nomura et 
al. 2011). In addition, eCB-degradation products are 
themselves precursors of bioactive lipid mediators, 
such as prostaglandins, prostamides and other 
eicosanoids, thus making their metabolic regulation 
and function tightly related, even more specially in 
particular cellular contexts such as an inflammatory 
response (Valdeolivas et al. 2013; Hermanson et al. 
2014). 
 
The location of enzymes engaged in the synthesis and 
degradation of eCBs is closely linked to the purpose of 
eCB signalling. As an example, DAGLα is found on the 
plasma membrane of the perisynaptic domain of 
neuronal soma, where is functionally coupled to PLCβ 
and  mGluR1/5 (Yoshida et al. 2006; Jung et al. 2007), 
and therefore it can modulate synaptic activity trough 
2-AG synthesis and retrograde activation of 
presynaptic CB1R (Figure 11). 
 
 
Figure 9. Main pathways for the synthesis and degradation of the 
endocannabinoids AEA and 2-AG. The subcellular distribution in 
neurons of enzymes regulating the levels of eCBs is shown, 
including the proposed role of these lipid mediators in retrograde 
(mainly for 2-arachidonoyl-glycerol (2-AG)), anterograde and 
intracellular (for anandamide (AEA)) signalling. The biosynthesis of 
AEA occurs through the action, among others, of NAPE-PLD, 
which is located in intracellular membranes both pre- and 
postsynaptically. AEA is degraded by FAAH, which is located 
postsynaptically. 2-AG is biosynthesized by DAGLα, which is 
located postsynaptically, and degraded by MGL, which instead is 
presynaptic. The complexity arising from the fact that many of 
these enzymes also regulate the levels of eCB-related mediators, 
with non-cannabinoid receptors as targets, is also depicted. Solid 
arrows denote transformation into active metabolites or 
activation; dashed arrows denote transformation into metabolites 
inactive at cannabinoid receptors; blunt arrow denotes inhibition. 
AA, arachidonic acid; AGs, 2-acylglycerols; DAGs, diacylglycerols; 
ER, endoplasmic reticulum; GPRs, orphan G-protein-coupled 
receptors; MAPK, mitogen-activated protein kinases; PIP2, 
phosphoinositide bisphosphate; PKA, protein kinase A; PLCβ, 
phospholipase Cβ; PPARs, peroxisome proliferator-activated 
receptors; TRPs, transient receptor potential channels; VGCCs, 
voltage-gated calcium channels. Adapted from Di Marzo et al. 
2015. 
CB1R SIGNALLING 
 
Activation of cannabinoid receptors has multiple 
cellular consequences, and depends on the ligand as 
well as on the receptor-ligand engagement context 
(Glass & Northup 1999; Laprairie et al. 2017) Different 
scenarios could be given by the interaction of the 
receptors with other molecules, as other receptors 
with which they form heteromers (Mackie 2005; Ferré 
et al. 2010), or cytoplasmic interactors as CRIP1a 
(Niehaus et al. 2007), as well as biochemical 
modifications of the receptor (Shim 2010) . 
 
Due to its GPCR nature, activation of CB1R or CB2R 
triggers GTP hydrolisis on a heteromeric G protein 
associated to it. Although interactions with other G 
proteins as Gq/11 (Lauckner et al. 2005), Gs (Hampson 
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et al. 2000), or G12/13 (Roland et al. 2014) has been 
shown to occur in particular contexts, the canonical 
signalling pathway involves Gi/o activation and the 
subsequent dissociation into the respective αi/o and 
βγ subunits (Pertwee 1997). Activation of the αi/o 
subunit leads to inhibition of AC, decrease in cAMP 
concentration, and hence reduction in the activity of 
cAMP-dependent cytoplasmatic proteins, such as PKA 
(Howlett 2002) and the exchange protein directly 
activated by cAMP (Epac) (Ramírez-Franco et al. 
2014). On the other hand, the βγ dimers generated are 
related to different signalling pathways, for example 
ERK (Bouaboula et al. 1995; Galve-Roperh et al. 2002), 
p38 MAPK (Liu et al. 2000; Rueda et al. 2000), and JNK 
(Rueda et al. 2000; Derkinderen et al. 2001) (Figure 10). 
 
 
Cannabinoids also regulate other pathways involved in 
the control of cell proliferation and survival, including 
the PI3K-Akt pathway (Gómez del Pulgar et al. 2000), 
ceramide biosynthesis (Galve Roperh et al. 2000), 
sphingomyelin hydrolysis through the adaptor protein 
FAN (Sánchez et al. 2001) and various ion channels 
(Pertwee 2005). For example, the well-known 
mechanism of CB1R-dependent inhibition of 
neurotransmitter release (Kreitzer & Regehr 2001) 
usually involves inhibition of N- and P/Q-type voltage 
sensitive Ca2+ channels (Caulfield & Brown 1992; 
Gebremedhin et al. 1999) and the activation of G 
protein-activated inwardly-rectifying K+ (GIRK) 
channels (Guo & Ikeda 2004; Mackie 2005), which 
hyperpolarizes and thus reduces the excitability of the 
plasma membrane (Howlett 2002) (Figure 11).  
 
 
 
Figure 10. Cannabinoid receptors-coupled signalling pathways. The stimulation of cannabinoid receptors activates numerous signal 
transduction pathways, in a cell- and tissue-specific manner. AC, adenylyl cyclase; ATF-2, activating transcription factor 2; PLC, phospholipase 
C; PIP2, phosphatidylinositol 4,5-bisphosphate; IP3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; PKA, protein kinase A; PKC, protein kinase 
C; PI3K, phosphatidylinositol 3-kinase; ROCK, Rho-associated protein kinase; NFAT, nuclear factor of activated T cells; CREB, cAMP response 
element binding protein. Adapted from (André & Gonthier 2010) 
 
30 
 
Prolonged exposure to receptor agonists results in a 
decreased ability of CB1R and CB2R to further activate 
effector pathways, namely receptor desensitization, 
and in a reduction in the number of receptor molecules 
on the cell surface, namely receptor internalization 
(Dudok et al. 2014; Lu & MacKie 2016). Under these 
conditions, cannabinoid receptors become a substrate 
for GPCR kinases (GRKs), which phosphorylates serine 
and/or threonine residues on the cytoplasmic 
domains, thus enabling the interaction with β-
arrestins. Binding of β-arrestins uncouples the 
receptor from G proteins and hence stimulates 
receptor internalization and β-arrestin-mediated 
signalling (Delgado-Peraza et al. 2016; Kendall & 
Yudowski 2017).  
 
CB1R FUNCTIONS IN THE CNS 
 
The eCB system plays a role in multiple physiological 
processes, both in the CNS and in peripheral tissues, in 
a cell- and tissue-specific manner. Due to the 
complexity of this system, which serves as a 
homeostatic modulator of several vital functions, it 
has become increasingly necessary to study, in a more 
in-detailed examination, the mechanism of action of 
its components. Moreover, eCBs offer a plethora of 
molecular targets and possible strategies to 
counteract multiple pathologies. Because the amount 
of physiological implications of cannabinoids exceeds 
by far the subject of this thesis, the following section 
focuses mostly on the role of CB1R in synaptic 
transmission and corticostriatal function. Finally, 
some of the protective aspects of cannabinoids in 
neurodegenerative diseases, with special emphasis on 
the role of CB1R, are also summarized. 
 
CB1R and synaptic transmission 
 
The best characterized mechanism by which eCBs 
modulate synaptic transmission trough CB1R involves 
a paracrine communication known as retrograde 
signalling. This term comes from the idea that, in 
contrast to the classical synaptic transmission, which 
is directed from the presynaptic to the postsynaptic 
zone, eCBs signal from the postsynaptic membrane, 
where they are generated, to the presynaptic terminal, 
where CB1R is located. The final consequence of this 
process is a reduction in neurotransmitter release, in a 
transient or long-term manner, on both excitatory and 
inhibitory synapses (Kano et al. 2009; Katona & Freund 
2012).  
 
 
 
 
Figure 11 eCB-mediated short- and long-term synaptic plasticity. A Short-term depression. Postsynaptic activity triggers Ca2+ influx via 
VGCCs. Other Ca2+ sources, like NMDARs and internal stores, may also contribute. Ca2+ promotes DGLα-mediated eCB production by a still 
unclear mechanism. Presynaptic activity can also lead to eCB mobilization by activating postsynaptic group I metabotropic glutamate receptors 
(I mGluRs). PLCβ can now act as a coincidence detector integrating pre- and postsynaptic activity. DGLα promotes 2-AG release which 
retrogradely targets presynaptic CB1Rs, and the βγ subunits probably couple to presynaptic VGCCs to reduce neurotransmitter release B eCB-
mediated excitatory long-term depression (LTD) and inhibitory LTD (iLTD). Patterned presynaptic stimulation releases glutamate (Glu) which 
activates postsynaptic mGluRs coupled to PLCβ and DGLα. 2-AG homosynaptically targets CB1Rs localized to excitatory terminals and 
heterosynaptically engages CB1Rs at inhibitory terminals. A Gαi/o-dependent reduction in AC and PKA activity suppresses transmitter release. 
At inhibitory synapses, decreased PKA activity, in conjunction with activation of the Ca2+-sensitive phosphatase calcineurin (CaN), shifts the 
phosphorylation status of an unidentified presynaptic target (T) required for iLTD. The active zone protein RIM1α and the vesicle- associated 
protein Rab3B are also necessary for iLTD. Induction of eCB- LTD may require presynaptic Ca2+ rise through VGCCs, NMDARs, or internal stores 
(not shown). Dashed lines indicate putative pathways. Adapted from Castillo et al. 2012. 
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The first evidence for eCB-mediated retrograde 
signalling came from the study of a particular form of 
synaptic plasticity in which these molecules play an 
important role. This short-term synaptic plasticity is 
called depolarization-induced suppression of 
inhibition (DSI), in the case of inhibitory synapses 
(Ohno-Shosaku et al. 2001; Wilson & Nicoll 2001), or 
depolarization-induced suppression of excitation 
(DSE), in the case of excitatory synapses (Kreitzer & 
Regehr 2001). Soon after, it was found that eCBs can 
also mediate long-term depression events at the 
presynaptic level (eCB-LTD), in both excitatory 
(Gerdeman et al. 2002; Robbe et al. 2002) and 
inhibitory terminals (Marsicano et al. 2002; Chevaleyre 
& Castillo 2003) (Figure 11). 
 
CB1R triggers the inhibition of neurotransmitter 
release by means of two major processes. In the case 
of short-term plasticity, it entails the inhibition of 
presynaptic Ca2+ influx trough VGCCs, most likely via 
the β/γ subunit of the Gi/o protein coupled to CB1R 
(Kreitzer & Regehr 2001; Wilson & Nicoll 2001; Brown 
et al. 2003). For long-term plasticity, the predominant 
mechanism requires inhibition of AC and 
downregulation of the cAMP/ PKA pathway via the 
Gαi/o subunit (Castillo et al. 2012). Induction of this 
form of plasticity requires combined presynaptic firing 
with CB1R activation, and thereby only active 
synapses detecting eCBs express long-term plasticity. 
The occurrence of eCB-LTD may involve the 
presynaptic proteins Rab3B/RIM1α (Tsetsenis et al. 
2011; Castillo et al. 2012) (Figure 11). 
 
The two main endocannabinoids, AEA and 2-AG, can 
modulate synaptic function. Both DSI and DSE 
requires 2-AG synthesis by DAGLα (Gao et al. 2010; 
Tanimura et al. 2010). On the other hand, AEA can 
participate in LTD, although at a slower rate than 2-
AG, by acting both through CB1R (eCB-LTD), and 
through TRPV1 (AEA-TRPV1-LTD) in an autocrine 
manner, in which AEA activates the postsynaptic 
vanilloid receptor. AEA-TRPV1-LTD is present at both 
glutamatergic and GABAergic synapses (Chávez et al. 
2010; Ohno-Shosaku & Kano 2014; Puente et al. 2015). 
There is a functional crosstalk between 2-AG and AEA 
signalling (Maccarrone et al. 2008), and some 
interesting findings suggest that 2-AG and AEA can be 
recruited differentially from the same postsynaptic 
neuron, depending on the type of presynaptic activity 
(Puente et al. 2011; Lerner & Kreitzer 2012). 
 
In addition, arachidonic acid (AA), which is both a 
precursor (in a lipid-esterified or amidated form) and a 
degradation product of eCBs, has been recently found 
to act also as a retrograde messenger, thus 
potentiating excitatory transmission in a process 
called depolarization-induced potentiation of 
excitation (DPE). DPE has to be taken into 
consideration, as the metabolic balance of eCBs can 
lead to considerable changes in AA levels, thereby 
presumably influencing as well synaptic transmission 
(Carta et al. 2014; Lutz et al. 2015). Moreover, despite 
2-AG and AEA being mainly hydrolyzed by MGL and 
FAAH, cyclooxygenase and lipoxygenase can also 
utilize these substrates to generate eCB-derived 
metabolites that are biologically active (Nomura et al. 
2011) and conceivably modulate synaptic function 
(Yang & Chen 2008; R. Chen et al. 2013). 
 
The eCB system in general, and CB1R in particular, are 
also present and functional in astrocytes. Thus, eCBs 
signalling is integrated into the concept of the 
‘tripartite synapse’, including pre- and postsynaptic 
elements and surrounding astroglial processes 
(Navarrete & Araque 2008). Astrocytic CB1Rs couples 
to PLC via Gq/11, which increases intracellular Ca2+ and 
triggers glutamate release (Navarrete & Araque 2010). 
This form of plasticity implies an additional control 
level within neuronal circuits as, through astroglial 
networks, eCB signalling can modify, in a regulated 
and specific manner, synaptic activity of physically 
distant neurons (Navarrete & Araque 2010; Martín et 
al. 2015). 
 
There are multiple physiological processes and 
behavioural aspects regulated by CB1R. To mention 
some examples, this receptor participates in the 
control of extinction of aversive memories and in 
stress responses (Marsicano et al. 2002; Senst & Bains 
2014), motor behaviour (Herkenham et al. 1991; 
Katona & Freund 2008), nocicepción in both CNS and 
peripheral nervous system (Cravatt & Lichtman 2004), 
energy balance (Quarta et al. 2010), and feeding 
behaviour (Bellocchio et al. 2010; Soria-Gómez et al. 
2014). eCBs are central players in the maintenance of 
nervous system homeostasis. In this context, both 
brain aging and neurodegenerative disorders are 
associated to drastic changes in the eCBs system  
(Galve-Roperh et al. 2008; Fernández-Ruiz et al. 2010; 
Scotter et al. 2010; Di Marzo et al. 2015). In fact, eCBs 
safeguard the nervous system against excitotoxicity, 
inflammation and oxidative stress, thus acting as a 
counterbalance in neuronal overactivation contexts 
and constituting a brake againts neuronal death 
(Monory et al. 2006; Katona & Freund 2008). 
 
CB1R in the corticostriatal circuitry 
 
CB1R mRNA is particularly highly expressed within the 
striatum (caudate-putamen), in a dorsolateral to 
ventromedial gradient (Figure 12) (Mailleux & 
Vanderhaeghen 1992; Marsicano & Lutz 1999), while 
adult pallidal and nigral neurons contain little or no 
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Figure 12. Expression pattern of CB1R in the cortex and striatum 
of conditional CB1R mutant mice. In situ hybridization showing 
CB1R mRNA expression in the brain of CB1Rf/f (WT), Glu-CB1R−/−, 
and GABA-CB1R−/− mice. In Glu-CB1R−/− mice, CB1R mRNA is 
absent from the majority of cortical glutamatergic neurons. In 
GABA-CB1R−/− mice, CB1R mRNA is absent from all GABAergic 
neurons and it is expressed only in non-GABAergic cells. Modified 
from Monory et al. 2006. 
 
CB1 mRNA.(Matsuda et al. 1993). It is present at 
terminals of both D1R-MSNs and D2R-MSNs, where it 
mediates endocannabinoid-dependent inhibition of 
GABA release and thus reduction of motor activity 
(Herkenham et al. 1991; Katona & Freund 2008) (Fig. 
13). In addition, CB1R is present at cortical projection 
neurons, but is not significantly present at other 
glutamatergic areas projecting to the dorsal striatum 
(Figure 13) (Mailleux & Vanderhaeghen 1992; 
Marsicano & Lutz 1999; Uchigashima et al. 2007; Wu et 
al. 2015). CB1R located on corticostriatal terminals 
thereby blunts glutamatergic output and gives rise to 
LTD (Gerdeman et al. 2002; Kreitzer 2009). 
 
Signalling through CB1R is also linked to corticostriatal 
function in several contexts like reward and addiction 
(Di Marzo et al. 2001; Hansson et al. 2007; Lutz et al. 
2015) as well as habit formation (Hilário et al. 2007; 
Gremel et al. 2016), mostly through the control of LTD 
and LTP. The eCB system modulates the activity of the 
neurotransmitters that participate in the control of 
basal ganglia function, namely dopamine, GABA and 
glutamate, to balance motor outputs. Since its 
location is mainly presynaptic (Figure 9), CB1R 
mediates corticostriatal plasticity by means of 
retrograde signalling (Figure 11) (Castillo et al. 2012), 
and its activation depresses corticostriatal 
glutamatergic synaptic transmission, thus being 
involved in the hypomotility and cataleptic effect 
induced by cannabinoid injection (Gough & Olley 1978; 
Monory et al. 2007).
 
 
Figure 13. Expression and physiological function of CB1R within the basal ganglia circuitry. CB1R is expressed by striatal MSNs both in their 
soma and in their presynaptic axon terminals innervating the external and internal segments of the GP and the SNr, and are also present in 
corticostriatal excitatory terminals and in excitatory projections from the STN to the GPi/SNr and SNc .Activation of presynaptic CB1R located 
on corticostriatal terminals reduces glutamate release. Similarly, in the output basal ganglia nuclei (GPi and SNr), CB1R activation inhibits both 
glutamate release from STN afferents and GABA release from striatal afferents. In the striatum, a population of CB1R is co-expressed with D1R 
and D2R and shares with these two receptors a common pool of G proteins, suggesting a convergence of their signal transduction mechanisms. 
DA, dopamine; SNpc, substantia nigra pars compacta; SNpr, substantia nigra pars reticulate. Adapted from Di Filippo et al. 2008. 
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Due to the direct modulation of MSNs synapses 
activity through eCBs, they represent one of the 
neurochemical substrates for the cross-talk between 
direct and indirect pathways (Fig. 13). The role of eCBs 
in the control of LTD is a major discussion issue in this 
context. Although this effect is observed in most 
MSNs, suggesting a lack of segregation in a specific 
pathway, the inhibition of glutamate release by 
retrograde eCB signalling is frequency-dependent and 
D2R-mediated (Kreitzer & Malenka 2007; Shen et al. 
2008; Calabresi et al. 2014). However, other studies 
demonstrating that eCB-LTD can be induced in both 
MSNs subpopulations have challenged this view 
(Wang et al. 2006; Bagetta et al. 2011). Even though 
this question is not yet clear, it appears that there may 
be preferential LTD at synapses onto D2-MSNs with 
less robust induction protocols, but LTD can certainly 
be induced at synapses onto D1-MSNs with sufficiently 
strong synaptic activation. Overall, there is general 
agreement that CB1R receptors are expressed on 
afferents that innervate both D1-MSNs and D2-MSNs 
(Lovinger & Mathur 2010). 
 
CB1R AND eCBs IN CNS DYSFUNCTION 
 
eCB mediated neuroprotection 
 
The eCB system represents an endogenous 
neuroprotective network in models of both acute 
neuronal damage, as stroke and traumatic brain 
injury (Panikashvili et al. 2001; Schurman & Lichtman 
2017), and neurodegenerative diseases, such as 
multiple sclerosis, Parkinson´s disease, Huntington´s 
disease, Alzheimer´s disease and amyotrophic lateral 
sclerosis (Pryce et al. 2013; Fernández-Ruiz, Romero, 
et al. 2015). The fact that components of this system 
are found altered in many neurological diseases and 
that eCBs levels are enhanced upon brain damage, in 
addition to their broad-spectrum activity, gave rise to 
the idea of use them as pharmacological targets 
against brain degeneration (Mechoulam et al. 2014; Di 
Marzo et al. 2015). Due to the promising 
neuroprotective potential of eCBs, several studies 
have attempted to dissect the mechanistic bases of a 
plethora of eCB-mediated actions. Different strategies 
to approach this issue have been used, including 
pharmacological treatments and genetic 
manipulation of eCB system components. For 
example, by means of cannabinoid-drug treatments, it 
has been shown that THC protects hippocampal 
neurons from excitotoxicity (Gilbert et al. 2007), 2-AG 
is neuroprotective against brain injury (Panikashvili et 
al. 2001), WIN-55,212-2 and eCBs counteract 
neurodegeneration in models of Multiple sclerosis 
(Pryce et al. 2003; Loría et al. 2010), and AEA prevents 
neuronal death after excitotoxic damage (van der Stelt 
et al. 2001), among to many others. 
In addition to those pharmacological studies, genetic 
manipulation of the eCB system has demonstrated 
that the lack of CB1R (CB1R knockout mice; CB1R-KO) 
renders mice more sensitive to excitotoxic damage 
compared to wild-type (WT) littermates (Parmentier-
Batteur et al. 2002; Marsicano et al. 2003). On general 
grounds, CB1R-mediated neuroprotection usually 
involves synaptic modulation (Katona & Freund 2008), 
while CB2R-mediated neuroprotection is more likely 
related to resolving excessive neuroinflammatory 
events that come along with most neurodegenerative 
and acute-brain damage processes (Palazuelos et al. 
2009; Valdeolivas & Satta 2012; Scheller & Kirchhoff 
2016), although it also participate in other cell survival 
mechanism (Fernández-Ruiz et al. 2007). As 
mentioned before, CB2R is expressed in various 
circulating and resident immune cells, particularly 
when these cells are overactivated, and its 
engagement is typically associated with a reduction in 
it pro-inflammatory activity. This includes the 
inhibition of the release of inflammatory mediators, 
including nitric oxide (NO), interleukin-2 (IL-2) and 
TNF-α, the inhibition of some cell-mediated immune 
processes, and the inhibition of proliferation and 
chemotaxis (Walter & Stella 2004). 
 
A common experimental approach to modulate eCB 
levels involves the use inhibitors of their degradation, 
which provides a means of elevating eCB levels and 
therefore of activating cannabinoid receptors in a 
more prolonged fashion and with higher sensitivity to 
physiological, on-demand regulation, than acute 
administration of cannabinoid receptor agonists 
(Galve-Roperh et al. 2008; Di Marzo et al. 2015). This 
strategy can mimic the beneficial neuromodulatory 
effects of CB1R activation and the anti-inflammatory 
effects of CB2R activation in a time- and tissue-
selective manner. For example, using FAAH inhibitors 
in mouse models it is possible to diminish the 
spasticity associated to multiple sclerosis (Pryce et al. 
2013), and provide neuroprotection against 
excitotoxicity (Karanian et al. 2005). 
 
The other principal eCB-degradative enzyme, MGL, 
has been also targeted, resulting in neuroprotection in 
models of Alzheimer´s disease (Chen et al. 2011) and 
Parkinson´s disease (Mounsey et al. 2015), among 
others. Interestingly, in both MGL KO mice and in 
animals treated with a MGL inhibitor, besides the 
expected increase in brain 2-AG levels, and therefore 
the promotion of cannabinoid receptor-mediated 
neuroprotection, it has been found that a profound 
decrease in the levels of free AA, as well as several 
eicosanoids, including PGE2, PGD2, PGF2α and 
thromboxane B2, occurs (Nomura et al. 2011). In 
addition, upon MGL inhibition or genetic deletion, the 
rise in brain eicosanoids and inflammatory cytokines 
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found upon LPS injection is prevented (Nomura et al. 
2011; Grabner et al. 2016). In these studies, the 
reduction in activated cytokines was not reversed by 
CB1R antagonists (Grabner et al. 2016)., but was 
mimicked by COX-1 blockade (Nomura et al. 2011), 
thus suggesting that they were due to changes in 
prostaglandin synthesis and COX-1 metabolites, but 
not to CB1R activation. On the other hand, COX-2 can 
also produce proinflammatory mediators by using 2-
AG as a substrate (Alhouayek & Muccioli 2014; 
Hermanson et al. 2014). As this enzyme is elevated in 
most neuroinflammatory processes, 2-AG 
accumulation might be harmful in some contexts or 
time points along damage progression (Van Der Stelt 
et al. 2006; Valdeolivas et al. 2013). 2-AG metabolism 
is not only a neuronal MGL-associated function, but 
most likely depends on the metabolic interplay 
between neurons and astrocytes, by which it provides 
a concerted oversight of 2-AG and, by doing so, allows 
protection of the nervous system from excessive CB1 
receptor activation and promotes eCB crosstalk with 
other lipid transmitter systems (Viader et al. 2015). All 
these issues being considered, it is likely that MGL is 
an important enzyme involved in regulating synaptic 
2-AG-based signalling as well as in controlling brain 
eicosanoid production (Figure 14).  
 
Figure 14. Distributed oversight of 2-AG metabolism and 
function in neurons and astrocytes. Proposed model of 
astrocytic-neuronal transcellular shuttling and metabolism of 2-
AG and AA. PIP2, phosphatidylinositol 4,5-bisphosphate; COX, 
cyclooxygenase. Adapted from Viader et al. 2015. 
 
CB1R-mediated neuroprotection 
 
Endocannabinoid signalling serves as a major 
feedback mechanism to prevent excessive presynaptic 
activity and thus fine tunes the functionality and 
plasticity of many synapses, especially glutamatergic 
and GABAergic (Katona & Freund 2008; Kano et al. 
2009). In concert with this neuromodulatory function, 
and as advanced above, studies in various animal 
models support that the CB1R plays an important role 
in the promotion of neuron survival in 
pathophysiological settings such as acute brain injury 
(Shohami et al. 2011) and neuroinflammatory 
conditions (Croxford et al. 2008). 
 
Most of the neuroprotective activity of CB1R is 
believed to rely on the attenuation of glutamatergic 
excitotoxicity (Katona & Freund 2008) (Figure 15). 
eCBs can modulate glutamatergic signalling by 
different mechanisms, but the more extensively 
studied implies the activation of CB1R located on 
glutamatergic synaptic terminals, where it inhibits 
neurotransmitter release (Marsicano et al. 2003; 
Monory et al. 2006; Chiarlone et al. 2014) (Figure 11). 
Although GABAergic axon terminals contain many 
more CB1R molecules than their glutamatergic 
counterparts, they are not involved in seizure 
susceptibility (Monory et al. 2006) or protection 
against excitotoxicity (Marsicano et al. 2003; Chiarlone 
et al. 2014). Instead, those GABAergic CB1R pools play 
a pivotal role in THC-induced long-term memory 
deficits (Puighermanal et al. 2009), and protection 
against age-related cognitive decline (Albayram et al. 
2011). Finally, since astrocytes participate in eCBs 
signalling, specifically in astrocyte-neuron 
communication through CB1R (Serrano et al. 2006; 
Navarrete & Araque 2008), and are central players in 
synaptic glutamate homeostasis (Rothstein et al. 
1996), they could also conceivably influence neuronal 
damage upon glutamatergic excitotoxicity. In fact, in 
the hippocampus, the maintenance of epileptic 
discharges is reduced when the neuron-to-astrocyte 
communication via CB1R is pharmacologically blocked 
(Coiret et al. 2012).  
 
CB1R also can exert autocrine neuroprotective 
functions, for example triggering intracellular signal 
transduction events that promote cell survival. In this 
context, the PI3K/Akt and the ERK pathways have 
been associated to eCB-mediated neuroprotection 
both in vitro (Gómez del Pulgar et al. 2000; Molina-
Holgado et al. 2005; Blázquez et al. 2015; Batista et al. 
2016) and in vivo paradigms (Ozaita et al. 2007; 
Blázquez et al. 2015).  
 
A key downstream signalling target of CB1R is the 
serine/threonine kinase mammalian target of 
rapamycin (mTOR), a molecular integrator that 
enables both cellular nutrient sensing and energy 
homeostasis through the ERK/MAPK, Akt and AMPK 
pathways. The acute injection of THC induces a rapid 
and transient stimulation of mTOR complex 1 
(mTORC1) activity in the hippocampus, striatum, 
cerebellum, frontal cortex and amygdala, whereas 
repeated     administration   of    THC   leads   to     more 
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Figure 15. Schematic representation of mechanisms underlying the glutamatergic and calcium-blunting properties of cannabinoids that 
may serve to provide neuroprotection in different pathological conditions. Adapted from Fernández-Ruiz et al. 2010 
 
.
sustained activation of mTORC1, lasting for several 
days after the cessation of the treatment 
(Puighermanal et al. 2009; Puighermanal et al. 2013). 
In addition, mTORC1 is activated upon increased eCB 
tone (Busquets-Garcia et al. 2011), and is involved in 
neural progenitor cell proliferation (Díaz-Alonso et al. 
2015) and oligodendrocyte differentiation (Gomez & 
Le 2011). The regulation of mTORC1 by CB1R is 
remarkably wide-ranging, as mTORC1 has also been 
implicated as a central regulator of autophagy, a 
cellular response that is believed to contribute to the 
ageing-associated loss of protein homeostasis. In fact, 
it has been shown that CB1R engagement protects 
MSNs from excitotoxic death via the PI3K/Akt/ 
mTORC1 pathway, which, in turn, induces brain-
derived neurotrophic factor (BDNF) expression 
through the selective activation of BDNF gene 
promoter IV, an effect that is mediated by multiple 
transcription factors (Blázquez et al. 2015). 
 
CB1R and eCBs in motor diseases  
 
The levels of some eCB system components, and in 
particular CB1R, are significantly altered in various BG 
disorders. Such alterations have been observed in 
samples obtained from patients (Glass et al. 1993; 
Glass et al. 2000; Lastres-Becker, Cebeira, et al. 2001) 
and animal models (Lastres-Becker, Cebeira, et al. 
2001; Centonze et al. 2005; Bisogno et al. 2008; 
Fernández-Ruiz, Romero, et al. 2015). These findings, 
together with the neuroprotective and 
neuromodulatory role of eCBs in the BG, have 
prompted the search for cannabinoids-based 
therapies as a treatment of BG disorders. 
 
In general, Parkinson’s disease (PD) and Huntington’s 
disease (HD) are the two basal ganglia disorders that 
have attracted most attention with regard to the 
potential clinical application of cannabinoids 
(Fernández-Ruiz et al. 2011). In this context, profound 
modifications in eCB signalling after dopamine 
depletion occur in experimental models of PD and 
patients. For example, in PD models, striatal levels of 
AEA are increased (Gubellini et al. 2002), which is 
associated with an increased spontaneous 
glutamatergic activity recorded from the large 
majority of MSNs, and this is reversed by L-DOPA 
treatment (Maccarrone et al. 2003). In addition, It has 
been demonstrated that eCB-LTD is selectively lost at 
indirect pathway MSN synapses, and that it can be 
rescued either in the presence of a D2R agonist or by 
the application of a FAAH inhibitor (Kreitzer & 
Malenka 2007). Also in HD, eCB levels suffer different 
alterations (Lastres-Becker, Fezza, et al. 2001; Bisogno 
et al. 2008; Centonze et al. 2005; Bari et al. 2013).  
 
Of note, CB2R is overexpressed by glial and peripheral 
immune cells from HD models (Sagredo et al. 2009; 
Palazuelos et al. 2009; Bouchard et al. 2012) as well as 
in post-mortem tissues from HD patients (Palazuelos 
et al. 2009) and, therefore, cannabinoid compounds 
that activated both CB1R and CB2R seems to be 
effective in HD, mostly by counteracting excitotoxicity 
and inflammation (Sagredo et al. 2009; Chiarlone et al. 
2014; Fernández-Ruiz, Moro, et al. 2015) (Figure 15). In 
addition, CB2R has been proposed has a neuronal loss 
marker in PD, since it is present in the substantia nigra 
(the principal neurodegenerative area in PD) at levels 
significantly lower in PD patients compared to controls 
(García et al. 2015). 
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In both disorders, early presymptomatic phases, 
characterized by neuronal malfunctioning, are 
associated with alterations of CB1R (Denovan-Wright 
& Robertson 2000; Glass et al. 2000; Blázquez et al. 
2011) (Fig. 16). The symptomatic phases are 
characterized by opposite changes in both disorders.  
In early HD, a profound loss of CB1R occurs, 
concomitant with MSN dysfunction, which is 
compatible with the hyperkinetic/choreic symptoms 
typical of these patients (Pazos et al. 2008). By 
contrast, a significant up-regulation of CB1R is found 
in early PD, which might constitute an adaptive 
response and is also compatible with the patients’ 
akinetic/rigid clinical profile (Fernández-Ruiz et al. 
2011) (Fig. 16).  
 
Importantly, genetic deletion of CB1R aggravates the 
symptoms in HD mouse models (Mievis et al. 2011; 
Blázquez et al. 2011), while THC treatment (Blázquez 
et al. 2011) or rescue of CB1R expression improves at 
least some neuropathological aspects of the disease 
(Naydenov et al. 2014; Blázquez et al. 2015). In this 
context, recent studies have pointed out an unbalance 
in the glutamatergic and GABAergic CB1R pools in HD 
models. It is known that CB1R is lost in HD transgenic 
mice in a brain region-specific manner, as it occurs in 
the striatum but not in the cortex (Denovan-Wright & 
Robertson 2000; Lastres-Becker et al. 2002; McCaw et 
al. 2004). In fact, while CB1R located in MSNs is 
dramatically downregulated, thus turning these cells 
insensitive to receptor agonists, CB1R located on 
glutamatergic terminals remains unaltered (Chiodi et 
al. 2012; Chiarlone et al. 2014). Moreover, CB1R 
located specifically on glutamatergic corticostriatal 
projections, rather than on MSNs, has been found to 
constitute a central player in eCB-dependent 
neuroprotection from excitotoxicity- and mtHtt-
induced damage (Chiarlone et al. 2014). Likewise, 
there is an increasing number of studies suggesting 
that CB1R pools located on different cell populations, 
and even intracellular compartments, may account for 
the observed distinct responses to eCB action 
(Busquets Garcia et al. 2016).  
 
Therefore, dissecting the cell population-specific role 
of each CB1R pool seems crucial to understand the 
underlying eCB-mediated neuroprotective 
mechanisms, as well as to pave the way to the possible 
design of CB1R-targetted neuroprotective therapeutic 
strategies. This issue constitutes a central conceptual 
focus of the present PhD Thesis. 
 
 
Figure 16 Changes of CB1R expression in the BG during the progression of Parkinson’s and Huntington’s diseases. Adapted from 
Fernández-Ruiz 2009
. 
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AIMS 
 
A key unanswered question in most neurodegenerative diseases is what precise factors dictate 
the selective damage of a particular neuronal population. The use of transgenic animals and/or 
recombinant adeno-associated virus (rAAV)-mediated gene delivery allows to express the 
DREADD in a particular cell population of a given brain region, offering a powerful strategy to 
solve cell-specific mechanism in health and disease. Specifically in HD, a neurodegenerative 
disease where the primarily affected structures are the cortex and striatum, the mechanisms 
by which striatal principal neurons (MSNs) are so highly vulnerable are incompletely 
understood. Between the plethora of neurotransmitter systems, the endocannabinoid system 
plays a pivotal role in striatal function and present a broad spectrum of neuroprotective actions. 
However, despite the widely reported neuroprotective role of the CB1 receptor, the assessment 
of its physiological relevance and therapeutic potential in neurological diseases is hampered, at 
least in part, by the lack of knowledge of the cell-population specificity of CB1R action.   
 
In this context, the GLOBAL AIM of this Doctoral Thesis embraces the study of direct versus 
indirect pathway mechanisms involved in corticostriatal dysfunction and neurodegeneration, 
as well as the selective neurobiological site of CB1R neuroprotective action within the 
corticostriatal circutry. 
 
This main objective can be divided into 2 SPECIFIC AIMS: 
 
Objective 1. Examine the molecular mechanisms and physiopathological relevance of Gq-
protein signalling in direct pathway and indirect-pathway MSNs. 
 
Objective 2. Study the role of different CB1R pools, namely those situated on GABAergic 
neurons (MSNs), glutamatergic neurons (corticostriatal projection neurons) or astrocytes, in 
the differential vulnerability of D1R- and D2R-MSNs. 
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MATERIALS AND METHODS-OBJECTIVE 1 
 
Animals 
 
We used mutant mice and their corresponding wild-
type littermates in which Cre recombinase expression 
was driven by the D1R promoter (Monory et al. 2007); 
colony founders provided by Günther Schütz, German 
Cancer Research Center), the D2R promoter (colony 
founders provided by University of California Davis 
Knockout Mouse Project Repository, Davis, CA), or 
both the D1R and D2R promoters (generated by 
crossing the aforementioned D1R-Cre and D2R-Cre 
mouse lines). All lines were in the C57BL/6N 
background. Wild-type C57BL/6N mice were 
purchased from Harlan Laboratories. Animal housing, 
handling, and assignment to the different 
experimental groups were conducted as described 
previously (Blázquez et al. 2011). All experimental 
procedures used were performed in accordance with 
the guidelines and with the approval of the Animal 
Welfare Committee of Madrid Complutense 
University according to the European Commission 
directives. 
 
Viral vectors  
 
Gq-coupled human M3 muscarinic DREADD (hM3Dq) 
fused to mCherry (provided by Brian L. Roth, 
University of North Carolina, Chapel Hill, NC; 
(Alexander et al. 2010) or mCherry alone was 
subcloned in a recombinant adeno-associated virus 
(rAAV) expression vector with a minimal CAG 
promoter (for generalized expression) or in a CAG-DIO 
vector (for Cre-dependent expression) using standard 
molecular biology techniques. For cell-specific 
ablation, a mCherry-FLEX-DTA cassette (Addgene 
plasmid #58536, provided by Naoshige Uchida, 
Harvard University) was cloned in a CAG-DIO-rAAV 
vector. All vectors used were of an AAV1/AAV2 mixed 
serotype and were generated by calcium phosphate 
transfection of HEK-293T cells and subsequent 
purification as described previously (Monory et al. 
2006). 
 
DREADD-induced neuronal manipulation in vivo 
 
Eight-week-old male C57BL/6N mice were injected 
stereotaxically with CAG-hM3Dq-mCherry-rAAV or 
control CAG-rAAV (in 1.5 µl of PBS) aimed at targeting 
the dorsal striatum. Each animal received 1 bilateral 
injection at the following coordinates (to bregma): 
anteroposterior +0.5, lateral ±2.0, and dorsoventral 
±3.0. Four weeks after surgery, mice were assigned to 
different experimental groups before starting the 
pharmacological treatments. Rotarod performance 
was analyzed along the last 3 d of treatment. Mice 
were subsequently killed by intracardial perfusion and 
their brains were excised for immunofluorescence 
analyses. 
 
Eight-week-old wild-type, D1R-Cre, D2R-Cre, and/or 
D1R/D2R-Cre mice were injected either unilaterally 
into the right brain hemisphere (for assessing 
rotational behavior) or bilaterally (for assessing motor 
activity, motor coordination, and sleep–wake pattern) 
with the Cre-dependent CAG-DIO-hM3Dq-mCherry-
rAAV at the aforementioned coordinates. Animals 
were left untreated for 4 weeks after surgery before 
the pharmacological treatments and behavioral tests 
(see below). 
 
Drug administration in vivo 
 
CNO (Santa Cruz Biotechnology) was prepared fresh in 
saline (0.9% NaCl) just before the experiments and 
injected intraperitoneally at 1 or 10 mg/kg. SP600125 
(2H-dibenzo [cd,g]indazol-6-one) was dissolved in 
45% (w/v) β-cyclodextrin (Sigma-Aldrich) and injected 
intraperitoneally at 15 mg/kg. 
 
Behavioral and electroencephalographic assays 
Spontaneous locomotor activity  
 
D1R-Cre, D2R-Cre, and D1R/D2R-Cre mice and their 
wild-type littermates were injected bilaterally with 
CAGDIO-hM3Dq-mCherry-rAAV as described above. 
After vector administration, passive retro-reflective 
markers (B&L Engineering; diameter 7.9 mm, 
weight_0.5 g) were attached with acrylic dental 
cement to the skull of each mouse, which was single-
housed in its cage. Acquisition (5 Hz frequency) was 
performed using 3 OptiTrack Flex3 cameras (Natural 
Point), allowing the continuous recording of the 
position of each animal during dark and light phases. 
Acquisition and automated tracking software were 
from MouvTech. Throughout the study, animals had 
unrestricted access to water and food and were 
subjected to a 12 h light/12 h dark cycle. Offline 
analysis was performed using homemade software 
developed with Matlab (The MathWorks). Mice were 
habituated to the home cage for 7 d. They were then 
injected with vehicle (saline), followed 24 h later by 
acute CNO (1 mg/kg) and then by chronic CNO (10 mg/ 
kg/d for 14 d). Total locomotor activity in 12 h light/12 
h dark cycles was recorded. 
 
Exploration, motor coordination, and spatial 
recognition  
 
D1R-Cre, D2R-Cre, and D1R/D2R-Cre mice and their 
wild-type littermates were injected bilaterally with 
CAG-DIO-hM3Dq-mCherry-rAAV as described above. 
They underwent a treatment schedule of 1 d of acute 
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CNO (1 mg/kg) followed by chronic CNO (10 mg/kg/d 
for 14 d) (or saline vehicle). Exploration analyses were 
conducted in an automated actimeter (ActiTrack; 
Panlab; (Blázquez et al. 2011) the first day of acute 
treatment (1 h after injection), as well as after the last 
day of treatment. Motor coordination (Rotarod test) 
and spatial recognition (Y-maze test) were evaluated 
along the last 3 d of treatment before CNO 
administration to avoid acute drug effects (Blázquez et 
al. 2011; Pietropaolo et al. 2014).  
 
Sleep–wake pattern  
 
D1R-Cre, D2R-Cre, and D1R/D2R-Cre mice and their 
wild-type littermates were injected bilaterally with 
CAG-DIOhM3Dq-mCherry-rAAV as described above 
and implanted a multisite electrode array for 
electroencephalographic recordings as described 
previously (Lebreton et al. 2015). Mice underwent two 
sessions of acute activation recording, one with 
vehicle (saline) and another, after 24 h, with CNO (1 
mg/kg) plus one session of chronic activation 
recording after the last day of chronic CNO treatment 
(10 mg/kg/d for 14 d or saline vehicle). 
Electrophysiological data were analyzed as described 
previously (Lebreton et al. 2015). 
 
Rotational behavior  
 
D1R-Cre and D2R-Cre mice were injected unilaterally 
with CAG-DIO-hM3Dq-mCherry-rAAV as described 
above. Mice were then acutely injected with vehicle 
(saline) or, after 24 h, with CNO (1 mg/kg); in both 
cases, animals were tested 1 h later in an open field. 
Subsequently, animals were injected for 15 d with CNO 
(10 mg/kg/d) together with SP600125 (15 mg/kg/d) or 
their respective vehicles. One day after the last 
treatment, all mice were injected with vehicle and, 
after 24 h, with CNO (1 mg/kg); in both cases, animals 
were tested 1 h later in an open field. Ipsilateral 
movements (complete turning to the right) and 
contralateral movements (complete turning to the 
left) were assessed by monitoring manually the total 
time spent in rotation for 5 min. No rotations were 
observed in wild-type mice expressing CAG-
DIOhM3Dq-rAAV and injected with vehicle or CNO.  
 
Immunomicroscopy  
 
Coronal free-floating sections (50 µm-thick) were 
obtained from paraformaldehyde-perfused mouse 
brains. Samples were incubated with antibodies 
against dopamine- and cAMP-regulated 
phosphoprotein of 32 kDa (DARPP-32; 1:1000; BD 
Biosciences, #611520), NeuN (1:500; Millipore, 
#MAB377), D1R (1:500; Frontier Science, #af500), D2R 
(1:500; Frontier Science, #af750), choline 
acetyltransferase (ChaT; 1:1000; Merck, #AB144P) or 
cFos (1:2000; Santa Cruz Biotechnology, #SC52), 
followed by staining with the corresponding Alexa 
Fluor 488, 594, or 647 antibodies (1:1000; Life 
Technologies) or with HRP-coupled secondary 
antibodies plus DAB chromogenic visualization 
(Vector Laboratories) (Blázquez et al. 2011). Nuclei 
were visualized with DAPI. Analysis of marker protein 
immunoreactivity in the dorsal striatum was 
conducted in a 1-in-10 series per animal (from bregma 
1.5 to ± 0.5 coronal coordinates). For DARPP-32, D1R, 
and D2R, data were calculated as immunoreactive 
area per total cell nuclei and are expressed as a 
percentage of the control. D1R and D2R 
immunofluorescence was counted simultaneously, so 
these are shown in the same samples. For NeuN and 
ChaT, data were calculated as number of positive cells 
per total cell nuclei and expressed as percentage of the 
control. Confocal fluorescence images were acquired 
using TCS-SP2 software and a SP2 AOBS microscope 
(Leica). Pixel quantification and colocalization were 
analyzed with ImageJ software.  
 
Western blotting  
 
Western blot analysis was conducted with antibodies 
raised against phosphorylated ERK (1:1000; Cell 
Signaling Technology, #9101), total ERK (1:1000; Cell 
Signaling Technology, #9102), phosphorylated JNK 
(1:1000; Cell Signaling Technology, #9255), total JNK 
(1:1000; Cell Signaling Technology, #9252), 
phosphorylated cJun (1:1000; Cell Signaling 
Technology, #2361), total cJun (1:1000; Cell Signaling 
Technology,#9156), phosphorylated PYK2 (1:1000; 
Cell Signaling Technology, #3291), total PYK2 (1:1000; 
Cell Signaling Technology, #3480), and β-tubulin III 
(1:4000; Sigma-Aldrich, #T8660), following standard 
procedures (Blázquez et al. 2011). Densitometric 
analysis was performed with Quantity One software 
(Bio-Rad).  
 
Cell culture  
 
Conditionally immortalized mouse striatal neuroblasts 
infected with a defective retrovirus transducing the 
temperature-sensitive A58/U19 large T antigen 
(Trettel et al. 2000), designated as STHdh cells; 
provided by Silvia Ginés, University of Barcelona, 
Spain) were grown at 33°C in DMEM supplemented 
with 10% fetal bovine serum, 1mM sodium pyruvate, 2 
mM L-glutamine, and 400 µg/ml geneticin (Blázquez 
et al. 2011). Cells were devoid of mycoplasma 
contamination. Primary striatal neurons were 
obtained from 2-d-old C57BL/6N mice using a papain 
dissociation system (Worthington). Striata were 
dissected and cells were seeded on plates precoated 
with 0.1 mg/ml poly-D-lysine at 200,000 cells/cm2 in 
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Neurobasal medium supplemented with B27 and 
Glutamax (Blázquez et al. 2011).  
 
Cell nucleofection and infection  
 
STHdh cells were nucleofected with a construct 
expressing hM3DqmCherry (or mCherry alone as 
control) under the CAG promoter (see above) using an 
Amaxa mouse neuron nucleofector kit (Lonza). Two 
days after nucleofection, cells were treated in 0.5% 
FBS medium with CNO (or H2O as vehicle) in the 
presence of different signaling pathway inhibitors. 
Cells were treated for up to 8 h for cell viability or 
Western blot assays (Blázquez et al. 2011). In a second 
set of experiments, the CAG-hM3Dq-mCherry 
construct was conucleofected with plasmids 
expressing shRNA directed to Jnk1, Jnk2, Jnk3, or Pyk2 
or a scrambled control (Origene). The extent of 
silencing induced by the different kinase-directed 
shRNA, as determined by RT-PCR, ranged between 
50% and 80% relative to the scrambled control. In a 
third set of experiments, STHdh cells were 
nucleofected with a CAG-DTA construct. Primary 
neurons were infected at day 2 in vitro with a rAAV 
expressing hM3Dq (or GFP as control) and kept until 
day 13 in vitro for cell viability experiments. 
 
Statistics  
 
Data are presented as mean ± SEM. Statistical 
comparisons were made by one-way or two-way 
ANOVA with post hoc Bonferroni, Tukey, or Neuman–
Keuls test or by unpaired Student’s t test. A p value of 
less than of 0.05 was considered significant. Graphs 
and statistics were generated by GraphPad Prism 6.01. 
 
MATERIALS AND METHODS-OBJECTIVE 2 
 
Animals 
 
We used conditional mutant mice, generated by the 
Cre-loxP technology, in which the CB1R gene is 
primarily absent from cortical glutamatergic neurons 
of the dorsal telencephalon (CB1Rfloxed/floxed;Nex-Cre/+ 
mice; herein referred to as Glu-CB1R-/- mice) (Monory 
et al. 2006) or from astroglial cells (CB1Rfloxed/floxed;GFAP-
CreERT2/+ mice; herein referred to as GFAP-CB1R-/- mice; 
treated with tamoxifen to induce Cre expression as 
described) (Han et al. 2012). We also used mice bearing 
a genetic deletion of the MGL gene in all body cells 
(either in heterozygous or homozygous form; MGL+/- 
and MGL-/- mice, respectively) or selectively in 
astroglial cells (MGLfloxed/floxed;GFAP-Cre/+ mice; herein 
referred to as GFAP-MGL-/- mice) (Grabner et al. 2016). 
BAC transgenic mice expressing the tdTomato and 
EGFP reporter genes under the control of the D1R and 
D2R promoter, respectively (Drd1a-tdTomato/Drd2-
EGFP mice), were also used (colony founders kindly 
provided by Dr. Rosario Moratalla, Cajal Institute, 
Madrid, Spain). Hemizygous mice transgenic for exon 
1 of the human huntingtin gene with a largely 
expanded CAG tract (~250 CAG repeats; R6/2L mice) 
were generated from R6/2 mice (The Jackson 
Laboratory) and subsequently crossed with 
CB1Rfloxed/floxed mice to obtain the double-mutant 
R6/2L:CB1Rfloxed/floxed line as described (Chiarlone et al. 
2014). Wild-type C57BL/6N mice were purchased from 
Harlan Laboratories. In all the experiments, mice were 
compared with their corresponding littermates. 
Animal housing, handling and assignment to the 
different experimental groups were conducted as 
described (Blázquez et al. 2011). Mice were sacrificed 
by intracardial perfusion and their brains were excised 
for tissue analyses. All the experimental procedures 
used were performed in accordance with the 
guidelines and with the approval of the Animal 
Welfare Committee of Universidad Complutense de 
Madrid and Comunidad de Madrid, and in accordance 
with the directives of the European Commission. 
 
Viral vectors 
 
Constructs expressing CFP-tagged human huntingtin 
exon 1 harboring a pathogenic polyQ tract of 94 CAG 
repeats or a normal, non-pathogenic polyQ tract of 16 
CAG repeats (Maynard et al. 2009) (kindly provided by 
Dr. José J. Lucas, Severo Ochoa Molecular Biology 
Center, Madrid, Spain), HA-tagged Cre recombinase 
(Monory et al. 2006), EGFP (Chiarlone et al. 2014) or 
Gq-coupled human M3 muscarinic DREADD (hM3Dq) 
fused to mCherry (Alexander et al. 2010) (kindly 
provided by Dr. Brian L. Roth, University of North 
Carolina, Chapel Hill, NC), were subcloned in rAAV 
expression vectors with a minimal CaMKIIα or GFAP 
promoter (kindly provided by Dr. Karl Deisseroth, 
Stanford University, Stanford, CA) by using standard 
molecular cloning techniques. All vectors used were of 
an AAV1/AAV2 mixed serotype, and were generated 
by polyethylenimine (PEI) transfection of HEK293T 
cells and subsequent purification (Monory et al. 2006). 
Vectors were injected stereotactically either into the 
dorsal striatum (vectors diluted in 3 µl PBS) or into the 
motor cortex projecting onto the dorsal striatum 
(vectors diluted in 1.5 µl PBS). In the case of the 
striatum, each animal received one bilateral injection 
at coordinates (to bregma): antero-posterior +0.5, 
lateral ±2.0, dorso-ventral -3.5. In the case of the 
cortex, each animal received 2 bilateral injections at 
coordinates (to bregma): antero-posterior +1.5, lateral 
±1.2, dorso-ventral -1.7; and antero-posterior -0.5, 
lateral ±1.2, dorso-ventral -1.2. We have described 
previously the placement of the rAAV vectors within 
the cortex and the striatum under those conditions 
(Chiarlone et al. 2014; Blázquez et al. 2015; Bellocchio 
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et al. 2016). In the DREADD experiments (Chiarlone et 
al. 2014), animals were left untreated for 6 weeks after 
rAAV vector injection prior to starting the 
pharmacological treatments for 4 weeks, after which 
RotaRod test was conducted and animals sacrificed. In 
the R6/2L:CB1floxed/floxed mouse experiments (Chiarlone 
et al. 2014), 4 week-old animals were injected with the 
rAAV vectors and, at week 20 of age, RotaRod test was 
conducted and animals were subsequently sacrificed. 
 
Drugs 
 
CNO (Santa Cruz Biotechnology) was prepared fresh in 
saline (0.9% NaCl) just before the experiments and 
injected i.p. at 1 mg/kg/d. Stock solution of MK-801 
(Sigma) was prepared in DMSO and, just before the 
experiments, diluted in saline (final DMSO 
concentration: 2%) for i.p. injections (0.03 mg/kg/d). 
SR141716 (rimonabant; kindly provided by Sanofi-
Aventis, Montpellier, France), THC (The Health 
Concept), and JZL-184 (Cayman Chemical) were 
stored in DMSO. Just before the experiments, 
solutions of vehicle [1% (v/v) DMSO in Tween-
80/saline (1:18, v/v)], SR141716 (1 mg/kg/d), THC (1 
mg/kg/d) or JZL-184 (8 mg/kg/d) were prepared for i.p. 
injections. SKF-81297 (Tocris) was prepared fresh in 
saline just before the experiments and injected i.p. at 1 
mg/kg.  
 
Confocal microscopy 
 
Coronal free-floating sections (50 μm-thick) were 
obtained from paraformaldehyde-perfused mouse 
brains. Samples were incubated with antibodies 
against NeuN (1:500; Chemicon #MAB377), DARPP-32 
(1:1000; BD #611520), D1R (1:500; Frontier Science 
#af500), D2R (1:500; Frontier Science #af750), PSD-95 
(1:500; Abcam #ab18258, S100β (1:500; Abcam 
#ab868), followed by staining with the corresponding 
Alexa Fluor 488, 594 or 647 antibodies (1:1000; Life 
Technologies). Nuclei were visualized with DAPI. 
Analysis of marker-protein immunoreactivity in the 
dorsal striatum was conducted as described 
(Bellocchio et al. 2016) in a 1-in-10 series per animal 
(from bregma +1.5 to -0.5 coronal coordinates). For 
DARPP-32, D1R, D2R and PSD-95, data were 
calculated as immunoreactive area per total cell nuclei, 
and expressed as percentage of the control. For NeuN, 
S100β, as well as for tdTomato and EGFP fluorescence 
in Drd1a-tdTomato/Drd2-EGFP mice, data were 
calculated as number of positive cells per total cell 
nuclei, and expressed as percentage of the control. 
Confocal fluorescence images were acquired using 
TCS-SP2 software and a SP2 AOBS microscope 
(Leica). Pixel quantification and co-localization were 
analyzed with ImageJ software (NIH, Bethesda, MD). 
 
Behavior 
 
Motor coordination (RotaRod performance) was 
evaluated along 3 consecutive days as described 
(Bellocchio et al. 2016). Exploration analyses were 
conducted in an automated actimeter (ActiTrack; 
Panlab) 30 min after acute treatment with vehicle or 
SKF-81297 (Bellocchio et al. 2016). 
 
Microdialysis 
 
Glutamate and GABA were measured from 8 week-old 
Glu-CB1R-/- mice or their CB1Rfloxed/floxed littermates. 
Fractions of dialysate were on-line analyzed for 
Glutamate content every 15 min using an HPLC system 
with electrochemical detection. The HPLC system 
consisted of a Waters 510 series pump in conjunction 
with an electrochemical detector (Mod. Intro, Antec, 
Leyden, The Netherlands). Dialysates were injected 
onto a 5 mm RP-18 column (LiChroCART 125-4, Merck, 
Darmstadt, Germany) via a VALCO valve fitted with a 
65 μL sample loop. Detection limit was defined by a 
signal to noise ratio of 2:1, being approximately 6 
fmol/sample. 
 
Synaptosomes  
 
Striatal synaptosomes were isolated from 8 week-old 
C57BL/6N mice as described (Martín et al. 2010). They 
were subsequently incubated with no additions, 
pertussis toxin (PTx) (1.5 mg/ml, 2 h), CCG-1423 (25 
µM, 45 min) or YM-25489 (10 µM, 45 min). HU-210 (5 
µM) was added to the synaptosomal preparations 1 
min before the glutamate release measures. 
Glutamate concentration in the extracellular medium 
was assayed. 
 
2-AG and AEA quantification 
 
The levels of 2-AG and AEA were measured as 
described previously (Gomez et al. 2010) by HPLC/MS. 
Striata were isolated from 8 week-old MGL+/+, MGL-/-, 
GFAP-MGLfloxed/floxed and GFAP-MGL-/- mice. Absolute 
2-AG and AEA levels were estimated by comparison 
with their respective d8-2-AG and d8-AEA standards. 
 
Statistics 
 
Data are presented as mean ± SEM. Statistical 
comparisons were made by one-way or two-way 
ANOVA with post hoc Bonferroni, Tukey, or Sidak test 
or by unpaired Student’s t test. A p value of less than 
of 0.05 was considered significant. Graphs and 
statistics were generated by GraphPad Prism 6.01. 
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CHAPTER 1 
The dorsal striatum plays a key role in the control of 
motor behavior. The functionality of striatal neurons is 
tightly controlled by various metabotropic receptors. 
Whereas the Gs/Gi-protein-dependent tuning of 
striatal neurons is fairly well known, the precise impact 
and underlying mechanism of Gq-protein-dependent 
signals remain poorly understood. In this chapter, by 
using different experimental approaches, especially 
the DREADD technology, we show that sustained 
activation of Gq-protein signaling impairs the 
functionality of striatal neurons and unveil the precise 
molecular mechanism underlying this process, which 
involves a PLC/Ca2+/PYK2/JNK pathway. Moreover, 
engagement of this intracellular signaling route is 
functionally active in the mouse dorsal striatum in vivo, 
as proven by the disruption of neuronal integrity and 
behavioral tasks. Acute Gq-protein activation in direct-
pathway or indirect-pathway neurons produces an 
enhancement or a decrease, respectively, of activity-
dependent parameters. In contrast, sustained Gq-
protein activation impairs the functionality of direct-
pathway and indirect-pathway neurons and disrupts 
the behavioral performance and 
electroencephalography-related activity tasks 
controlled by either anatomical framework. 
Collectively, these findings define the molecular 
mechanism and functional relevance of Gq-protein-
driven signals in striatal circuits under normal and 
overactivated states. 
 
 
 
CAPÍTULO 1 
El estriado dorsal desempeña un papel clave en el 
control motor. La función de las neuronas estriatales 
está finamente controlada por varios receptores 
metabotrópicos. Mientras que la modulación de las 
neuronas del estriado dependiente de proteínas Gs/Gi 
es bastante conocido, el impacto exacto y el 
mecanismo subyacente de señales dependiente de la 
proteína Gq siguen sin comprenderse por completo. En 
este capítulo, utilizando diferentes aproximaciones 
experimentales, especialmente la tecnología DREADD, 
se muestra que la activación sostenida de la 
señalización a través de proteínas Gq daña la 
funcionalidad de las neuronas del estriado, y se revela 
el mecanismo molecular exacto que subyace a este 
proceso e involucra la vía de señalización de 
PLC/Ca2+/PYK 2/JNK. Es más, el compromiso de esta 
ruta de señalización intracelular es también ocurre en 
el estriado dorsal de ratón in vivo, como demuestra la 
alteración de la integridad neuronal y las tareas 
conductuales. La activación aguda de las proteínas Gq 
en las neuronas de la vía directa o indirecta produce un 
aumento o una disminución, respectivamente, de 
parámetros dependientes de actividad. Por el 
contrario, la activación sostenida de proteínas Gq 
deteriora la funcionalidad de las neuronas de la vía 
directa e indirecta y altera tanto el comportamiento 
como el registro electroencefalográfico (EEG) derivado 
de la actividad motora controlados por estas dos vías 
anatómicas. Colectivamente, estos resultados definen 
el mecanismo molecular y la relevancia funcional de la 
señalización mediada por proteínas Gq en los circuitos 
estriatales durante estados normales y de 
sobreactivación. 
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RESULTS-OBJECTIVE 1 
 
Sustained Gq-protein signaling disrupts the 
balanced control of behavior exerted by D1R-MSNs 
and D2R-MSNs in vivo 
 
To study the impact of Gq-driven signaling on striatal 
circuits, we set up an experimental model to 
manipulate direct-pathway or indirect-pathway MSNs 
selectively and reliably in vivo. For this purpose, we 
first injected a FLEX (CAG-DIO) rAAV encoding 
mCherry into the dorsal striatum of D1R-Cre and D2R-
Cre mice, which allowed delineating the connectivity 
to output nuclei (Fig. 1A). Counting of mCherry-
positive cells in D1R-Cre and D2R-Cre mice showed 
that recombination was slightly higher in the former 
mouse line (63 ± 5% and 40 ± 4% of mCherry-positive 
cells in D1R-Cre and D2R-Cre mice, respectively; n = 7 
animals per group). We also analyzed mCherry 
expression in ChaT-positive interneurons and found 
that our CAG-DIO-rAAV-driven infection procedure 
generated no detectable recombination in D1R-Cre 
mice (0% of ChaT-positive cells infected; n = 7 mice) 
and only a negligible recombination in D2R-Cre mice 
(<3% of ChaT-positive cells infected; n = 7 mice). Next, 
a CAG-DIO-rAAV encoding hM3Dq fused to mCherry 
was injected in the same experimental conditions. The 
Cre-driven expression of the transgene was achieved 
selectively in D1R-MSNs and D2R-MSNs, as evidenced 
by D1R/mCherry and D2R/mCherry colabeling 
analyses (Fig. 1B). Moreover, the ability of the 
transgene to trigger neuronal activation was proven by 
the enhanced cFos immunoreactivity observed in the 
striata of D1R-Cre and D2R-Cre mice (but not wild-
type mice) that had been acutely treated with CNO 
[one single intraperitoneal injection at 1 mg/kg 
(Alexander et al. 2010) (Fig. 1C)]. 
 
In a first experimental paradigm aimed at assessing 
dorsal striatum functionality, we observed that acute 
activation of Gq-protein signaling in D1R-MSNs 
enhanced exploratory activity in an open field, 
whereas acute activation in D2R-MSNs produced the 
opposite effect (Fig. 2A). Strikingly, upon chronic CNO 
treatment [one daily intraperitoneal injection of CNO 
at 10 mg/kg for 14 d; (Alexander et al. 2010; Chiarlone 
et al. 2014)] the acute Gq-evoked hyperlocomotor 
reactivity on D1R-MSNs was abolished and the acute 
Gq-evoked hypolocomotor reactivity on D2R-MSNs 
did not only disappeared, but even turned to an 
opposite hyperlocomotor reactivity (Fig. 2B).
 
Figure 1. Expression and activity of hM3Dq-mCherry in D1R-MSNs and D2R-MSNs in vivo. D1R-Cre and D2R-Cre mice were injected 
stereotaxically into the dorsal striatum with CAG-DIO-mCherry- rAAV (A) or CAG-DIO-hM3Dq-mCherry-rAAV (B, C), and left untreated for 4 
weeks. A, Representative images delineating the connectivity from the striatum to output nuclei in D1R-Cre and D2R-Cre mice. Str, Striatum; 
GPe, external globus pallidus; GPi, internal globus pallidus; SNr, substantia nigra pars reticulata. Scale bar, 1 mm. B, Fluorescence colabeling of 
D1R/mCherry and D2R/mCherry shows the specificity of Cre-driven recombination. Examples of cells that are double-positive for D1R/mCherry 
or D2R/mCherry are indicated by arrows. Scale bar, 30 µm. C, Animals subsequently received one single intraperitoneal injection of vehicle or 
CNO (1 mg/kg) and, after 2 h, were killed for cFos immunohistochemistry. Scale bar, 75 µm.
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Figure 2. Sustained Gq-protein signaling disrupts the balanced control of behavior exerted by D1R-MSNs and D2R-MSNs in vivo. Wild-
type, D1R-Cre, D2R-Cre, and D1R/D2R-Cre mice were injected stereotaxically into the dorsal striatum with CAG-DIO-hM3Dq-mCherry-rAAV 
and left untreated for 4 weeks. A, Animals subsequently received one single intraperitoneal injection of vehicle or CNO (1 mg/kg) and, 1 h later, 
their ambulation was tested in an open field. B, Animals subsequently received one daily intraperitoneal injection of vehicle or CNO (10 mg/kg) 
for 14 consecutive days and their ambulation was tested in an open field. C, D, Animals used for continuous ambulatory activity recordings were 
implanted during surgery light-reflecting devices. They subsequently received one single intraperitoneal injection of vehicle, followed after 24 
h by CNO (1 mg/kg; acute CNO) and, after 24 h, one daily intraperitoneal injection of vehicle or CNO (10 mg/kg) for 14 consecutive days (chronic 
CNO). Total daily ambulations for the 12 h light period (7:00 –19:00), expressed as percentage of vehicle treatment, are shown for 16 consecutive 
days (C), as well as for the acute day and the last chronic-treatment day (D). E, Animals used for electroencephalographic recordings were 
implanted during surgery with electrode-miniature array devices. They subsequently underwent 2 sessions of acute-activation 
electroencephalographic recording, one with vehicle (saline) and another, after 24 h, with CNO (1 mg/kg) plus one session of chronic-activation 
electroencephalographic recording after the last day of chronic CNO treatment (10 mg/kg/d for 14 consecutive days; or saline vehicle). In each 
case, animals were subjected to recording for 3 h and sleep–wake changes induced by CNO treatment were expressed as percentage of the 
respective vehicle treatment. *p < 0.05, **p < 0.01 from the corresponding vehicle group (A, B) or the wild-type group (D, E). 
.
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In a second experimental paradigm, the effect of acute 
and chronic Gq activation in the direct or indirect 
pathway was monitored using passive retro-reflective 
markers attached to the head of each mouse 
expressing hM3Dq-mCherry in D1R-MSNs or D2R-
MSNs. Singly housed mice were thus continuously 
tracked in their home cage during 16 consecutive days 
under vehicle (one single intraperitoneal saline 
injection), acute CNO (one single intraperitoneal 
injection at 1 mg/kg the day after) and subsequent 
chronic CNO (one daily intraperitoneal injection at 10 
mg/kg for 14 d). Consistent with the aforementioned 
open-field data, acute Gq activation in D1R-MSNs 
increased continuous ambulatory activity, whereas 
acute Gq activation in D2R-MSNs led to the opposite 
outcome (Fig. 2C,D). Sustained Gq activation in D1R-
MSNs abolished the acute hyperactivity, whereas 
sustained Gq activation in D2R-MSNs turned the acute 
hypoactivity into hyperactivity (Fig. 2C,D). These 
behavioral changes were visible only during light cycle 
(data not shown for dark cycle). The different response 
to chronic CNO treatment shown by D1R/D2R- Cre 
mice in Figure 2, C and D, versus Figure 2B most likely 
reflects the different type of test used, namely 
locomotor activity in the home cage versus locomotor 
reactivity in a novel environment. The latter can be 
subjected to other behavioral components such as 
anxiety and risk assessment, which, however, fall 
beyond the scope of the present study. 
 
A third experimental paradigm was used to evaluate 
whether the aforementioned behavioral changes in 
activity were accompanied by actual 
electroencephalographic changes, specifically in the 
sleep–wake pattern. Therefore, we found that acute 
Gq activation in D1R-MSNs, in concert with 
hyperactivity, produced an increased (REM) sleep (Fig. 
2E, right). Acute Gq activation in D2R-MSNs, in 
concert with hypoactivity, decreased time spent in 
both slow-wave amount of wake (Fig. 2E, left), as well 
as a (Fig. 2E, middle) and rapid eye movement induced 
an increased amount of sleep, specifically in the slow-
wave phase (Fig. 2E, middle). Conversely, sustained 
Gq activation in D1R-MSNs abolished, not only the 
acute hyperactivity, but also the acute wakefulness 
state (Fig. 2E, left), whereas sustained Gq activation in 
D2R-MSNs not only induced hyperactivity, but also 
enhanced the time spent in wake (Fig. 2E, left) and 
reduced the time spent in REM sleep (Fig. 2E, right). 
Spectral analysis of electroencephalograms did not 
reveal changes in major brain rhythms in the delta, 
theta, or gamma frequencies during different vigilance 
states (data not shown).  
 
Collectively, these findings show that direct-pathway 
and indirect-pathway MSNs can be “turned on” by 
acute Gq-protein signaling or “turned off” by sustained 
Gq-protein signaling in vivo  
 
Diphtheria-toxin-mediated ablation of D1R-MSNs 
and D2R-MSNs recapitulates the behavioral 
phenotype of sustained Gq-protein signaling 
 
To evaluate whether the observed changes elicited by 
sustained Gq-protein signaling in vivo are due to the 
dysfunction of MSNs, we first analyzed the 
immunoreactivity of the MSN marker DARPP-32 in 
D1R-Cre and D2R-Cre mice expressing hM3Dq-
mCherry in the dorsal striatum. Chronic CNO 
treatment (10 mg/kg/d for 2 consecutive weeks) 
decreased DARPP-32 immunoreactivity similarly in 
D1R-Cre mice (relative value of CNO vs vehicle: 62 ± 
6%; n = 8 –9 animals per group; p < 0.01) and D2R-Cre 
mice (relative value of CNO vs vehicle: 70 ± 5%; n = 7– 
8 animals per group; p < 0.01). This regime of CNO 
administration had no significant effect on wild-type 
mice injected with CAG-DIO-hM3Dq-mCherry-rAAV 
(relative value of CNO vs vehicle: 96 ± 9; n = 7–9 
animals per group). Next, we evaluated the behavioral 
phenotype of D1R-Cre and D2R-Cre mice that had 
been injected stereotaxically into the dorsal striatum 
with a FLEX-rAAV encoding diphtheria toxin, which is 
well known to produce cell-population-specific 
ablation (Kreitzer & Berke 2011; Durieux et al. 2012; 
Kim et al. 2014). We selected three behavioral tests 
that rely at least in part on the dorsal striatum: the 
open field (to assess exploratory activity), Rotarod (to 
assess motor coordination), and Y-maze (to assess 
short-term spatial memory), and compared the 
phenotype of chronic CNO-treated hM3Dq-mCherry-
expressing mice (Fig. 3A) with that of diphtheria-toxin-
expressing mice (Fig. 3 E, F). Overall, the disrupting 
effects evoked by the selective expression of 
diphtheria toxin in D1R-MSNs or D2R-MSNs 
recapitulated very closely the respective changes 
elicited by sustained Gq signaling in the two MSN 
populations. Specifically, aside from the exploration 
assays, in which either chemogenetically or diphtheria 
toxin-induced dysfunction of D2R-MSNs enhanced 
locomotor activity (Fig.3 B, G), we found that either 
chemogenetically or diphtheria- toxin- induced 
dysfunction of D1R-MSNs impaired motor 
coordination (Fig. 3C, H), whereas either 
chemogenetically or diphtheria-toxin-induced 
dysfunction of D2R-MSNs impaired short-term spatial 
memory (Fig. 3 D, I; no differences in total arm entries 
were found among the different animal groups tested; 
data not shown). 
 
The lack of motor coordination deficits shown by our 
D2R-Cre mice upon chronic CNO administration (Fig. 
3C), compared with the data reported by Durieux et al. 
(2012) on mice in which A2AR-expressing neurons had
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Figure 3. Diphtheria-toxin-mediated ablation of D1R-MSNs and D2R-MSNs recapitulates the behavioral phenotype of sustained Gq-
protein signaling. A–D, Wild-type, D1R-Cre, D2R-Cre, and D1R/D2R-Cre mice were injected stereotaxically into the dorsal striatum with CAG-
DIO-hM3Dq-mCherry-rAAV and left untreated for 4 weeks. Animals subsequently received one daily intraperitoneal injection of vehicle (saline) 
or CNO (10 mg/kg) for 2 consecutive weeks. Shown is the scheme of the chronic CNO treatment experiment. The arrows indicate injections 
(blue, rAAV; red, vehicle/CNO; A). Effect of chronic CNO treatment on ambulation (open field; B), motor coordination (Rotarod; C), and spatial 
recognition (Y-maze; D). E–I, Wild-type, D1R-Cre, D2R-Cre, and D1R/D2R-Cre mice were injected stereotaxically into the dorsal striatum with 
a rAAV encoding mCherry-FLEX-DTA and left untreated for 4 weeks. Scheme of the diphtheria toxin expression experiment. The blue arrow 
indicates rAAV injections (E). Fluorescence labeling of mCherry and DARPP-32 shows the effect of Cre-driven recombination in the mCherry-
FLEX-DTA animals. Scale bar, 50 µm (F). Effect of diphtheria toxin expression on ambulation (open field; G), motor coordination (Rotarod; H), 
and spatial recognition (Y-maze; I). *p<0.05, **p<0.01 from the corresponding vehicle group (B–D), wild-type group (G, I), or pre-rAAV group 
(H). DTA, Diphtheria toxin fragment A.
55 
 
 
Figure 4. Sustained Gq-protein signaling induces the death of STHdh cells via PLC/Ca 2+/PYK2/JNK. STHdh cells were nucleofected with 
constructs expressing hM3Dq-mCherry or mCherry. A, Cells were incubated for 8 h with vehicle or the indicated doses of CNO. B, Cells were 
incubated for 8 h with vehicle or 50 µM CNO, together with vehicle or the indicated additions (see experimental details in Table 1). C, Cells were 
also nucleofected with a nontargeted shRNA, or with shRNAs directed against Jnk1, Jnk2, Jnk3, or Pyk2 and subsequently incubated for 8 h 
with vehicle or 50 µM CNO. Relative cell viability is shown in all panels. D, STHdh cells were incubated for the times indicated with vehicle or 50 
µM CNO. E, STHdh cells were incubated for 2 h with vehicle or 50 µM CNO, together with vehicle or the indicated additions (see experimental 
details in Table 1). In D and E, the representative Western blots with the molecular weight of the protein bands (left) and quantification of 
optical density values of the protein bands relative to those of loading controls (right) are shown. In E (left), images from different parts of the 
same gel or from different gels were grouped. *p < 0.05, **p < 0.01 from the corresponding vehicle-treated cells. #p < 0.05, ##p < 0.01 from 
the corresponding CNO-vehicle-treated cells. Bis, Bisindolylmaleimide; Pep, pepstatin A. 
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been ablated, could be due to the different 
experimental conditions used. Therefore, we only 
analyzed Rotarod performance after training, whereas 
they found a Rotarod impairment only at the 
beginning of the training period, after which animals 
reached the same values as controls. Their D1R-MSN-
ablated mice showed, like ours, a persistent Rotarod 
impairment also at the end of the training period 
(Durieux et al. 2012). 
 
Together, these observations suggest that sustained 
Gq-protein signaling might impair striatal circuits in 
vivo by inducing the inactivation of direct-pathway 
and indirect-pathway MSNs.  
 
Sustained Gq-protein signaling induces the death of 
MSNs via a PLC/Ca 2+/PYK2/JNK pathway 
 
To analyze the molecular mechanism of Gq-driven 
action on MSNs, we first used cultures of STHdh 
mouse striatal neuroblasts, a well-established MSN-
like cell model (Trettel et al. 2000). Cells were 
electroporated with a plasmid encoding hM3Dq-
mCherry (or only mCherry) and subsequently treated 
with CNO (or vehicle). Exposure of cells expressing 
hM3Dq-mCherry (but not mCherry) to CNO decreased 
viability in a dose- dependent manner (Fig. 4A). From 
these assays, a dose of 50 µM CNO was selected for 
further experiments aimed at deciphering the signal 
transduction pathways responsible for Gq-driven cell 
death (Table 1). The phospholipase C (PLC) inhibitor 
U73122 (but not its inactive analog U73343), the 
intracellular Ca2+ chelator BAPTA-AM, and the 
intracellular Ca2+-release inhibitor 2-APB prevented 
Gq-evoked cell death (Fig. 4B), thus supporting the 
involvement of PLC/Ca2+ signaling. In contrast, the 
general protein kinase C (PKC) inhibitor 
bisindolylmaleimide was ineffective. When assessing 
potential downstream effectors of PLC/Ca2+, we found 
that the cJun N-terminal kinase (JNK) inhibitor 
SP600125 prevented Gq-induced cell death, whereas 
blockade of the extracellular signal- regulated kinase 
(ERK) cascade (with the MEK inhibitor U0126), 
phosphatidylinositol 3-kinase (PI3K; with LY294002), 
Akt (with Akti-1/2), or mammalian target of rapamycin 
complex 1 (mTORC1; with rapamycin) did not affect 
Gq action (Fig. 4B). Gq-driven STHdh cell death was 
caspase independent (as evidenced by the lack of 
effect of the pan-caspase inhibitor ZVAD-FMK), but 
lysosome dependent (as inferred from the preventive 
effect of the lysosomal-protease/cathepsin inhibitors 
pepstatin A and E64d; Fig. 4B). 
 
To further clarify the involvement of the JNK cascade 
in cell death, we conducted additional experiments in 
STHdh cells. First, Gq-evoked cell death was 
prevented   by   a   shRNA   targeting   JNK3,   the  most  
 
Figure 5. Sustained Gq-protein signaling induces the death of 
striatal neurons. A, Primary mouse striatal neurons were infected 
with CAG-hM3Dq-mCherry-rAAV or control CAG-GFP- rAAV at 
day 2 in vitro. At day 13 in vitro, they were incubated for 8 h with 
the indicated doses of CNO. Quinolinic acid (QA) was used as a 
control neurotoxin to demonstrate a comparable sen- sitivity to 
death of CAG-hM3Dq-mCherry-rAAV-infected neurons and CAG-
GFP-rAAV-infected neurons. B, Primary mouse striatal neurons 
were infected with hM3Dq-mCherry-rAAV at day 2 in vitro. At day 
13 in vitro, they were incubated for 8 h with vehicle or 50 µM CNO, 
together with vehicle or the indicated additions (see experimental 
details in Table 1). *p < 0.05, **p < 0.01 from the corresponding 
vehicle-treated cells.  
 
relevant of the three JNK family members in the brain 
(Fig. 4C).  
 
Second, Western blot experiments showed that 
activation of Gq signaling led to a sustained (up to 8 h) 
phosphorylation (activation) of JNK, which was 
accompanied by a phosphorylation (activation) and 
stabilization (increased levels) of its canonical 
substrate, the transcription factor cJun (Fig. 4D). In 
contrast, the phosphorylation (activation) of ERK, 
which was used as a control pathway triggered by 
acute Gq-evoked activation (Girault 2012), was only 
transient and returned to basal levels after2h of CNO 
challenge (Fig. 4D). Third, consistent with the 
aforementioned cell death experiments, the sustained 
Gq-evoked activation of JNK and cJun was PLC/Ca2+ 
dependent (as shown by the preventive effect of 
U73122 and BAPTA-AM) and PKC independent (as 
shown by the lack of effect of bisindolylmaleimide; 
Fig. 4E). 
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We next investigated the link between Ca2+ and JNK. 
Proline-rich tyrosine kinase 2 (PYK2) is a cytoplasmic 
non-receptor tyrosine kinase enriched in neurons that 
controls various neurobiological functions and that, by 
acting as a Ca2+ effector, can activate mitogen- 
activated protein kinase cascades (Girault et al. 1999). 
Therefore, we investigated whether PYK2 was 
involved in our experimental setting. The Gq-evoked 
death of STHdh cells was prevented by the dual 
PYK2/focal adhesion kinase inhibitor PF431396 (Fig. 
4B), as well as by a Pyk2-directed shRNA (Fig. 4C). 
Likewise, activation of Gq signaling led to the 
phosphorylation (activation) of PYK2 and this effect  
 
was prevented by U73122 and BAPTA-AM, but not by 
SP600125 (Fig. 3E), thus supporting that PYK2 is 
downstream of PLC/Ca 2+ and upstream of JNK. 
 
We subsequently investigated whether the Gq-
triggered effects observed in STHdh cells could be 
extrapolated to a more physiological experimental 
model as primary striatal neurons. Indeed, activation 
of Gq signaling upon challenge of hM3Dq-mCherry 
expressing primary mouse striatal neurons to CNO 
also led to a PLC/Ca2+/JNK-dependent, ERK-
independent cell death process (Fig. 5 A, B). 
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In sum, these data show that sustained Gq-protein 
activation signals neuronal cell death via a 
PLC/Ca2+/PYK2/JNK-dependent pathway. 
 
Sustained Gq-protein signaling disrupts the 
functionality of D1R-MSNs and D2R-MSNs in vivo 
via JNK 
 
To evaluate the functional relevance of JNK in vivo, we 
first injected C57BL/6N mice stereotaxically into the 
dorsal striatum with a rAAV encoding hM3Dq-
mCherry (or control rAAV). The transgene was driven 
by the CAG promoter to allow its expression in all 
MSNs. In agreement with our aforementioned cell 
culture observations, engagement of Gq signaling 
(one single intraperitoneal injection of CNO at 10 
mg/kg in hM3Dq-mCherry-expressing mice) triggered 
striatal JNK activation in vivo, as determined by the 
SP600125-sensitive phosphorylation (activation) of 
cJun (Fig. 6A; we were unable to obtain technically 
reliable Western blots from mouse striatal extracts 
with commercial anti-pJNK antibodies). 
 
Furthermore, after sustained Gq signaling (one daily 
intra-peritoneal injection of CNO at 10 mg/kg for 10 d), 
we found a loss of MSNs, as determined by the 
Figure 7. Sustained Gq-protein signaling induces the loss of MSNs in vivo via JNK. C57BL/6N mice were injected 
stereotaxically into the dorsal striatum with CAG-hM3Dq-mCherry-rAAV or control CAG-rAAV, and left untreated for 4 
weeks. Animals subsequently received one daily intraperitoneal injection of vehicle or CNO (10 mg/kg), together with 
one daily intraperitoneal injection of vehicle or SP600125 (15 mg/kg), for 10 consecutive days. A, DARPP-32 expression 
(relative values of DARPP-32 immunoreactivity). B, D1R expression (relative values of D1R immunoreactivity). C, D2R 
expression (relative values of D2R immunoreactivity). Representative images are shown in all panels. Scale bar, 50µm. 
*p < 0.05, **p < 0.01 from the corresponding vehicle/vehicle group; # p < 0.05 from the corresponding CNO/vehicle 
group. 
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reduction of the neuronal marker NeuN (Fig. 6 B, C) 
and the MSN marker DARPP-32 (Fig. 7A). This loss of 
MSNs was equally evident in the D1R-MSN population 
(Fig. 7B) and the D2R-MSN population (Fig. 7C). 
Moreover, these alterations in neuronal markers were 
accompanied by a deficit in the Rotarod test (Fig. 6D), 
a well-established behavioral readout of the dorsal 
striatum. Remarkably, these Gq-evoked effects were 
prevented by pharmacological blockade of JNK 
(Figs.6B–D, 7A–C) and were not simply caused by the 
viral expression of a novel receptor or by an off-target 
action of CNO (either hM3Dq-mCherry expression in 
the absence of CNO or treatment of control rAAV-
infected animals with CNO was ineffective; Figs. 6A–
D, 7A–C).  
 
Finally, we assessed whether JNK-driven signaling 
affects either the direct pathway or the indirect 
pathway separately by monitoring a clear-cut 
behavioral task as contraversive movements 
(Tecuapetla et al. 2014). Selective acute unilateral 
activation of Gq signaling in D1R-MSNs or D2R-MSNs 
induced contralateral or ipsilateral movements, 
respectively (Fig. 8A). This acute effect was abrogated 
in those animals that had been chronically treated with 
CNO (Fig. 8B). In turn, this impairing effect of chronic 
CNO treatment on contralateral/D1R-MSN-
dependent movements (Fig. 8B, left) and ipsilateral / 
D2R-MSN-dependent movements (Fig. 8B, right) was 
rescued by the coadministration of a JNK inhibitor to 
the animals. Collectively, these data show that JNK 
mediates the inactivation of MSNs and the disruption 
of striatal circuits evoked by sustained Gq-protein 
signaling in vivo.
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CHAPTER 2 
The vast majority of striatal neurons are GABAergic 
medium spiny neurons (MSNs). These cells receive 
glutamatergic input primarily from the cortex, and 
form two major efferent pathways: the direct 
(striatonigral) pathway, expressing dopamine D1 
receptor (D1R-MSNs), and the indirect (striatopallidal) 
pathway, expressing dopamine D2 receptor (D2R-
MSNs). Different mechanisms that lead to the 
degeneration of MSNs have been defined in preclinical 
models of striatal damage. However, a key 
unanswered question is which precise molecular 
factors may dictate a selective susceptibility of D1R-
MSNs and D2R-MSNs in archetypical striatal 
neurodegenerative diseases such as Huntington’s 
disease (HD). In this chapter, by using an array of 
genetic, chemogenetic and pharmacological 
strategies to manipulate cannabinoid CB1R function in 
a spatiotemporally-restricted manner in vivo, we show 
that CB1R located on corticostriatal projections, by 
blunting glutamatergic output, selectively safeguards 
D1R-MSNs of the mouse dorsal striatum from cortical 
mtHtt-induced damage. Specifically, expression of 
mtHtt in the motor cortex damages D1R-MSNs but not 
D2R-MSNs upon (i) pharmacological blockade of CB1R 
with rimonabant or (ii) conditional genetic deletion of 
CB1R in cortical principal neurons. This neurotoxic 
process is rescued by administration of the NMDA 
receptor antagonist MK-801. Likewise, a selective 
vulnerability of D1R-MSNs vs. D2R-MSNs is observed 
when corticostriatal glutamatergic projections are 
overactivated remotely by means of a DREADD 
pharmacogenetics approach and CB1R is 
pharmacologically blocked. CB1R located on 
corticostriatal projections, by inhibiting glutamatergic 
transmission, also protects MSNs from mtHtt-
expressing astroglia. Finally, astroglial MGL controls 
the availability of the 2-AG to ensure protection of 
MSNs. Taken together, these findings define cortical 
CB1R as a key neurochemical player in dictating a 
dissimilar vulnerability of D2R-MSNs vs. D1R-MSNs, 
and may contribute to understand the role of 
coordinated cannabinergic-glutamatergic signaling in 
the control of the corticostriatal direct pathway and its 
dysregulation in HD. 
 
 
 
CAPÍTULO 2 
La gran mayoría de las neuronas estriatales son 
neuronas GABAérgicas espinosas medianas (MSNs del 
inglés medium spiny neurons). Estas células reciben 
aferencias glutamatérgicas principalmente de la 
corteza y forman dos vías eferentes principales: la vía 
directa (estriatonigral), que está fomada por MSNs 
que expresan el receptor de dopamina D1 (D1R-MSNs) 
y la vía indirecta (striatopallidal), formada por MSNs 
que expresan el receptor de dopamina D2 (D2R-
MSNs).Se han descrito diferentes mecanismos que 
conducen a la degeneración de los MSNs en modelos 
preclínicos de daño estriatal. Sin embargo, una de las 
preguntas que aún no se han resuelto es qué factores 
moleculares específicos pueden dictar una 
susceptibilidad selectiva entre D1R-MSNs y D2R-
MSNs en enfermedades neurodegenerativas 
estriatales arquetípicas, como la enfermedad de 
Huntington (EH). En este capítulo, mediante 
estrategias genéticas, quimiogenéticas y 
farmacológicas para manipular la función de CB1R de 
manera espaciotemporalmente restringida in vivo, se 
muestra que el CB1R situado en las proyecciones 
corticoestriatal, reduciendo la señalización 
glutamatérgica, protege selectivamente las D1R-
MSNs estriatales frente al daño derivado de la 
expresión de mtHtt en corteza. En concreto, la 
expresión de mtHtt en corteza daña las D1R-MSNs 
pero no las D2R-MSNs en el contexto de (i) bloqueo 
farmacológico de CB1R con rimonabant o (ii) delección 
condicional de CB1R en neuronas corticales 
principales. Este efecto neurotóxico se previene con la 
administración del antagonista del receptor NMDA 
MK-801. Asimismo, se observa una vulnerabilidad 
selectiva de D1R-MSNs y D2R-MSNs cuando se 
sobreactivan de forma remota las proyeccioes 
corticoestriatales glutamatérgicas, mediante una 
aproximación farmacogenética con DREADD, 
mientras CB1R está bloqueado farmacológicamente. 
El CB1R situado en las proyecciones corticoestriatales, 
mediante inhibición de la transmisión glutamatérgica, 
también protege las MSNs del daño derivado por la 
expresión de mHtt en astrocitos. Por último, la MGL 
astroglial controla la disponibilidad del 2-AG, 
participando así en la protección de las MSNs. Así, el 
CB1R cortical representa un factor neuroquímico clave 
para determinar la diferente vulnerabilidad entre D1R-
MSNs y D2R-MSNs, pudiendo contribuir a entender la 
coordinación entre señalización cannabinérgica-
glutamatérgica en el control de la vía directa 
corticoestriatal y su alteración en la EH. 
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RESULTS-OBJECTIVE 2 
 
D1R-MSNs and D2R-MSNs are equally vulnerable to 
cell-autonomous mutant huntingtin-induced 
damage 
 
To evaluate the potentially different vulnerability of 
D1R-MSNs and D2R-MSNs to huntingtin-induced 
degeneration we first used a rAAV-vector delivery 
strategy based on the expression of CFP-tagged 
human huntingtin exon 1 harboring a pathogenic 
polyQ tract of 94 CAG repeats (herein used as a model 
of mutant huntingtin, mtHtt) or a normal, non-
pathogenic polyQ tract of 16 CAG repeats (herein used 
as a model of wild-type huntingtin, wtHtt). The 
expression of the transgene was driven by a minimal 
CaMKIIα promoter in order to confine it to the main 
cell populations affected in HD, namely MSNs (when 
viral injections were performed into the dorsal 
striatum) and principal cortical neurons (when viral 
injections were performed into the motor cortex). Viral 
inoculation was conducted in BAC transgenic mice 
expressing the tdTomato and EGFP reporter genes 
under the control of the D1R and D2R promoter, 
respectively (Fig. 1B). 
 
When selectively expressed in MSNs of the dorsal 
striatum, mtHtt produced, 2 weeks after viral 
injection, a remarkable loss of the pan-MSN marker 
dopamine- and cAMP-regulated phosphoprotein of 32 
kDa (DARPP-32), as well as a parallel reduction of cells 
that were positive for tdTomato fluorescence (i.e., 
D1R-MSNs) or EGFP fluorescence (i.e., D2R-MSNs) 
(Fig. 1C). This was further corroborated by the 
comparable mtHtt-induced decrease of D1R and D2R 
staining that was found when immunofluorescence 
studies were conducted with antibodies raised against 
each of the two receptors (Fig. 1C). Of note, D1R-
MSNs and D2R-MSNs were equally vulnerable to 
mtHtt-induced damage (Fig. 1C). Moreover, this loss 
of MSNs had a notable functional impact as evidenced 
by the impairment of Rotarod performance, a well-
established motor coordination paradigm that relies, 
at least large part, on striatal function (Fig. 1E). In 
contrast to this damaging effect of mtHtt expressed by 
MSNs in situ, no significant loss of neuronal markers or 
decline in RotaRod performance was observed when 
mtHtt was selectively expressed in principal neurons of 
the motor cortex, even 4 weeks after viral injection 
(Fig. 1D-E). 
 
Taken together, these data indicate that D1R-MSNs 
and D2R-MSNs are equally sensitive to cell-
autonomous mtHtt-induced toxicity, and that 
expression of mtHtt in cortical principal neurons is not 
sufficient per se to produce a significant damage of 
MSNs, at least under these experimental conditions. 
 
Expression of mutant huntingtin in the cortex 
damages D1R-MSNs but not D2R-MSNs upon CB1R 
pharmacological blockade 
 
CB1R, one of the most abundant metabotropic 
receptors in the brain, is highly expressed in both 
MSNs and corticostriatal projections (Katona & Freund 
2008), plays a key role in the control of motor behavior 
(Castillo et al. 2012), and protects MSNs in animal 
models of excitotoxicity (Fernández-Ruiz et al. 2011) 
and HD (Blázquez et al. 2011; Mievis et al. 2011; 
Chiarlone et al. 2014). However, it is not known 
whether CB1R-evoked neuroprotection may be 
selective for different MSN populations, and, if so, 
which precise population(s) of CB1R molecules would 
be involved in such effect. To evaluate this question we 
first injected -as above- CaMKIIα promoter-driven 
wtHtt or mtHtt-expressing rAAV vectors into the 
dorsal striatum or the motor cortex of D1R-
tdTomato/D2R-EGFP reporter mice, and subsequently 
treated them with vehicle or the CB1R-selective 
antagonist SR141716 (rimonabant) at 1 mg/kg/d (i.p.) 
for 2 weeks (viral inoculation into the striatum) or 4 
weeks (viral inoculation into the cortex) (Fig 2A). 
Rimonabant did not affect striatum-autonomous 
mtHtt-mediated loss of D1R-MSN or D2R-MSN 
markers, nor worsened motor coordination deficits 
under these conditions (Fig. 2B,C). In remarkable 
contrast, CB1R pharmacological blockade worsened 
these hallmarks of striatal integrity when mtHtt was 
selectively expressed in principal neurons of the motor 
cortex (Fig. 2B,C). Moreover, MSN damage under 
these conditions exclusively entailed D1R-MSNs, while 
D2R-MSNs remained unaffected (Fig. 2B).  
 
Taken together, these observations support that, 
when CB1R activity is compromised, expression of 
mtHtt in cortical principal neurons determines a 
dissimilar susceptibility of D1R-MSNs vs. D2R-MSNs 
to damage. 
 
CB1R located on corticostriatal projections protects 
D1R-MSNs but not D2R-MSNs from cortex-elicited 
damage 
 
To test the aforementioned hypothesis more cogently 
we used three different experimental paradigms in 
which cortical CB1R function and neuronal activity 
were manipulated in vivo in a spatiotemporally-
selective manner. 
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In a first experimental paradigm, conditional mutant 
mice bearing a genetic deletion of CB1R in dorsal 
telencephalic glutamatergic neurons 
(CB1Rfloxed/floxed;Nex-Cre/+ mice; herein referred to as Glu-
CB1R-/- mice), and their CB1Rfloxed/floxed control 
littermates, were injected with CaMKIIα promoter-
driven wtHtt or mtHtt-expressing rAAV vectors into 
the motor cortex (Fig. 3A). As above, no significant 
mtHtt-evoked striatal toxicity was observed in control 
mice (Fig. 3B,D). In contrast, cortical mtHtt induced a 
neurotoxic effect on the striatum of Glu-CB1R-/- mice, 
as determined by a loss of striatal DARPP-32 and 
postsynaptic density protein 95 (PSD-95) expression, 
as well as a decline in Rotarod performance (Fig. 3B,D). 
Remarkably, and in line with the rimonabant 
experiment   on   D1R-tdTomato/D2R-EGFP  reporter 
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mice described above, the impact of cortical mtHtt 
expression on Glu-CB1R-/- mice involved D1R-MSNs 
exclusively, while D2R-MSNs remained essentially 
intact (Fig. 3C).  
 
In a second experimental paradigm, we crossed R6/2L 
mice, a transgenic model of HD that expresses in all 
body cells exon 1 of the human huntingtin gene with 
an largely expanded CAG tract, with CB1Rfloxed/floxed 
mice, thus generating a R6/2L:CB1Rfloxed/floxed line, that 
allows the spatiotemporally-controlled excision of the 
loxP-flanked CB1R gene by Cre recombinase 
(Chiarlone et al. 2014). These R6/2L:CB1Rfloxed/floxed 
animals (and their CB1Rfloxed/floxed control littermates) 
were injected into the dorsal striatum or the motor 
cortex with a rAAV vector encoding Cre (or EGFP as 
control) under the control of the CaMKIIα promoter 
(Fig. 4A). We have previously shown that, under these 
conditions, CB1R gene inactivation in the motor cortex 
of R6/2L:CB1Rfloxed/floxed mice reduces striatal DARPP-
32 expression and Rotarod performance (Chiarlone et 
al. 2014). As shown here in Fig. 4B, selective CB1R 
gene inactivation in dorsal-striatum MSNs did not 
affect D1R-MSNs and D2R-MSNs. In contrast, this 
procedure of selective CB1R gene inactivation in 
cortical principal neurons impacted D1R-MSNs 
selectively, while D2R-MSNs remained intact. (Fig. 
4C). 
 
 
 
In a third experimental paradigm, we sought to 
extrapolate the above observations on cortical mtHtt-
induced striatal damage to another model of cortex-
initiated striatal damage. Thus, we selectively 
enhanced neuronal activity with a designer receptor 
exclusively activated by designer drug (DREADD). This 
chemogenetic technique is based on the expression of 
engineered GPCRs that are selectively activated by 
systemically bioavailable, brain-penetrant and 
otherwise pharmacologically inert ligands such as 
clozapine-N-oxide (CNO) (Lee et al. 2014). Specifically, 
wild-type C57BL/6N mice were injected into the motor 
cortex with a rAAV vector encoding a Gq protein- 
coupled DREADD (hM3Dq) fused to mCherry under 
the control of the CaMKIIα promoter. Animals were 
subsequently treated with vehicle or CNO, in 
conditions known to evoke sustained cortical 
activation and thereby excitotoxic damage on the 
striatum (10 mg/kg/d, i.p., for 4 weeks) (Alexander et 
al. 2010; Chiarlone et al. 2014), as well as with vehicle 
or rimonabant (1 mg/kg/d, i.p.) (Fig.5A). As shown in 
Fig. 5B-D, CB1R pharmacological blockade sensitized 
D1R-MSNs but not D2R-MSNs to prolonged cortical 
overactivation. 
 
Taken together, these findings support that CB1R 
located on corticostriatal projections protects D1R-
MSNs but not D2R-MSNs from mtHtt or 
excitotoxicity-induced damage as derived from 
cortical principal neurons. 
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CB1R located on corticostriatal projections protects 
D1R-MSNs from cortex-elicited damage by 
inhibiting glutamatergic transmission 
 
To evaluate whether cortical CB1R controls 
glutamatergic signaling onto the striatum we first 
measured by microdialysis extracellular glutamate 
concentration in the dorsal striatum of Glu-CB1R-/- 
mice and CB1floxed/floxed littermates. Neuronal 
depolarization with KCl produced a consecutive 
sequence of peaks of glutamate release that was 
higher in Glu-CB1R-/- mice than in control animals (Fig. 
6A). As a control we analyzed in parallel GABA 
concentration and found no significant change upon 
cortical CB1R genetic ablation (Fig. 6A). Next, we 
isolated striatal synaptosomes from C57BL/6N mice 
and evaluated the effect of CB1R on glutamate 
release, thus assessing the activity of CB1R located on 
corticostriatal projections (Chiarlone et al. 2014). The 
cannabinoid receptor agonist HU-210 (5 µM) reduced 
KCl-evoked glutamate output from striatal 
synaptosomes. As a proof of specificity, and in 
agreement with the coupling of CB1R to Gi/o and 
G12/13 proteins in cortical principal neurons (Castillo et 
al. 2012; Roland et al. 2014), the effect of HU-210 on 
glutamate release was attenuated by pertussis toxin 
(which inactivates Gi/o) and CCG-1423 (which inhibits 
G12/13 protein/Rho-mediated signaling) (Fig. 6B).  
 
 
 
To assess the functional impact of the CB1R receptor-
mediated control of glutamatergic signaling on striatal 
integrity in vivo we injected Glu-CB1R-/- mice with 
CaMKIIα promoter-driven wtHtt or mtHtt-expressing 
vectors into the motor cortex, and treated them with 
vehicle or the NMDAR-selective antagonist MK-801 at 
0.03 mg/kg/day (i.p.) for 4 weeks (Fig. 6C). MK-801 
administration effectively rescued the loss of striatal 
DARPP-32 and D1R, but not D2R expression (Fig. 
6D,E) and the decline in Rotarod performance elicited 
by cortical mtHtt expression in Glu-CB1R-/- mice (Fig. 
6F). As an additional functional readout, cortical mtHtt 
expression in Glu-CB1R-/- mice was found to abrogate 
the characteristic stimulant-like pattern on motor 
reactivity evoked by acute administration of the D1R-
selective agonist SKF-81297 (1 mg/kg, i.p.), which 
points to an impairment of direct-pathway striatal 
circuitry (Fig. 6G). Of note, MK-801 treatment was able 
to rescue this effect (Fig. 6G).  
 
Taken together, these data support that CB1R located 
on corticostriatal projections protects D1R-MSNs from 
cortical mtHtt-evoked damage by inhibiting 
glutamatergic transmission. 
 
69 
 
 
70 
 
CB1R located on corticostriatal projections protects 
MSNs from astroglia-elicited damage by inhibiting 
glutamatergic transmission 
 
Astrocytes are pivotal elements in the control of brain 
glutamatergic signaling (Murphy-Royal et al. 2017). In 
HD, mtHtt aggregates accumulate in astrocytes from 
patients (Shin et al. 2005) and animal models (Chou et 
al. 2008; Bradford et al. 2009) of the disease, and 
preclinical evidence supports that this can contribute 
to drive disease progression, at least in part through 
alterations in glutamate homeostasis (Benraiss et al. 
2016; Jiang et al. 2016; Meunier et al. 2016; Jansen et 
al. 
2017). In addition, astrocytes express CB1R, 
metabolize endocannabinoids, and modulate 
endocannabinergic transmission (Stella 2010; 
Navarrete & Araque 2010; Han et al. 2012). Hence, we 
studied the possible role of astroglial CB1R on mtHtt-
evoked striatal damage.  
 
For this purpose we first injected into the dorsal 
striatum of C57BL/6N mice rAAV vectors encoding 
wtHtt or mtHtt under the control of a minimal glial 
fibrillary acidic protein (GFAP) promoter, in order to 
confine its expression to astrocytes (Fig. 7A,B). 
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Under these experimental conditions, mtHtt 
produced, 2 weeks after viral injection, a detectable 
loss of NeuN, DARPP-32, and PSD-95 expression, in 
concert with astrogliosis (as determined by the 
astroglial marker S100β) and motor coordination 
deficits. (Fig. 7C).  
 
To test a possible neuroprotective role of astroglial 
CB1R in this setting, conditional mutant mice bearing 
an inducible genetic deletion of CB1R in astroglial cells 
(CB1Rfloxed/floxed;GFAP-CreERT2/+ mice; herein referred to as 
GFAP-CB1R-/- mice), together with their CB1floxed/floxed 
control littermates, were injected with GFAP 
promoter-driven wtHtt or mtHtt-expressing vectors 
into the dorsal striatum (Fig. 8A). Selective CB1R 
genetic inactivation in astroglial cells did not sensitize 
MSNs to damage induced by astrogial mtHtt 
expression (Fig. 8B,C). In contrast, when mtHtt 
expression was achieved in striatal astrocytes of Glu-
CB1R−/− mice, we found that selective CB1R genetic 
inactivation in cortical principal neurons exacerbated 
the decline of striatal DARPP-32 expression and motor 
coordination performance (Fig. 8B,C). 
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We next tested whether cortical CB1R protects MSNs 
from astroglial mtHtt-induced damage by blunting 
glutamatergic signaling. For this purpose we injected 
C57BL/6N mice with GFAP promoter-driven wtHtt or 
mtHtt-expressing vectors into the dorsal striatum, and 
treated them for 2 weeks with vehicle or MK-801 (0.03 
mg/kg/d, i.p.) (Fig. 8D). MK-801 administration 
effectively rescued the loss of striatal DARPP-32 (Fig. 
8E), the decline in Rotarod performance (Fig. 8F) and 
the impairment of SKF-81297-induced hyperactivity 
elicited by mtHtt expression in striatal astrocytes (Fig. 
8G).  
 
Taken together, these data support that CB1R located 
on corticostriatal projections, by inhibiting 
glutamatergic transmission, protects MSNs, not only 
from cortical mtHtt-evoked damage, as shown above, 
but also from astroglial mtHtt-evoked damage. 
 
MGL located on striatal astrocytes fine-tunes 
neuroprotective endocannabinoid signaling 
The experiments described above support that 
astroglial CB1R does not protect MSNs from mtHtt-
induced damage. However, other endocannabinoid 
system elements located on astrocytes could 
modulate neuroprotective signaling in corticostriatal 
circuits. Specifically, as astrocytes are a key site for 
endocannabinoid degradation (Walter et al. 2004; 
Uchigashima et al. 2011; Viader et al. 2015) and 2-AG 
is the main endocannabinoid involved in corticostriatal 
circuit neuromodulation (Uchigashima et al. 2007; 
Tanimura et al. 2010), we asked whether astroglial 
monoacylglycerol lipase (MGL; the main enzyme that 
deactivates 2-AG) could fine-tune a neuroprotective 
endocannabinoid tone. For this purpose, we first 
injected GFAP promoter-driven wtHtt or mtHtt-
expressing rAAV vectors into the dorsal striatum of 
C57BL/6N mice, and treated them for 2 weeks with 
vehicle or the MGL-selective inhibitor JZL-184 (8 
mg/kg/d, i.p.). The cannabinoid receptor agonist -Δ9-
tetrahydrocannabinol (THC), the main bioactive 
ingredient of cannabis, was used in parallel (at 1 
mg/kg/d, i.p.). MGL pharmacological blockade, as well 
as cannabinoid receptor pharmacological stimulation, 
prevented the deleterious effects elicited by astroglial 
mtHtt expression on striatal markers and motor 
coordination-related performance (Fig. 9B,C). 
 
To evaluate more directly the role of astroglial MGL, 
conditional mutant mice bearing a genetic deletion of 
MGL in astroglial cells (MGLfloxed/floxed;GFAP-Cre/+ mice; 
herein referred to as GFAP-MGL-/- mice), together with 
their MGLfloxed/floxed control littermates, were 
inoculated GFAP promoter-driven wtHtt or mtHtt-
expressing vectors into the dorsal striatum (Fig.10A). 
Selective genetic inactivation of astroglial MGL 
prevented the deleterious effects evoked by mtHtt 
expression in striatal astrocytes (Fig. 10B,C).  
 
Taken together, these data support that MGL located 
on striatal astrocytes controls the availability of a 2-AG 
pool that ensues protection of MSNs, conceivably by 
engaging CB1R located on corticostriatal terminals. 
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Here, we first manipulated MSNs selectively by means 
of the DREADD technology to unveil how Gq-protein-
evoked signaling affects neuronal functionality (Fig. 1). 
A DREADDi approach was used previously to study the 
effects of the selective inhibition of D1R-MSNs or D2R-
MSNs in the rat dorsomedial striatum by expressing 
hM4Di in a herpes virus vector with promoter 
elements for dynorphin or enkephalin, respectively 
(Ferguson et al. 2011) CNO administration did not 
change acute locomotor responses to amphetamine, 
but altered behavioral plasticity associated with 
repeated drug treatment (Ferguson et al. 2011). A 
similar approach found that the hM4Di-evoked 
inhibition of D2R-MSNs in the mouse nucleus 
accumbens enhanced the motivation to obtain 
cocaine (Bock et al. 2013).  
 
Collectively, these and other related studies 
demonstrate that chemogenetic manipulation of 
MSNs with DREADDs (Farrell et al. 2013; Ferguson et 
al. 2013), DREADDi (Ferguson et al. 2011; Bock et al. 
2013; Ferguson et al. 2013) or DREADDq (the present 
study) is a viable tool to assess the impact of specific 
G-protein-mediated signals on the conceptually 
proposed opposing roles of the direct and indirect 
striatal pathways. Moreover, the lack of effect of MSN 
inhibition (via DREADDi) on acute locomotor 
responses (Ferguson et al. 2011) compared with the 
remarkable effects of MSN activation via DREADDs 
(Ferguson et al. 2013) or DREADDq (the present study) 
points to a hierarchical subordination of inhibitory to 
stimulatory metabotropic pathways in simple 
behavioral tasks.  
 
Likewise, Gq, Gs, and Gi-coupled DREADD-mediated 
manipulation of the circadian pacemaker in the mouse 
suprachiasmatic nucleus showed a prominent role of 
the Gq axis over Gi (and Gs) signaling in controlling 
circadian rhythms (Brancaccio et al. 2013). In contrast, 
significant—and opposing— effects of Gq and Gi 
signaling per se were found upon the chemogenetic 
manipulation of, for example, mouse agouti-related 
protein-expressing neurons (Krashes et al. 2011) and 
calcitonin-gene-related peptide-expressing neurons 
(Carter et al. 2013) in the control of feeding behavior. 
Therefore, it is conceivable that the actual relative 
strength of Gq, Gs, and Gi signals to control neural 
activity varies significantly among different brain 
regions and biological processes in vivo.  
 
The precise metabotropic mechanisms involved in the 
control of the integrity and function of MSNs are not 
fully understood. A large body of evidence supports 
that cAMP-dependent cascades are highly relevant 
and, in fact, both DREADDs and DREADDi alter 
neuronal activity and plasticity in striatal circuits 
through changes in cAMP production (Ferguson et al. 
2011; Bock et al. 2013; Farrell et al. 2013; Ferguson et 
al. 2013). Activation of Golf-coupled D1R in direct-
pathway MSNs engages multiple signaling pathways, 
such as PKA, ERK, and CREB, by increasing cAMP 
production, whereas activation of Gi-coupled D2R in 
indirect-pathway MSNs leads to downregulation of 
these cascades (Girault 2012; Cahill et al. 2014). Other 
Gs-coupled receptors (e.g., A2AR, which is mostly 
located in striatopallidal MSNs) and Gi-coupled 
receptors (e.g., CB1R, which is highly enriched in the 
terminals of both striatonigral and striatopallidal 
MSNs) make a major contribution as well to tuning the 
functioning of basal ganglia circuits via cAMP and 
other related intracellular signals (Kreitzer 2009; 
Girault 2012). 
 
The class I metabotropic glutamate receptors mGlu1 
and mGlu5 are the most relevant group of striatal Gq-
coupled receptors. Although activation of the ERK 
pathway in the striatum can be readily achieved by 
D1R and ionotropic (NMDA) glutamate receptors, 
mGlu1/5 receptors also activate ERK through Ca2+ 
release from intracellular stores in synergy with D1R, 
thereby participating, for example, in drug-induced 
behavioral plasticity (Girault 2012). However, here, by 
manipulating Gq-evoked activity selectively in MSNs, 
we unveil that JNK, rather than ERK or other signaling 
pathways such as PKC and PI3K/Akt/mTORC1, is the 
key functional effector of the Gq/PLC/Ca2+ axis (Fig.2 
A, B). Glutamate has been shown to stimulate JNK in 
striatal neurons (Schwarzschild et al. 1997) and to 
cooperate with dopaminergic signaling (mostly via 
D1R) to induce MSN excitotoxicity (McLaughlin et al. 
1998; Tang et al. 2007; Paoletti et al. 2008; J. Y. Chen 
et al. 2013). Moreover, cocaine (Go et al. 2010) and 
methamphetamine (Jayanthi et al. 2002) 
administration, by overstimulating D1R-mediated 
dopaminergic signaling, induces MSN death and 
striatal damage at least in part via JNK, an effect that 
is favored by activation of class I mGlu receptors 
(Jayanthi et al. 2002; Go et al. 2010). 
 
Therefore, our data align well with prior evidence and 
strongly support the notion that the JNK cascade plays 
a pivotal converging role in mediating the 
malfunctioning of striatal circuits that occurs after 
overactivation of glutamatergic and dopaminergic 
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transmission(J. Y. Chen et al. 2013; Cahill et al. 2014). 
Specifically regarding HD, the involvement of JNK in 
mutant huntingtin-mediated striatal neurotoxicity is 
supported by a number of in vitro and in vivo studies 
(Apostol et al. 2008; Perrin et al. 2009; Taylor et al. 
2013). Although we are aware that the primary 
mechanisms underlying the sustained Gq-protein-
induced toxicity of MSNs and the DTA-induced 
toxicity of MSNs are conceivably distinct, pilot 
experiments conducted in our STHdh cell cultures 
show that DTA-induced death also seems to be JNK 
dependent, as shown by the preventive effect of 
SP600125 (unpublished observations). 
 
PYK2 was originally characterized as a Ca2+-dependent 
protein kinase that can link elevations of cytosolic free 
Ca2+ concentration (Yu et al. 1996) with JNK activation 
upon different triggers (Dikic et al. 1996; Tokiwa et al. 
1996). PYK2 is highly responsive to neuronal activity. 
Upon depolarization, it autophosphorylates on 
tyrosine residues, clusters on postsynaptic densities, 
and exposes an SH2-binding domain that recruits Src 
family kinases, thereby activating various signaling 
pathways (Girault et al. 1999; Bartos et al. 2010). 
Therefore, PYK2 may connect neuronal 
activity/plasticity with processes such as neuronal 
survival and neurite outgrowth/retraction (Girault et 
al. 1999; Ivankovic-Dikic et al. 2000; Kinoshita et al. 
2014) In addition, PYK2 is activated in the rat 
hippocampus after brain ischemia and kainate-
induced convulsions (Tian et al. 2000), which suggests 
a role for the kinase in the effects of these insults. 
Therefore, our present findings extend this evidence 
and specifically show that PYK2 is a novel mediator of 
Gq/Ca2+-driven striatal dysfunction (Fig. 2A). 
 
In conclusion, the first block of Results of this work 
sheds new light onto how metabotropic signals control 
neuronal integrity and functionality. It also supports 
that the sustained DREADDq-evoked modulation of 
the direct versus indirect pathway may be adopted as 
a new tool to understand physiopathological 
alterations occurring in basal-ganglia-related diseases 
such as HD, PD, and L-DOPA-induced dyskinesia. For 
example, regarding HD, the impairment of indirect- 
pathway circuitry evoked by sustained Gq/JNK 
signaling seems to recapitulate the 
dyskinesia/hyperkinesia, as well as the insomnia/ 
reduced REM sleep occurring from early stages of the 
disease, whereas the impairment of direct-pathway 
circuitry evoked by sustained Gq/JNK signaling seems 
to recapitulate the bradykinesia/parkinsonism 
occurring at later stages of the disease [Fig. 2B (Walker 
2007; Arnulf et al. 2008)]. Whether Gq/JNK signaling 
affects, not only motor behavior, but also other 
prominent striatal functions such as cognition and 
motivation may be the subject of future studies. 
 
The second part of this work focused on a key 
unanswered question in most neurodegenerative 
diseases: what precise factors dictate the selective 
vulnerability of a particular neuronal population? In the 
precise case of HD, the pattern of neurodegeneration 
is very typical of regional locations as well as neuronal 
types in the striatum. Thus, MSNs, especially those 
found in the dorsal striatum (caudate-putamen), 
represent the main and earliest cell population altered, 
whereas, for example, striatal interneurons are 
typically unaffected or only mildly affected at late 
stages of the disease (Walker 2007). Many studies 
based on techniques such as PET, autoradiography, 
and immunomicroscopy have reported reductions in 
striatal D1R and D2R density from early disease stages 
in HD patients and animal models. Nonetheless, it is 
generally believed that D2R-MSNs are affected at 
earlier stages of the disease and to a greater extent 
than D1R-MSNs, which is consistent with the notion 
that early-onset chorea-like movements result from a 
preferential dysfunction/loss of D2R-MSNs, while 
later-onset bradykinesia and dystonia are a 
consequence of an additional dysfunction/loss of D1R-
MSNs (Walker 2007; Han et al. 2010; Ross et al. 2014).  
 
Here, we unveil a new key player in this intricate 
neurochemical scenario by showing that CB1R located 
on corticostriatal projections, through the control of 
glutamatergic transmission, dictates a selective 
protection of D1R-MSNs. CB1R is one of the most 
abundant metabotropic receptors in the basal ganglia, 
Figure 2. Proposed mechanism of action and impact of 
sustained Gq-protein signaling on striatal circuitry. A, Gq-
protein-coupled signaling upon hM3Dq overactivation in MSNs 
in vitro induces cell death via a PLC/Ca2+/PYK2/JNK pathway. B, 
Gq-protein-coupled signaling upon hM3Dq overactivation in 
MSNs in vivo induces neuronal dysfuction via JNK, which 
translates into loss of hyperlocomotion and motor 
discoordination (upon D1R-MSN dysfunction) or into 
hyperlocomotion and wakefulness (upon D2R-MSN 
dysfunction). 
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where endocannabinoid signaling serves as a major 
feedback mechanism aimed at preventing excessive 
presynaptic activity (Glass et al. 2000; Katona & 
Freund 2008; Atwood et al. 2014). In particular, CB1R 
is highly expressed on terminals of both D1R-MSNs 
and D2R-MSNs, where it mediates endocannabinoid-
dependent inhibition of GABA release and thus 
reduction of motor activity (Katona & Freund 2008; 
Castillo et al. 2012). CB1R is also expressed on 
glutamatergic terminals projecting from the cortex 
onto the striatum, thereby blunting glutamatergic 
output and mediating the so-called endocannabinoid-
dependent long-term depression (Gerdeman et al. 
2002; Kreitzer 2009). This process was shown to 
require D2R activation and so was proposed to occur 
exclusively in D2R-MSNs (Kreitzer & Malenka 2007). 
However, other findings support that, rather than 
being specific for D2R-MSNs, endocannabinoid-
dependent long-term depression may exhibit a certain 
preference to occur at D2R-MSNs over D1R-MSNs, 
and is most likely evoked by different mechanisms in 
each MSN population (Wang et al. 2006; Bagetta et al. 
2011; Mathur & Lovinger 2012; Wu et al. 2015).  
 
On anatomical grounds, different cortical excitatory 
efferents onto D1R-MSNs and D2R-MSNs have been 
proposed: D1R-MSNs seem to receive input 
preferentially from small, bilateral intratelencephalic 
projections, while D2R-MSNs seem to receive input 
preferentially from larger, ipsilateral collaterals of the 
pyramidal tract (Lei et al. 2004; Raymond et al. 2011). 
Likewise, excitatory synapses exhibit higher release 
probability and larger NMDAR currents on D2R-MSNs 
than on D1R-MSNs (Kreitzer & Malenka 2007). 
Overall, these findings suggest that CB1R located on 
corticostriatal terminals projecting onto D2R-MSNs 
might blunt physiological glutamatergic transmission 
preferentially aimed at controlling D2R-evoked 
dopaminergic control of motor behavior. Concertedly, 
our results support that CB1R located on 
corticostriatal terminals projecting onto D1R-MSNs 
might blunt pathological glutamatergic transmission 
preferentially aimed at controlling D1R-evoked 
dopaminergic neurotoxicity (Fig. 3). As D1R is in 
considerable excess over D2R in the striatum, it is 
plausible that the former will be more significantly 
engaged than the latter upon dopamine spillover 
(Raymond et al. 2011).  
 
On mechanistic grounds, one could speculate that, 
upon intense activation of intratelencephalic 
glutamatergic projections, glutamate spillover out of 
the synapse would evoke on targetted D1R-MSNs the 
activation of the perisynaptic machinery of 
endocannabinoid generation, composed of type 1 
metabotropic glutamate receptors (mostly mGluR5), 
heterotrimeric Gq/11 proteins, PLCCβ, and DAGL-α, 
thus triggering the production of 2-AG (Uchigashima 
et al. 2007; Katona & Freund 2008), which would 
retrogradely engage CB1R located on glutamatergic 
terminals, inhibiting in turn excess excitatory 
transmission (Castillo et al. 2012) and buffering the 
neurototoxic effects of extrasynaptic NMDA receptors 
on D1R-MSNs (Tang et al. 2007; Paoletti et al. 2008; 
Milnerwood et al. 2010; Okamoto et al. 2009; J. Y. 
Chen et al. 2013). 
 
Figure 3. Mechanisms of cannabinoid-induced protection of D1R-MSNs upon mtHtt expression in the cortex. When mHtt-evoked damage 
occurs specifically in cortocostriatal projection neurons, corticostriatal CB1R (but not astroglial CB1R or MSN CB1R) exerts D1R-MSN protection 
by blunting glutamate release. 
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A significant number of studies have dealt with the 
expression and function of CB1R in HD. As a matter of 
fact, HD constitutes the best currently available mode 
disease to assess the pathophysiological relevance 
and therapeutic potential of CB1R in 
neurodegenerative diseases. This is due to at least 
three important reasons: (i) CB1R is highly expressed 
in the striatum at synapses established by neurons 
containing GABA (especially MSNs, the cells that 
primarily degenerate in HD) or glutamate (especially 
corticostriatal projection neurons, which critically 
control MSN function) as transmitters, and plays a key 
role in the control of motor behavior (the process that 
is most characteristically affected in HD) (Katona & 
Freund 2008; Kreitzer 2009; Castillo et al. 2012). (ii) We 
(Blázquez et al. 2011) and others (Mievis et al. 2011) 
have demonstrated a neuroprotective role of CB1R in 
transgenic mouse models of HD; for example, double-
mutant mice expressing mtHtt exon 1 in a CB1R-/- 
background show an overt HD-like phenotype at 
earlier ages than their single-mutant littermates 
expressing mtHtt exon 1 in a normal CB1R+/+ 
background. (iii) An early and remarkable down-
regulation of CB1R expression has been documented 
in the caudate-putamen of HD patients (Glass et al. 
2000) and animal models (Denovan-Wright & 
Robertson 2000; McCaw et al. 2004), this down-
regulation reflecting the damage pattern of MSNs 
characteristic of the disease; in contrast, the 
expression and function of CB1R located on 
corticostriatal projections remains unaffected along 
HD progression (Chiodi et al. 2012; Chiarlone et al. 
2014).  
 
Hence, it is plausible that the maintenance of CB1R on 
corticostriatal projections constitutes an adaptive 
mechanism aimed at buffering concerted 
glutamatergic-dopaminergic excitotoxicity on D1R-
MSNs (Fig. 3). Evidence obtained from HD patients 
and mouse models shows that patterns of 
communication between cortical projections and 
MSNs become altered from very early, even 
asymptomatic stages of the disease, thus indicating 
that a dysfunctional cortical input to the striatum 
determines the onset and progression of neurological 
signs (Thu et al. 2010; Ghiglieri et al. 2012; Unschuld et 
al. 2012; Estrada-Sánchez & Rebec 2013).  
 
Likewise, it is generally accepted that MSN 
dysfunction and associated behavioral deficits in HD 
are caused by the expression of mtHtt not only in 
MSNs (cell-autonomous toxicity) but also in cortical 
pyramidal neurons (non-cell-autonomous toxicity) (Gu 
et al. 2005; Wang, Gray, X. Lu, et al. 2014; Estrada-
Sanchez et al. 2015). However, it is still unknown 
whether these regional features of mtHtt expression 
define a potential vulnerability of D1R-MSNs vs. D2R-
MSNs to damage. Here we show that, in the case of 
the control of MSN survival by the pool of CB1R 
molecules located on corticostriatal projections, 
cortical pyramidal neurons –but not MSNs or 
astrocytes- constitute an indispensable site of mtHtt 
expression for a selective protection of D1R-MSNs vs. 
D2R-MSNs to be observed. In addition, when mtHtt is 
expressed in astrocytes, MGL located in these cells 
fine-tunes the availability of 2-AG to achieve cortical 
CB1R-mediated neuroprotection (Fig. 4). 
 
This exciting finding adds to the conceptual view on 
how non-cell-autonomous mtHtt actions orchestrate 
complex alterations in the corticostriatal circuit and 
may help to understand the intrincate 
pathophysiology of basal ganglia disorders. 
 
 
Figure 4. Mechanisms of cannabinoid-induced neuroprotection of D1R-MSNs upon mtHtt expression in astrocytes. When mHtt-evoked 
damage occurs specifically in striatal astrocytes: (I) Corticostriatal CB1R (but not astroglial CB1R or MSN CB1R) exerts D1R-MSN protection by 
reducing excitotoxicity. (II) The suppression of astroglial MGL activity also exerts neuroprotection. 
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CONCLUSIONS 
 
The functionality of MSNs is tightly controlled by various metabotropic receptors. An imbalance in any of these 
receptors could lead to dysfunction and degeneration of the corticostriatal neuronal network, and may have different 
consequences depending on the MSN population. CB1R, which is highly expressed in the striatum and plays a key 
role in its related functions, represents one of these metabotropic signalling systems that determines the differential 
cellular responses within the corticostriatal system. 
 
 The results obtained in this Thesis allow us to obtain the following CONCLUSIONS: 
I. Striatal circuits can be “turned on” by acute Gq-protein signalling or “turned off” by sustained Gq-protein 
signalling. Specifically, sustained Gq-protein signalling inactivates MSNs of the dorsal striatum by an 
intracellular pathway that relies on JNK.  
 
II. CB1R located on corticostriatal projections, mainly by blunting glutamatergic output, selectively safeguards 
D1R-MSNs of the dorsal striatum. 
 
Collectively, these findings define the molecular mechanism and functional relevance of Gq-protein-driven signals in 
striatal circuits under normal and overactivated states, and define cortical CB1R as a key neurochemical player in 
dictating a dissimilar vulnerability of D2R-MSNs vs. D1R-MSNs. Altogether, they may contribute to understand the 
role of coordinated cannabinergic-glutamatergic signaling in the control of the direct and indirect corticostriatal 
pathways, and their dysregulation in basal ganglia disorders. 
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